AMKR za měsíc klesl o 9,6 %, ale firma hlásí silný růst pokročilých produktů: ve 2. čtvrtletí 2026 tržby činily 1,56 mld. USD oproti 1,23 mld. USD před rokem.
Key Takeaways AMKR fell 9.6% in a month, but the pullback may offer a lower-priced entry into its long-term growth story.Advanced products generated $1.56B in Q2 2026, up from $1.23B a year earlier, supporting AMKR's growth.AMKR is expanding capacity in Arizona, Korea and Vietnam to aid advanced packaging and data-center demand. Amkor Technology (AMKR - Free Report) has struggled to keep pace with its industry and broader sector, with shares down 9.6% over the past month. In comparison, the Zacks Electronics - Semiconductors industry has declined 1.9%, while the broader Computer and Technology sector has edged up 0.5%.
AMKR shares have also underperformed Micron Technology (MU - Free Report) , Cohu, Inc. (COHU - Free Report) and KLA Corporation (KLAC - Free Report) over the same period. Micron Technology led the group with an 18.1% gain, followed by Cohu’s 2.5% increase, while KLA Corporation has declined 3.7%.
One-Month Price Comparison
Image Source: Zacks Investment Research
AMKR’s recent decline appears to be driven primarily by near-term Communications weakness, ongoing smartphone and memory-related pressures, the temporary System-in-Package (SiP) transition and concerns surrounding its heavy capacity investments. However, these challenges need to be viewed against Amkor’s broader long-term strategy. The company is increasing investment in advanced packaging, expanding its manufacturing footprint and deepening relationships with key semiconductor players.
Importantly, Amkor's recent investments are increasingly aligned with some of the semiconductor industry's strongest structural growth trends. The company is seeing rising demand for Advanced Packaging, AI and high-performance computing (HPC), automotive and ADAS applications, while its strategic partnerships with TSMC and NVIDIA could strengthen its position.
Therefore, this recent price drop could present an opportunity for investors to buy shares at a lower price and participate in Amkor's long-term growth potential.
Strong Advanced Packaging Growth Supports AMKRAmkor’s long-term growth prospects are increasingly tied to the structural shift toward Advanced Packaging, as rising AI, high-performance computing (HPC) and data-center complexity require higher integration, performance and power efficiency. The company has established capabilities across 2.5D integration, high-density fan-out (HDFO), advanced flip chip, wafer-level processing and advanced SiP. Its second quarter 2026 results showed this opportunity gaining traction, with advanced products generating $1.56 billion of revenue, up from $1.23 billion a year earlier. It also reported growing customer engagements across 2.5D, HDFO and emerging co-packaged optics, including a data-center CPU HDFO program that began ramping in the second quarter.
The opportunity extends beyond near-term revenue growth because advanced packaging can support higher-value applications and improve Amkor’s overall product mix and earnings power. The company is deepening strategic relationships with TSMC and NVIDIA, while expanding advanced-packaging capacity in Arizona and Korea. Management said several technology platforms were already operating at full capacity and that customer engagements increasingly involve longer planning horizons and capacity alignment. This is important for investors, as a greater mix of advanced packaging will enable AMKR to capture more value from the growth of AI and HPC, while simultaneously facilitating better utilization of its expanded manufacturing base.
Geographic Diversification Gives AMKR a Competitive EdgeAmkor’s broad and strategically located manufacturing footprint is a key competitive advantage, giving customers greater geographic flexibility, supply-chain resiliency and regional manufacturing options. The company’s facilities across key regions in Asia and Europe allow customers to diversify supply chains and mitigate operational risks, while its U.S. headquarters and new Arizona facility strengthen its ability to support customers seeking to regionalize semiconductor production. Importantly, AMKR’s geographic diversity also allows it to qualify production at multiple sites and optimize asset utilization, providing greater flexibility as customer demand shifts across markets and technologies.
Amkor is expanding this footprint in a way that is increasingly aligned with long-term customer requirements. Phase 1 of the Arizona facility is fully committed, while new capacity is being added in Korea, including a Songdo assembly and test building and additional Gwangju cleanroom capacity expected to support data-center and advanced-packaging opportunities from 2028 onward. Amkor is also expanding facilities in Vietnam, Portugal and Taiwan. The move of SiP production from Korea to Vietnam is particularly strategic because it frees capacity in Korea for rapidly scaling, higher-value Computing programs while increasing SiP and NAND capacity in Vietnam.
Amkor’s geographic diversification could become an increasingly important competitive advantage as semiconductor customers seek greater supply-chain resilience and regionalized production. While Micron Technology, Cohu and KLA Corporation also maintain broad global footprints, their geographic networks support different business models. AMKR’s footprint is directly aligned with its OSAT operations, enabling customers to access packaging and test capacity across multiple locations. Its investments in Arizona, Korea, Vietnam, Portugal and Taiwan further strengthen this flexibility and align capacity with evolving customer requirements. For investors, this could help AMKR win new programs, deepen customer relationships and support more durable long-term growth.
AMKR Stock Trades Lower Than Its Growth ProspectsAmkor shares appear attractively valued, offering investors a potentially compelling entry point relative to the company’s growth outlook. The stock’s Zacks Value Score of A indicates an attractive valuation, while its VGM Score of B suggests better returns.
Amkor’s earnings outlook further strengthens the investment case. The Zacks Consensus Estimate for 2026 earnings stands at $2.6 per share, implying robust year-over-year growth of 73.3%. This strong expected earnings expansion suggests that the stock’s current valuation may not fully reflect its growth potential.
AMKR also trades at a forward P/B ratio of 2.53X, well below the industry and sector averages of 8.72X and 8.87X, respectively. The significant valuation discount, combined with strong projected earnings growth, indicates that AMKR may be trading below levels justified by its underlying growth prospects, presenting potential upside for value-oriented investors.
AMKR’s P/B Ratio (TTTM)
Image Source: Zacks Investment Research
Parting Thoughts on AMKRAmkor’s recent pullback provides an attractive entry point for investors seeking to capitalize on the company’s strong long-term growth potential. Strong Advanced Packaging demand, AI and HPC opportunities, geographic diversification and strategic partnerships provide solid growth drivers. Combined with attractive valuation and robust earnings expectations, AMKR’s growth-driven prospects make the current dip a potential buying opportunity for investors.
AMKR currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Írán pohrozil americkým energetickým aktivům v Perském zálivu a ropa WTI vystřelila nad 91,48 USD za barel. Trh už se přesouvá do ropných, rafinérských a tankerových titulů.
Iran's latest threat against US energy assets in the Gulf sent oil past $91 a barrel, and the money is already rotating into a handful of names before most investors notice the trade is live.
Iran told Reuters on September 7 that US energy assets in the Gulf are vulnerable after the latest round of clashes, and the market is already pricing the threat: WTI printed $91.48 per barrel on September 1, up 9.0% in a week. If Tehran follows through, the money is already moving into the five names below. Miss the rotation and you are buying the top.
1. Transocean (The Rig Shortage No One Is Pricing) Transocean (NYSE:RIG | RIG Price Prediction) is a rig lessor. It owns and leases the ultra-deepwater and harsh-environment floaters that operators need when Middle East supply gets unreliable and majors race to sanction non-OPEC barrels. CEO Keelan Adamson told investors that “supply disruptions around the world, continued growth in oil and gas capex, and strong demand for our rigs all reinforce our view that we are in a multi-year upcycle for offshore drilling.”
The Q2 2026 numbers back him up. Transocean carries a $7.1 billion backlog at an implied average dayrate above $450,000, added $3.1 billion in contracts year to date including the Equinor award, and posted 97.0% fleet-wide revenue efficiency. Management expects deepwater utilization to move well into the 90% range during 2027.
The stock has already begun to move: RIG is up 88.71% over the past year and 41.65% year to date through September 4. That is the setup nobody is watching. The heavyweight below is the one everybody already owns.
2. Diamondback Energy (The Permian Cash Machine) Diamondback Energy (NASDAQ:FANG) is the pure-play US shale barrel that gets repriced every time an Iranian drone flies. Its production sits in the Permian, not the Persian Gulf, and its CEO Kaes Van’t Hof has been the loudest voice on Wall Street framing the trade. On the Q2 call he said “the disruption of oil flows through the Strait of Hormuz has triggered the largest supply shock in the history of the global oil market” and told investors he believes the restocking required to rebuild global inventories has structurally raised the floor for oil prices.
Q2 2026 turned that thesis into cash. Diamondback booked adjusted EPS of $6.48 on $5.56 billion in revenue, beating estimates by 8.32% and 12.3%, with a realized oil price of $96.82 per barrel versus $63.23 a year earlier and free cash flow of $2.33 billion. The board doubled the buyback authorization to $16.0 billion, with $9.9 billion remaining.
Shares are up 34.77% year to date through September 4. Fine. Now ask who monetizes the barrel after Diamondback pumps it.
3. Marathon Petroleum (The Refiner Running Hot) Marathon Petroleum (NYSE:MPC) is the crack-spread trade. When Gulf tensions curtail foreign refinery runs and US fuel prices hit a record Labor Day high, according to the Associated Press, MPC captures the spread. Management said on the Q2 call that global refining downtime is running roughly 4 million barrels per day above historical norms, driven by Persian Gulf disruptions and Ukrainian strikes on Russian infrastructure.
Q2 results were a monster. MPC delivered EPS of $17.73 versus a $13.9518 consensus, revenue of $51.99 billion, and R&M margin of $36.33 per barrel versus $17.58 a year earlier. Systemwide crude utilization ran 94%, with Gulf Coast refineries at 100%, and the company returned over $2.8 billion to shareholders in the quarter with $6.1 billion left on the buyback.
The market has noticed. MPC is up 141.93% year to date and 30.97% in the past month alone through September 4. Which brings us to the ships that move the barrels the refiners cannot get any other way.
Marathon Petroleum Refining Snapshot Metric Q2 2026 Year Ago R&M adjusted EBITDA $6.66B $1.89B R&M margin per barrel $36.33 $17.58 Net income to MPC $5.14B $1.22B 4. Scorpio Tankers (The Rerouting Trade) Scorpio Tankers (NYSE:STNG) operates the product tankers that carry gasoline, diesel, and jet fuel around the world. When Hormuz traffic reroutes and Red Sea risk pushes owners around the Cape of Good Hope, sailing distances balloon and ton-mile demand spikes. Management described the setup bluntly: “I’ve never seen a July or August market like this. This is not what you would consider to be a normal summer low.”
For Q2 Scorpio posted revenue of $408.73 million, up 77.5% year over year, and average daily TCE revenue more than doubled to $52,661 from $25,569. Q3 is already booking at elevated levels: LR2 spot rates at $65,000 per day with 34% booked, MR at $29,000 per day with 46% booked. The balance sheet is fortified with roughly $2.0 billion of unrestricted cash plus a $483.2 million undrawn revolver.
STNG has rallied 64.86% year to date through September 4. Solid. But there is one operator whose fleet is levered directly to the choke point itself.
5. Frontline (The Payoff Trade on the Choke Point) Frontline (NYSE:FRO) is the pure-play VLCC and Suezmax operator whose earnings live and die by the Strait of Hormuz. CEO Lars Barstad did not hedge on the Q2 call: “The current market dwarfs the previous cycles.” Frontline cited an 82% reduction in crude oil exports from inside the Strait of Hormuz and a 23% increase in idling days per VLCC, both of which tighten effective fleet supply even as headline volumes fall.
Q2 delivered a profit of $659.2 million, or $2.96 per share, the best quarter Frontline has ever recorded, with Q2 VLCC TCE of $152,700 per day and Suezmax of $111,400 per day. Management then paid the money out: the latest declared dividend of $2.61 per share is the largest in Frontline’s recent history, and Barstad framed the capital-return posture starkly: “Our proposition to investors continues to be that we pay everything out.”
The market has already awarded the payoff. FRO is up 127.11% year to date and 133.08% over the past year through September 4. It is the cleanest way to own the choke point without predicting whether it closes.
Year-to-Date Price Performance Trade in One Breath Iran’s warning is the catalyst; the setup is already in motion. Offshore rigs get scarcer, US shale barrels get bid, refiners bank the crack, and the tankers that carry what is left charge whatever the market will pay. Every one of these names posted a blowout Q2 into the same disruption Tehran is now threatening to widen. Waiting for confirmation means paying up.
Contact [email protected] for any questions or corrections.
Labcorp koupila MLM Medical Labs a rozšířila globální síť centrálních laboratoří pro klinické studie na čtyři kontinenty. Získává tím silnější biomarkerové a specializované testování.
Acquisition establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents
, /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed.
The acquisition enhances Labcorp's position as a leading independent central laboratory services provider by expanding its presence in key clinical research regions and strengthening its biomarker and specialty testing capabilities. The transaction expands Labcorp's laboratory footprint and establishes Labcorp as the only central laboratory provider with a wholly owned laboratory network across four continents: North America, Europe, Asia and Africa. The combination brings together Labcorp's global scale, breadth of scientific capabilities and operational infrastructure with MLM's established laboratory network and science-led service model.
"Clinical trial sponsors today need scientific expertise, global reach and operational flexibility to advance increasingly complex development programs," said Brian Caveney, M.D., EVP and president, biopharma laboratory services and chief medical and scientific officer, Labcorp. "MLM complements Labcorp's existing strengths and enhances our ability to support sponsors of all sizes, from emerging biotechs to leading pharmaceutical companies. Together, we are well positioned to provide the capabilities, regional expertise and high-touch support sponsors need to advance innovative therapies worldwide."
This integrated global infrastructure enhances Labcorp's ability to support complex multinational clinical trials with consistent scientific, operational and regulatory oversight from a single trusted partner. The acquisition also expands Labcorp's laboratory footprint in critical clinical research markets, including Africa, where MLM operates the continent's first fully CAP-accredited central laboratory.
In addition, the acquisition strengthens Labcorp's scientific and regulatory expertise and broadens access to biomarker and specialty testing capabilities that support increasingly complex clinical development programs.
This acquisition reflects Labcorp's ongoing commitment to investing in central laboratory services and meeting the evolving needs of clinical trial sponsors worldwide.
Evercore served as exclusive financial advisor to Labcorp and Pierson Ferdinand and Hogan Lovells served as Labcorp's legal counsel.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the acquisition of MLM Medical Labs and how its capabilities are anticipated to benefit clinical trial sponsors.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
Nutanix zakončil srpen s více než 16% růstem akcií po silných výsledcích za čtvrté fiskální čtvrtletí a celý rok. Výnosy dosáhly těsně nad 757 milionů USD a zisk na akcii (EPS) činil 0,60 USD.
Cloud and enterprise software company Nutanix (NTNX -0.16%) probably doesn't want the summer to end, given how well its stock did in August. Boosted by the estimates-trouncing fiscal fourth-quarter and full-year report it posted toward the end of the month and a subsequent wave of analyst price targets, its shares exited August with a more than 16% gain.
A fabulous final frame The month didn't exactly start on a high note for Nutanix. Four days into it, the company divulged in a regulatory filing that it aimed to reduce its workforce by roughly 5%. Stating that this decision was reached after a review of its business structure, Nutanix said the move will cost it roughly $33 million to $43 million. The reductions should be complete by the end of October.
Image source: Getty Images.
The company had better news to impart with that earnings report. The final frame of its 2026 fiscal year saw it book just over $757 million in revenue, up 16% year over year. Annual recurring revenue at the end of the quarter and year was also 16% higher, at $2.55 billion.
Net income not under generally accepted accounting principles (non-GAAP, or adjusted) was more than $175 million, or $0.60 per diluted share. That was a robust 61% higher than the fourth quarter of fiscal 2025 result.
It was also far above the consensus analyst estimate of $0.49. The same could be said for the company's revenue that quarter, which well exceeded the average pundit expectation of slightly more than $738 million.
In its earnings release, Nutanix quoted CEO Rajiv Ramaswami as saying the quarter "was a strong finish to fiscal 2026, a year in which we delivered solid top and bottom line performance and added over 3,000 new customers."
Management clearly doesn't believe that will be the last time the company will outperform.
It proffered strong guidance for both revenue and free cash flow (FCF) for the entirety of fiscal 2027. The top-line is forecast at $3.18 billion to $3.23 billion, while the outlook for FCF is $850 million to $950 million.
Premium Feature
Moneyball Superscore
82/100
Today's Change
(
-0.16
%) $
-0.11
Current Price
$
67.95
A bunch of bulls For obvious reasons, investors liked what they heard about the quarter and reacted by driving Nutanix's stock higher in the days that followed. Some were probably influenced by the series of analyst price target raises immediately following earnings. The raisers included pundits from top financial companies Bank of America, Morgan Stanley, and Wells Fargo.
I'd be inclined to agree with those prognosticators and the bullish investors buying in at the end of the month. Nutanix continues to have a compelling business proposition with its "hyperconverged infrastructure," which bundles advanced compute, networking, and storage on a single platform. I think this stock has quite a high ceiling these days.
Wells Fargo is an advertising partner of Motley Fool Money. Bank of America is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Nutanix. The Motley Fool has a disclosure policy.
Sempra oslavila další kapitolu růstu na NYSE a zdůraznila růstovou strategii podpořenou rekordním kapitálovým plánem 65 miliard USD. Firma chce v roce 2027 generovat zhruba 95 % zisku z regulovaných amerických utilit.
Ceremony Highlights One of America's Leading Utility Growth Businesses
, /PRNewswire/ -- Sempra (NYSE: SRE) celebrated its next chapter of growth as Chairman and Chief Executive Officer Jeffrey W. Martin and members of the board of directors rang the opening bell at the New York Stock Exchange (NYSE). The ceremony reflected Sempra's continued momentum as it advances its mission to build America's leading utility growth business.
Press and Social Media Credit Use: @NYSE "We are pleased to celebrate our longstanding relationship with the NYSE as we renew our commitment to help lead our industry in meeting rising energy demand across some of America's largest and fastest-growing markets," said Jeffrey W. Martin, chairman and CEO of Sempra. "This is an exciting time for our company. By simplifying our business model and strengthening our financial position, we are better positioned to invest in critical energy infrastructure that serves nearly 40 million consumers. By continuing to enhance safety, reliability and resilience, we are working hard every day to create meaningful long-term value for our stakeholders."
To help meet growing energy demand, Sempra has refined its corporate strategy to strengthen its position in major economic markets and shift capital to meet the growing needs of its U.S. utilities.
"Across the next decade, we expect economic growth will be fueled by domestic manufacturing, investments in critical infrastructure and advances in AI technologies that reshape how America competes on the global stage. At Sempra, we understand that modernizing and expanding the energy grid is central to that effort," said Martin.
Sempra's utility growth strategy is supported by a record $65 billion capital plan,1 with approximately 95% of planned investments directed toward regulated utilities, alongside a capital recycling program designed to efficiently fund growth and strengthen the company's financial position. These actions reflect Sempra's disciplined execution of its 2026 value creation initiatives and support its objective of generating approximately 95% of earnings from regulated U.S. utilities in 2027, as well as having more than 60% of its rate base located in Texas through the end of the decade.2 The strategy is designed to support continued investment in modernizing and expanding energy infrastructure while helping power America's growing economy.
About Sempra
Sempra's mission is to build America's leading utility growth business. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving energy resilience in California and Texas, the two largest economies in the U.S. The company is recognized as a leader in responsible business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in The Wall Street Journal's Management Top 250 and Fortune's World's Most Admired Companies. More information about Sempra is available at sempra.com, including investor.sempra.com/corporate-updates which contains important information for investors, and on social media @sempra.
We use the investor.sempra.com/corporate-updates webpage as a means of disclosing important information to investors, some of which may be material, and complying with our disclosure obligations under SEC Regulation FD. The information on this webpage is supplemental to the information we disseminate to investors through other channels, including filings with the SEC, press releases, and public conference calls and webcasts, and investors should monitor all these sources for material information about us.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions about the future, involve risks and uncertainties, and are not guarantees. Future results may differ materially from those expressed or implied in any forward-looking statement. These forward-looking statements represent our estimates and assumptions only as of the date of this press release. We assume no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.
In this press release, forward-looking statements can be identified by words such as "believe," "expect," "intend," "anticipate," "contemplate," "plan," "estimate," "project," "forecast," "envision," "should," "could," "would," "will," "confident," "may," "can," "potential," "possible," "proposed," "in process," "construct," "develop," "opportunity," "preliminary," "pro forma," "strategic," "initiative," "target," "outlook," "optimistic," "poised," "positioned," "maintain," "continue," "progress," "advance," "goal," "aim," "commit," or similar expressions, or when we discuss our guidance, priorities, strategies, goals, vision, mission, projections, intentions or expectations.
Factors, among others, that could cause actual results and events to differ materially from those expressed or implied in any forward-looking statement include: California wildfires, including potential liability for damages regardless of fault and any inability to recover all or a substantial portion of costs from insurance, the wildfire fund established by California Assembly Bill 1054 and the wildfire fund continuation account established by California Senate Bill 254, rates from customers or a combination thereof; decisions, disallowances or denials of cost recovery, audits, investigations, inquiries, ordered studies, regulations, legislative actions, denials or revocations of permits, consents, approvals or other authorizations, renewals of franchises, and other actions, including the failure to honor contracts and commitments, by the (i) Comisión Nacional de Energía, California Public Utilities Commission (CPUC), U.S. Department of Energy, Electric Reliability Council of Texas, Inc., U.S. Federal Energy Regulatory Commission, U.S. Internal Revenue Service, Public Utility Commission of Texas and other regulatory bodies and (ii) U.S., Mexico and states, counties, cities and other jurisdictions therein and in other countries where we do business; the success of business development efforts, construction projects, acquisitions, divestitures, and other significant transactions, such as the planned sale of a portion of our equity interest in Sempra Infrastructure Partners, including risks related to, as applicable, (i) being able to reach a positive final investment decision, (ii) negotiating pricing and other terms in definitive contracts, (iii) completing construction projects or other transactions on schedule and budget, (iv) realizing anticipated benefits from any of these efforts if completed, (v) obtaining regulatory and other approvals and (vi) third parties honoring their contracts and commitments, including with respect to closing or post-closing payments; changes to our capital expenditure plans and their potential impact on rate base or other growth; changes, due to evolving economic, political and other factors and increasing geopolitical instability as a result of wars or other conflicts in various parts of the world, to (i) trade and other foreign policy, including the imposition of tariffs by the U.S. and foreign countries (and uncertainty related to the implementation and enforceability thereof), and (ii) laws and regulations, including those related to tax and the energy industry in the U.S. and Mexico; litigation, arbitration, property disputes and other proceedings; cybersecurity threats, including by nation-state actors, of ransomware or other attacks on our systems, the energy grid or our other infrastructure, or the systems of third parties with which we conduct business; the availability, uses, sufficiency, and cost of capital resources and our ability to borrow money or otherwise raise capital on favorable terms and meet our obligations, which can be affected by, among other things, (i) actions by credit rating agencies to downgrade our credit ratings or place those ratings on negative outlook, (ii) instability in the capital markets, and (iii) fluctuating interest rates and inflation; the impact of efforts to increase affordability of U.S. utility customer rates on our ability to obtain cost recovery from applicable regulators, our capital expenditure and other growth plans and our ability to advance statewide policies; the impact on affordability of customer rates, cost of capital and operating margin due to (i) volatility in inflation, interest rates, commodity prices, tariff rates, and foreign currency exchange rates and (ii) with respect to SDG&E's and SoCalGas' businesses, the cost of meeting the demand for lower carbon and reliable energy in California; the impact of air quality and climate-related policies, laws, rules, regulations, trends and required disclosures, including actions to reduce or eliminate reliance on natural gas, increased uncertainty in the political or regulatory environment for California natural gas distribution companies, the risk of nonrecovery for stranded assets, and uncertainty related to emerging technologies; weather, natural disasters, pandemics, accidents, equipment failures, explosions, terrorism, information system outages or other events, such as work stoppages, that disrupt our operations, damage our facilities or systems, cause the release of harmful materials or fires or subject us to liability for damages, fines and penalties, some of which may not be recoverable through regulatory mechanisms or insurance or may impact our ability to obtain satisfactory levels of affordable insurance; the availability and reliability of electric power, natural gas and natural gas storage and transportation capacity, including disruptions caused by failures in the transmission grid or pipeline and storage systems or limitations on the injection and withdrawal of natural gas from storage facilities; Oncor Electric Delivery Company LLC's (Oncor) ability to reduce or eliminate its quarterly dividends due to regulatory and governance requirements and commitments, including by actions of Oncor's independent directors or a minority member director; and other uncertainties, some of which are difficult to predict and beyond our control.
These risks and uncertainties are further discussed in the reports that Sempra has filed with the U.S. Securities and Exchange Commission (SEC). These reports are available through the EDGAR system free-of-charge on the SEC's website, www.sec.gov, and on Sempra's website, www.sempra.com. Investors should not rely unduly on any forward-looking statements.
Sempra Infrastructure Partners and its subsidiaries, and the Sempra Texas utilities (Oncor and Sharyland Utilities) are not the same companies as the Sempra California utilities, SDG&E or SoCalGas, nor are they regulated by the California Public Utilities Commission (CPUC).
1 Sempra's 2026-2030 capital plan (i) includes Sempra's proportionate ownership interest in projected capital expenditures at unconsolidated equity method investees while excluding Sempra's projected future contributions to those equity method investees and (ii) excludes noncontrolling interests' proportionate ownership interest in projected capital expenditures at Sempra and at unconsolidated equity method investees. Sempra's 2026-2030 capital plan reflects Sempra's 80.25% ownership of Oncor and assumes Sempra's projected 70% ownership of SI Partners through March 31, 2026, and 25% ownership thereafter. All projects in progress and future projects are subject to a number of risks and uncertainties. Sempra's capital plan and expectations regarding potential increases to its capital requirements are based on a number of assumptions, the failure of which to be accurate could materially impact Sempra's actual capital expenditures.
2 Reflects Sempra's proportionate share of its utilities' combined projected 2030 rate base, based on Sempra's ownership interest in each utility.
AeroVironment obdržel první mezinárodní objednávku na laserový systém LOCUST v hodnotě přes 50 milionů USD. Jde o první přímý komerční prodej této technologie proti dronům.
Operationally proven laser weapon system receives first international purchase order valued at more than $50 million, highlighting growing global demand for scaled directed energy defense for counter-UAS missions.
ARLINGTON, Va.--(BUSINESS WIRE)--AeroVironment, Inc. (“AV”) (NASDAQ: AVAV) today announced it has received its first international purchase order for the LOCUST® Laser Weapon System. The landmark, first of its kind direct commercial sale (DCS) order, valued at more than $50 million, marks a significant milestone in the global adoption of AV’s directed energy counter‑drone capabilities.
The landmark, first of its kind direct commercial sale (DCS) order, valued at more than $50 million, marks a significant milestone in the global adoption of AV’s directed energy counter‑drone capabilities.
Share The purchase order covers an initial delivery of AV’s mission‑proven LOCUST systems and associated support. The award follows AV's recent selection by the U.S. Army for a $464.8 million Enduring-High Energy Laser (E-HEL) contract, representing the first-ever production contract for high energy laser weapon systems in United States history.
“This first international order signals increasing global recognition that high‑energy laser weapon systems are essential to modern air defense,” said Wahid Nawabi, President, Chairman and Chief Executive Officer at AV. “The threat from low-cost drones is global and has fundamentally changed the economics of warfare. LOCUST gives our customers an affordable, scalable way to defeat drone threats at scale without relying solely on expensive interceptors.”
“This first international order for LOCUST is a pivotal milestone in our directed energy roadmap,” said Mary Clum, President of Space, Cyber, and Directed Energy at AV. “We are not only accelerating the fielding of an operationally proven laser weapon system, we are also establishing a foundation for sustained and expanded international adoption to provide layered innovation in counter‑drone defense.”
To support the growing demand for LOCUST, AV recently announced it is investing more than $30 million to expand its Albuquerque, New Mexico manufacturing campus, creating a vertically integrated production hub to scale domestic and international production of directed energy, space, and advanced defense technologies while also adding more than 450 jobs and generating over $670 million in economic impact.
In addition to this latest international award, LOCUST has helped drive first‑of‑their‑kind milestones for U.S. directed energy, from achieving the military’s first acknowledged laser kills on the southern border and defeating multiple drones from the deck of the USS George H. W. Bush, to successful integrations on Infantry Squad Vehicles and Joint Light Tactical Vehicles under the AMP‑HEL initiative and multiple high‑profile live‑fire events at White Sands Missile Range observed by military and defense leaders, including Secretary of War Pete Hegseth who recently operated the system at White Sands.
The Federal Aviation Administration and the Department of War have also signed a landmark safety agreement creating a pathway for LOCUST to operate safely in U.S. airspace, following FAA review of the system’s domestic deployment.
These achievements firmly establish LOCUST as one of the most operationally proven laser weapon systems in the American arsenal.
MORE ON LOCUST
LOCUST is an operationally proven high-energy laser weapon system that combines advanced sensing, tracking and directed-energy defeat capabilities against Group 1-3 unmanned aircraft systems and other aerial threats. The modular system supports fixed-site, palletized and mobile deployment and can integrate with multiple cueing sensors and command-and-control (C2) networks.
Recently featured on CBS News’ 60 Minutes, the operationally‑proven LOCUST laser weapon system delivers engagements for less than $10 per shot and provides sustained defense unconstrained by the reload limitations of traditional air defense systems, offering a truly transformative solution for modern air defense.
LOCUST serves as a central piece of AV’s Halo_Shield™ modular layered air defense platform, providing best‑in‑breed detection, surveillance, and directed energy defeat capability alongside AV’s Titan® C‑UAS system and Freedom Eagle™‑1 next‑generation missile. Halo_Shield is an interoperable, distributed, and layered system that detects, tracks, and defeats drones, swarms, and other evolving aerial threats.
About AV
AeroVironment (“AV”) (NASDAQ: AVAV) is a defense technology leader delivering integrated capabilities across air, land, sea, space, and cyber. The Company develops and deploys autonomous systems, loitering munitions, counter‑UAS technologies, space‑based platforms, directed energy systems, and cyber and electronic warfare capabilities—built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo™, a modular, mission‑ready suite of AI‑powered software tools that empowers warfighters and enables full‑battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future‑defining capabilities at speed, scale, and operational relevance. For more information, visit www.avinc.com.
Safe Harbor Statement
Certain statements in this press release may constitute “forward‑looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions that involve risks and uncertainties, which could cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, our ability to perform under existing contracts and obtain new ones; regulatory changes; competitor activities; market growth; product development challenges; and general economic conditions. For a more detailed discussion of these risks, please refer to AeroVironment’s filings with the Securities and Exchange Commission. We undertake no obligation to update forward‑looking statements as a result of new information or future events.
Hsbc Holdings PLC increased its position in Hasbro, Inc. (NASDAQ:HAS – Free Report) by 104.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 798,597 shares of the company’s stock after acquiring an additional 408,015 shares during the quarter. Hsbc Holdings PLC owned about 0.57% of Hasbro worth $66,071,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HAS. CYBER HORNET ETFs LLC bought a new position in Hasbro in the 2nd quarter worth approximately $25,000. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Hasbro during the fourth quarter worth $27,000. MUFG Securities EMEA plc bought a new position in shares of Hasbro in the second quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. grew its position in shares of Hasbro by 1,190.0% in the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 387 shares of the company’s stock valued at $32,000 after purchasing an additional 357 shares in the last quarter. Finally, Cedar Mountain Advisors LLC purchased a new position in shares of Hasbro in the first quarter valued at $37,000. 91.83% of the stock is currently owned by institutional investors.
Hasbro Price Performance Shares of NASDAQ:HAS opened at $92.53 on Tuesday. Hasbro, Inc. has a 52-week low of $69.50 and a 52-week high of $106.98. The firm has a fifty day moving average of $89.28 and a 200 day moving average of $90.80. The firm has a market capitalization of $13.05 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 1.59 and a beta of 0.47. The company has a debt-to-equity ratio of 4.16, a quick ratio of 1.46 and a current ratio of 1.66.
Hasbro (NASDAQ:HAS – Get Free Report) last released its quarterly earnings results on Tuesday, July 21st. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.12. Hasbro had a return on equity of 141.11% and a net margin of 15.97%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the business posted $1.30 earnings per share. The company’s revenue for the quarter was up 16.2% on a year-over-year basis. As a group, research analysts anticipate that Hasbro, Inc. will post 6.17 EPS for the current fiscal year. Hasbro Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 2nd. Investors of record on Wednesday, August 19th were issued a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend was Wednesday, August 19th. Hasbro’s dividend payout ratio (DPR) is currently 50.36%.
Insider Activity at Hasbro In other Hasbro news, CFO Gina M. Goetter sold 11,000 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $95.44, for a total transaction of $1,049,840.00. Following the transaction, the chief financial officer directly owned 88,104 shares in the company, valued at $8,408,645.76. This trade represents a 11.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Hight sold 3,186 shares of Hasbro stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $93.71, for a total transaction of $298,560.06. Following the transaction, the insider directly owned 67,557 shares in the company, valued at $6,330,766.47. This trade represents a 4.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 50,472 shares of company stock worth $4,736,533 in the last quarter. 0.71% of the stock is owned by company insiders.
Analysts Set New Price Targets A number of analysts recently issued reports on HAS shares. Jefferies Financial Group decreased their price objective on Hasbro from $120.00 to $110.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Weiss Ratings raised Hasbro from a “sell (d+)” rating to a “hold (c+)” rating in a report on Friday, July 31st. Citigroup reaffirmed a “buy” rating on shares of Hasbro in a report on Thursday, July 23rd. Bank of America decreased their price target on Hasbro from $115.00 to $105.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Finally, DA Davidson lowered their price target on shares of Hasbro from $100.00 to $95.00 and set a “neutral” rating on the stock in a report on Wednesday, July 22nd. Twelve investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $109.43.
Get Our Latest Research Report on Hasbro
Hasbro Company Profile (Free Report)
Hasbro, Inc is a global play and entertainment company, known for designing, manufacturing and marketing a diverse portfolio of toys, games and consumer products. Founded in 1923 as Hassenfeld Brothers and headquartered in Pawtucket, Rhode Island, the company has grown into one of the foremost names in the toy industry, with a presence in retail, digital and entertainment channels worldwide.
The company’s brand portfolio features iconic properties such as Monopoly, Play-Doh, Nerf, My Little Pony and Transformers.
Read More Five stocks we like better than Hasbro 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for Hasbro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hasbro and related companies with MarketBeat.com's FREE daily email newsletter.
Acclaimed roller coaster will debut at a Six Flags park during the 2028-2029 seasons, launching speculation among coaster fans worldwide
, /PRNewswire/ -- Six Flags Entertainment Corporation (NYSE:FUN), North America's largest regional amusement-resort operator, has acquired ArieForce One, the celebrated steel roller coaster that captured the imagination of thrill-seekers around the world and quickly earned recognition as one of the most acclaimed coaster experiences of the modern era. Six Flags will introduce the attraction at one of its parks during the 2028-2029 operating seasons.
Six Flags acquires ArieForce One, one of the most acclaimed coasters of the modern era While the coaster's future home remains under wraps, today's announcement officially launches what is expected to become one of the most closely watched and passionately debated conversations in the theme park industry: Where will ArieForce One rise again?
For three years, ArieForce One built a devoted following among roller coaster enthusiasts who traveled from across the country and around the world to experience its signature blend of speed, airtime, inversions and nonstop intensity. Named in honor of Fun Spot America founder John Arie Sr. by the family-owned company that developed the attraction, ArieForce One represented both an ambitious investment and a personal legacy for the Arie family.
When the attraction closed in August, fans openly mourned the loss of a coaster many considered one of the finest steel roller coasters ever built. Since then, the question has echoed throughout enthusiast communities, online forums and social media channels: Can one of the world's most celebrated coasters be saved?
Today, Six Flags proudly answers that question.
"From the moment ArieForce One closed, we knew how much this coaster meant to the enthusiast community and to guests who traveled from around the world to experience it," said Mark Pauls, chief operating officer of Six Flags. "This is a ride that consistently generated excitement, acclaim and passionate fan support. We are thrilled to preserve its legacy, invest in its future and bring this extraordinary attraction to a new generation of guests. This acquisition represents our commitment to delivering world-class thrills and creating unforgettable experiences across the Six Flags portfolio."
"When we built ArieForce One, we wanted to create something truly special. Something that would put Fun Spot America on the map with coaster enthusiasts and families around the world and create memories that would last a lifetime," said John Arie Jr, CEO of Fun Spot America. "Seeing ArieForce One preserved and finding a new home with Six Flags means a great deal to me and my family. Its story isn't ending, it's beginning a new chapter, and we are excited that future generations will get to experience ArieForce One.
Pauls added that while fans now know ArieForce One's future is secure, one major mystery remains.
"Part of the excitement is that the story isn't over," Pauls said. "We know fans will immediately begin theorizing about which Six Flags park is the perfect fit. The passion surrounding ArieForce One is unlike anything we've seen in recent years, and when the time comes to reveal its new home, we believe that announcement will be just as exciting as the acquisition itself."
Manufactured by Rocky Mountain Construction, ArieForce One quickly earned industry acclaim for its relentless pacing, massive airtime moments, innovative elements and unforgettable ride experience. The coaster became a bucket-list attraction for enthusiasts and a fixture on best-in-the-world rankings, making its closure one of the most discussed stories in the amusement industry. To honor that legacy, Six Flags plans to retain the classic ArieForce One name, honoring the coaster's history and preserving the identity that helped make it a fan favorite.
Now, its next chapter begins.
Since news of the closing began circulating, coaster enthusiasts have filled fan communities with theories about acquisitions and where the attraction might ultimately be installed. From parks already known for their world-class coaster collections to destinations seeking a marquee signature attraction, enthusiasts have begun making their cases for why their favorite park should become the new home of ArieForce One.
"The coaster enthusiast community has spent months wondering whether ArieForce One would be saved and where it might ultimately find a new home," said Derek Perry, president-elect of American Coaster Enthusiasts (ACE), the world's largest amusement ride enthusiast organization. "Preservation is central to ACE's mission, so enthusiasts everywhere were hopeful this remarkable coaster would have a future beyond its original park. Today's announcement answers one question and opens the door to another. The speculation about which park will receive ArieForce One is going to be enormous."
Perry added, "Its farewell brought enthusiasts together from across the globe to celebrate a ride they love, and now they'll be watching every clue and announcement as Six Flags prepares for its next chapter."
Once reassembled and enhanced at its new Six Flags destination, the attraction is expected to become one of the premier thrill experiences in North America, drawing coaster enthusiasts, vacationers and adrenaline seekers alike.
ArieForce One Ride Stats:
Manufacturer: Rocky Mountain Construction (RMC) Ride Type: Steel roller coaster Height: 154 feet (approximately 15 stories tall) First Drop: 146 feet Top Speed: 64 mph Track Length: Approximately 3,400 feet Inversions: 4 Duration: Approximately 2 minutes Signature Elements: World's largest zero-gravity stall Raven Truss Dive Outward-banked airtime hill Multiple high-intensity airtime (negative-G) moments Original location: Fun Spot America Atlanta, Fayetteville, Georgia Name origin: Honors Fun Spot America founder John Arie Sr. Opening date: March 31, 2023 Closing date: August 2, 2026 Additional details regarding the attraction's future location, construction timeline and reopening plans will be announced at a later date. Until then, the coaster community's biggest mystery remains unsolved.
Which Six Flags park will become the new home of ArieForce One?
Fans, enthusiasts and thrill-seekers around the world can begin making their predictions now.
"ArieForce One has already cemented its place among the most celebrated roller coasters of its generation," Pauls said. "Today we're thrilled to announce that its future is secure. Next, we'll reveal where its next chapter begins."
Six Flags is home to North America's largest collection of roller coasters with more than 250 across its portfolio, including some of the most iconic roller coasters in North America—like Fury 325, Top Thrill 2, Millennium Force, Leviathan, El Toro, The Beast and Tormenta.
About Six Flags Entertainment Corporation
Six Flags Entertainment Corporation (NYSE: FUN) is North America's largest regional amusement-resort enterprise. The Company operates a premier portfolio of 20 amusement parks, 14 water parks, and nine resort properties across 13 U.S. states, Canada, and Mexico, as well as an amusement park in Saudi Arabia. Focused on its purpose of creating FUN, thrills, and a lifetime of memories, Six Flags provides immersive entertainment to millions of guests every year with world-class coasters, themed rides, and thrilling water parks powered by beloved intellectual property such as Looney Tunes®, DC Comics®, and PEANUTS®.
About Fun Spot America Theme Parks
Fun Spot America Theme Parks is a family-owned and operated amusement park company known for delivering family-friendly fun, world-class thrills and memorable guest experiences. Founded by John Arie Sr., Fun Spot America operates theme parks in Orlando and Kissimmee, Florida. The company developed ArieForce One at its former Atlanta location as one of the most ambitious investments in its history, creating a coaster that earned worldwide recognition among enthusiasts.
About American Coaster Enthusiasts
With more than 7,000 members worldwide, ACE is the largest and longest-running ride enthusiast organization in the world. Members of ACE have access to exclusive park benefits and opportunities plus RollerCoaster! Magazine and the opportunity to attend national, local and even international tours at parks. ACE hosts more than 100 in-person and digital events around the world annually and has been prominently featured on various news programs and cable networks.
Editor's Notes: Media Kit available here: Six Flags Acquires ArieForce One. Please credit "Courtesy of American Coaster Enthusiasts" when assets are in use.
MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / September 8, 2026 / MSC INDUSTRIAL SUPPLY CO. (NYSE:MSM) ("MSC," "MSC Industrial," the "Company," "we," "us," or "our"), a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services, today announced that it has named Rob Kuhns to the role of Executive Vice President and Chief Financial Officer.
Kuhns brings over 30 years of financial expertise to the role. He most recently served as Vice President and Chief Financial Officer at TopBuild Corp., a leading distributor of insulation and building products, where he helped drive market capitalization growth from $6B to $14B through disciplined capital allocation, strategic acquisitions, and operational execution.
"We are very much looking forward to welcoming Rob to the MSC leadership team as our new CFO," said Martina McIsaac, President and CEO of MSC. "He is an accomplished leader with deep knowledge of financial strategy and a proven track record of delivering profitable growth. Combined with his extensive experience in industrial and distribution industries and his broad financial leadership expertise, Rob will be instrumental as we continue to advance our strategy, evolve to achieve our long-term financial targets and create value for all stakeholders."
Prior to his tenure with TopBuild Corp., Kuhns held various senior corporate finance roles at Mohawk Industries, NCH Corporation, and Ingersoll Rand. He earned a bachelor's degree in accounting from Shippensburg University and his master's degree in business administration from Southern Methodist University.
Kuhns will be based at MSC's corporate office in Davidson, North Carolina.
# # #
Contact Information
Investors:
Media:
Ryan Mills, CFA
Leah Kelso
VP, Investor Relations & Business Development
VP, Communications & Sales Enablement
[email protected]
[email protected]
About MSC Industrial Supply Co.
MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking, maintenance, repair and operations (MRO), and production fastener and hardware products and services. With approximately 2.5 million products, industry‑leading inventory management and supply chain solutions, and more than 80 years of experience, we help customers improve productivity, profitability, and operational performance.
Our team of over 7,000 associates partners closely with customers across industries to keep their operations running efficiently today while enabling them with insights and comprehensive solutions to continually rethink, retool, and optimize for a more productive tomorrow.
For more information on MSC Industrial, please visit mscdirect.com.
Statements in this press release may constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words "will," "may," "believes," "anticipates," "thinks," "expects," "estimates," "plans," "intends" and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management's assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; our ability to accurately forecast customer demands; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships, including tariff policies; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology ("IT") systems and complying with data privacy laws; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.
Nykredit A/S ve 2. čtvrtletí nově koupila 2 148 akcií MACOM Technology Solutions za zhruba 817 000 USD. Společnost zároveň oznámila čtvrtletní EPS 1,40 USD a tržby 342,24 milionu USD.
Nykredit A S acquired a new stake in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,148 shares of the semiconductor company’s stock, valued at approximately $817,000.
Several other hedge funds also recently made changes to their positions in the company. Bell Investment Advisors Inc acquired a new stake in shares of MACOM Technology Solutions during the second quarter worth about $49,000. GHP Investment Advisors Inc. acquired a new stake in shares of MACOM Technology Solutions in the 1st quarter valued at about $31,000. Keating Financial Advisory Services Inc. acquired a new stake in shares of MACOM Technology Solutions in the 2nd quarter valued at about $58,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in MACOM Technology Solutions during the 2nd quarter worth approximately $67,000. Finally, Measured Wealth Private Client Group LLC purchased a new position in MACOM Technology Solutions during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 76.14% of the company’s stock.
MACOM Technology Solutions Price Performance Shares of NASDAQ:MTSI opened at $268.95 on Tuesday. MACOM Technology Solutions Holdings, Inc. has a fifty-two week low of $121.97 and a fifty-two week high of $418.90. The company has a quick ratio of 1.78, a current ratio of 2.34 and a debt-to-equity ratio of 0.04. The firm’s 50-day simple moving average is $285.53 and its 200-day simple moving average is $294.74. The company has a market cap of $20.54 billion, a price-to-earnings ratio of 86.48, a PEG ratio of 1.49 and a beta of 1.71.
MACOM Technology Solutions (NASDAQ:MTSI – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The semiconductor company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.05. The firm had revenue of $342.24 million during the quarter, compared to analysts’ expectations of $336.08 million. MACOM Technology Solutions had a net margin of 20.70% and a return on equity of 17.82%. The firm’s revenue for the quarter was up 35.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.90 earnings per share. MACOM Technology Solutions has set its Q4 2026 guidance at 1.970-2.030 EPS. As a group, equities research analysts predict that MACOM Technology Solutions Holdings, Inc. will post 4.26 earnings per share for the current year. Insider Transactions at MACOM Technology Solutions In other news, COO Robert Dennehy sold 252 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $275.20, for a total transaction of $69,350.40. Following the completion of the transaction, the chief operating officer directly owned 12,758 shares of the company’s stock, valued at approximately $3,511,001.60. This represents a 1.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO John Kober sold 7,389 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $326.08, for a total value of $2,409,405.12. Following the completion of the sale, the chief financial officer directly owned 33,583 shares of the company’s stock, valued at $10,950,744.64. This represents a 18.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 10,261 shares of company stock valued at $3,484,495. Corporate insiders own 0.36% of the company’s stock.
Wall Street Analyst Weigh In A number of brokerages have weighed in on MTSI. Needham & Company LLC boosted their price objective on MACOM Technology Solutions from $400.00 to $410.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Benchmark began coverage on MACOM Technology Solutions in a research report on Thursday, August 13th. They set a “buy” rating and a $375.00 price objective for the company. Weiss Ratings downgraded MACOM Technology Solutions from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, August 21st. BMO Capital Markets started coverage on MACOM Technology Solutions in a report on Friday, August 21st. They issued a “market perform” rating and a $335.00 target price on the stock. Finally, Susquehanna dropped their target price on MACOM Technology Solutions from $350.00 to $300.00 and set a “neutral” rating on the stock in a report on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, MACOM Technology Solutions has an average rating of “Moderate Buy” and a consensus target price of $341.25.
Read Our Latest Research Report on MTSI
(Free Report)
MACOM Technology Solutions is a semiconductor company specializing in high-performance analog, microwave, millimeter-wave and photonic semiconductor solutions. Its product portfolio includes amplifiers, switches, modulators, detectors and integrated circuits designed to optimize signal integrity, power management and data transmission. MACOM’s offerings address both digital and optical domains, providing critical building blocks for next-generation communications infrastructure.
The company’s solutions serve a diverse set of end markets, including wireless and wireline telecom, data centers, satellite communications, aerospace and defense, industrial and automotive applications.
Read More Five stocks we like better than MACOM Technology Solutions 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding MTSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI – Free Report).
Receive News & Ratings for MACOM Technology Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MACOM Technology Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
Beam Therapeutics oznámila, že po jednáních s FDA chce pro BEAM-302, terapii pro AATD, usilovat o zrychlené schválení. Data z 29 pacientů ukázala přijatelnou bezpečnost a silné biomarkerové výsledky.
Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD).
AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease.
The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and lung complications associated with the disease.
Promising Efficacy and Safety ProfileThe clinical trial evaluated single doses of BEAM-302 across two groups: Part A for patients with AATD-related lung disease and Part B for those with mild to severe liver disease.
As of the June 2026 data cutoff, results from 29 patients demonstrated an acceptable safety profile. The most frequent side effects were mild-to-moderate infusion-related reactions, affecting 41% of participants.
Read Next
Researchers also observed mostly mild, temporary liver enzyme elevations.
Patients receiving a 60 mg dose achieved sustained, functional alpha-1 antitrypsin (AAT) levels well above the protective 11 µM threshold. The therapy also reduced human neutrophil elastase activity and cut mutant Z-AAT proteins by 84% in both cohorts.
Additionally, BEAM-302 decreased toxic protein aggregates known to worsen liver disease and amplify lung inflammation. After treatment, newly produced, corrected M-AAT made up 93% of circulating AAT, exceeding the levels typically seen in genetic carriers.
Path To Accelerated ApprovalFollowing discussions with the U.S. Food and Drug Administration (FDA), Beam plans to pursue an accelerated approval pathway for the therapy.
The submission will evaluate AAT biomarkers over a 12-month period using the 60 mg dose as the primary endpoint.
To support a future biologics license application, the biotechnology firm anticipates enrolling roughly 50 additional patients with AATD-associated lung disease into an expansion of the ongoing trial.
Beam initiated dosing for this pivotal global cohort in July.
BEAM Stock Price Activity: Beam Therapeutics shares were down 7.17% at $27.53 during premarket trading on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Read Next
Market News and Data brought to you by Benzinga APIs
Public Employees Retirement System of Ohio ve 2. čtvrtletí koupil nový podíl ve Science Applications International, a to 12 219 akcií za zhruba 1,349 mil. USD. SAIC zároveň reportoval EPS 3,01 USD a tržby 1,88 mld. USD, obojí nad odhady.
Public Employees Retirement System of Ohio bought a new stake in Science Applications International Corporation (NASDAQ:SAIC – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,219 shares of the company’s stock, valued at approximately $1,349,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Los Angeles Capital Management LLC bought a new position in Science Applications International during the 4th quarter worth about $25,000. Transamerica Financial Advisors LLC boosted its position in shares of Science Applications International by 477.8% during the fourth quarter. Transamerica Financial Advisors LLC now owns 260 shares of the company’s stock worth $26,000 after buying an additional 215 shares during the period. Rakuten Securities Inc. grew its holdings in shares of Science Applications International by 1,915.4% during the second quarter. Rakuten Securities Inc. now owns 262 shares of the company’s stock worth $30,000 after buying an additional 249 shares in the last quarter. Wexford Capital LP acquired a new stake in Science Applications International in the 3rd quarter valued at approximately $29,000. Finally, Global Retirement Partners LLC acquired a new stake in Science Applications International in the 4th quarter valued at approximately $35,000. 76.00% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets A number of research firms have weighed in on SAIC. Jefferies Financial Group upped their price target on Science Applications International from $130.00 to $140.00 and gave the stock a “hold” rating in a research report on Tuesday, September 1st. TD Cowen reiterated a “hold” rating on shares of Science Applications International in a report on Monday, August 31st. BNP Paribas Exane initiated coverage on shares of Science Applications International in a report on Wednesday, May 27th. They set a “neutral” rating and a $95.00 target price for the company. Wall Street Zen raised shares of Science Applications International from a “buy” rating to a “strong-buy” rating in a research report on Sunday, August 30th. Finally, Truist Financial boosted their price target on shares of Science Applications International from $110.00 to $130.00 and gave the stock a “hold” rating in a research report on Tuesday, September 1st. Two analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $124.44.
View Our Latest Stock Analysis on Science Applications International Science Applications International Stock Performance Shares of NASDAQ:SAIC opened at $126.75 on Tuesday. Science Applications International Corporation has a 52-week low of $81.08 and a 52-week high of $142.66. The company has a market capitalization of $5.31 billion, a P/E ratio of 14.82 and a beta of 0.30. The company has a 50-day simple moving average of $120.38 and a 200 day simple moving average of $106.24. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.20 and a current ratio of 1.20.
Science Applications International (NASDAQ:SAIC – Get Free Report) last posted its quarterly earnings results on Monday, August 31st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.31 by $0.70. The business had revenue of $1.88 billion during the quarter, compared to analysts’ expectations of $1.76 billion. Science Applications International had a return on equity of 34.68% and a net margin of 5.13%.Science Applications International’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company posted $3.63 earnings per share. Sell-side analysts forecast that Science Applications International Corporation will post 10.73 earnings per share for the current year.
Science Applications International Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, October 23rd. Investors of record on Friday, October 9th will be issued a dividend of $0.37 per share. The ex-dividend date of this dividend is Friday, October 9th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.2%. Science Applications International’s payout ratio is presently 17.31%.
Science Applications International Company Profile (Free Report)
Science Applications International Corp. (SAIC) is a leading provider of technical, engineering, and enterprise IT services to the U.S. government, including the Department of Defense, the intelligence community, and civilian agencies. The company’s core offerings encompass systems engineering and integration, mission support, cybersecurity, data analytics, and cloud solutions. SAIC’s work spans the full program lifecycle, from research and development to deployment and sustainment, addressing complex defense, space, and national security challenges.
Founded in 1969 by J.
Further Reading Five stocks we like better than Science Applications International 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding SAIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Science Applications International Corporation (NASDAQ:SAIC – Free Report).
Receive News & Ratings for Science Applications International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Science Applications International and related companies with MarketBeat.com's FREE daily email newsletter.
Quoin Pharmaceuticals získala od FDA druhé označení pro vzácné pediatrické onemocnění pro QRX003 v léčbě Peeling Skin Syndrome. Pokud bude NDA schválena, může získat Priority Review Voucher (PRV).
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS).
The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. This is the second RPD designation granted for QRX003, following the previously granted RPD designation for Netherton Syndrome.
The FDA’s Rare Pediatric Disease Designation program is intended to encourage the development of new therapies for serious and life-threatening diseases that primarily affect individuals under 18 years of age. If a New Drug Application (NDA) for QRX003 is approved, Quoin may qualify to receive a Priority Review Voucher (PRV), which can be redeemed to receive priority review for another marketing application or may be sold or transferred.
“We are very pleased to announce the receipt of Rare Pediatric Disease Designation for QRX003 for Peeling Skin Syndrome. This designation means that Quoin could potentially receive two PRVs, which, given the current trading value of PRVs, could have an aggregate non-dilutive cash value in excess of $300 million,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “With the IND cleared by FDA, the Quoin team is preparing to initiate the Phase 2 clinical study before the end of this year with plans to enroll up to 12 pediatric and adult Peeling Skin patients in the U.S. and Europe. This will be the first formal study ever conducted in the U.S. for this disease under an open IND.”
About Peeling Skin Syndrome (PSS)
Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin's innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “look forward to,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential of QRX003 as a therapeutic candidate for Peeling Skin Syndrome and a profoundly underserved pediatric population, Quoin’s eligibility to receive Priority Review Vouchers upon approval of a New Drug Application for QRX003, including the potential to receive two PRVs with an aggregate non-dilutive cash value in excess of $300 million; the initiation of a Phase 2 clinical study for Peeling Skin Syndrome before the end of 2026 with plans to enroll up to 12 pediatric and adult patients in the U.S. and Europe; and Quoin’s belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO [email protected]
Investor Relations
PCG Advisory
Jeff Ramson [email protected]
(646) 863-6341
ABM ve 3. čtvrtletí zvýšila tržby o 4,2 % na rekordních 2,3 miliardy USD a čistý zisk o 19 % na 49,7 milionu USD. Zároveň zvýšila střed výhledu upraveného EPS na 3,95 až 4,10 USD a očekávání volného cash flow pro celý fiskální rok 2026 na přibližně 210 milionů USD.
Raises Midpoint of Outlook For Fiscal 2026 Adjusted EPS and Increases Free Cash Flow Expectations
Revenue increased 4.2% to a quarterly record of $2.3 billion, including organic growth of 2.1% and acquisition-related growth of 2.1%Net income increased 19% to $49.7 million, or $0.84 per diluted share, as compared to $41.8 million, or $0.67, in the prior year Adjusted net income grew 19% to $61.5 million, or $1.04 per diluted share, versus $51.7 million, or $0.82, in the prior yearAdjusted EBITDA improved 11% to $139.6 million, versus $125.8 million last yearOperating cash flow was $146.8 million and free cash flow totaled $128.4 millionThrough nine months, operating cash flow was $275.0 million and free cash flow was $199.6 million, both significantly improved over the prior year period Company raises outlook for full year adjusted EPS and operating cash flow and free cash flow NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ABM (NYSE: ABM), a leading provider of facility, engineering and infrastructure solutions, today announced financial results for its fiscal third quarter ended July 31, 2026
"Our third quarter results reflected strong operational and financial performance, including record quarterly revenue, robust EPS growth and substantial cash generation. Our team executed well and delivered on our expectations despite a backdrop of macro uncertainty and adverse timing of certain projects," said Scott Salmirs, President and Chief Executive Officer. "Aviation and Manufacturing & Distribution ("M&D") delivered strong organic revenue growth, with M&D benefiting from healthy technology markets and further supported by our recent WGNstar acquisition. Technical Solutions ("ATS") revenue growth was impacted by some project deferrals, while Business & Industry ("B&I") revenue performance was largely as anticipated. We expect ATS to ramp sequentially in the fourth quarter as we execute on many of the deferred projects."
Mr. Salmirs continued, "Disciplined working capital management drove exceptional year-to-date free cash flow, which in turn accelerated our deleveraging ahead of schedule. We also secured a $300 million accounts receivable facility at favorable rates, further strengthening our capital structure. And our focus on cost discipline resulted in a $3 million reduction in ongoing corporate costs versus the prior year. Together, these actions contributed to our third quarter results and helped keep us on track to deliver on our full-year outlook, as well as provide longer-term benefits."
Mr. Salmirs concluded, "As we enter the fourth quarter, we are focused on finishing the year strong and executing with discipline. We are raising the midpoint of our adjusted EPS outlook and increasing our expectations for full year free cash flow based on our strong third quarter results, and are confident in our ability to achieve it."
Third Quarter Fiscal 2026 Results
Revenue increased 4.2% year over year to a record of $2.3 billion, including 2.1% organic growth and 2.1% growth from acquisitions. Revenue growth was led by M&D and Aviation, which grew 18% and 12%, respectively. M&D’s growth was driven by the WGNstar acquisition, recent client wins and ongoing expansions, especially in technology-related markets, while Aviation’s growth reflected healthy air travel trends and the continued ramp of the recently won London Heathrow contract. ATS grew 4%, driven by strong HVAC activity and contributions from its recent acquisition; however, revenue was below expectations due to the deferral of certain projects by a large client. Education grew modestly, while Business & Industry (“B&I”) declined 2.6%, largely as expected, reflecting the previously announced exit of a large UK-based client and continued softness on the US west coast.
Net income increased 19% to $49.7 million, or $0.84 per diluted share, compared to $41.8 million, or $0.67 per diluted share, in the prior year period. The increase in net income primarily reflects higher segment operating profit, lower tax expense and reduced ongoing corporate costs, partially offset by higher interest expense related to the WGNstar acquisition. EPS growth of 25% was further driven by the Company’s share repurchase activities earlier in the year. Net income margin was 2.1% versus 1.9% in the prior year.
Segment operating margin improved 40 basis points sequentially to 7.7%, essentially in line with the prior year, as operational efficiencies helped to offset pressures in Aviation and increased acquisition-related amortization in M&D.
Adjusted net income increased 19% to $61.5 million, or $1.04 per diluted share, compared to $51.7 million, or $0.82 per diluted share in the prior year period. The year-over-year growth primarily reflects the factors discussed above, with per share results further benefiting from the Company's share repurchase activities.
Adjusted EBITDA increased 11% to $139.6 million compared to $125.8 million last year, largely reflecting higher segment operating profit and lower corporate costs.
Adjusted results exclude items impacting comparability. A description of items impacting comparability can be found in the “Reconciliation of Non-GAAP Financial Measures” table.
Third quarter net cash provided by operating activities was $146.8 million, and free cash flow was $128.4 million, compared to $175.0 million and $150.2 million, respectively, in the prior year period.
For the nine months ended July 31, 2026, net cash provided by operating activities was $275.0 million, and free cash flow was $199.6 million, compared to $101.0 million and $42.4 million, respectively, in the prior year period. This significant improvement was primarily driven by strong working capital management and stabilization in the Company’s enterprise resource planning (“ERP”) system implementation. A reconciliation of net cash provided by operating activities to free cash flow can be found in the “Reconciliation of Non-GAAP Financial Measures” table.
Leverage & Liquidity
At the end of the third quarter, the Company’s total indebtedness stood at $1.8 billion, including $22.4 million in standby letters of credit, resulting in a total leverage ratio of 2.9x, as defined by the Company's revolving credit facility. Available liquidity was $605.8 million, including $110.5 million in cash and cash equivalents. The Company expects to further reduce its total leverage ratio by fiscal year-end.
During the quarter, the Company entered into a $300 million trade receivables financing agreement, which diversifies its funding sources at favorable rates relative to its existing revolving credit facility.
Quarterly Cash Dividend
After the quarter’s close, the Board declared a cash dividend of $0.29 per common share, payable on November 2, 2026, to shareholders of record on October 1, 2026.
Outlook
The Company's full year organic revenue growth outlook remains unchanged, with performance expected near the top end of the 3% to 4% range, and total revenue growth continues to be expected toward the top end of the 4% to 5% range. Segment operating margin, defined as total segment operating profit divided by total revenue, is now projected to be in the range of 7.7% to 7.8%, versus the previous range of 7.8% to 8.0%. Full-year interest expense remains forecast at approximately $110 million, and the normalized tax rate is still expected to be between 29% and 30%, excluding discrete and non-taxable items. The Company is raising the midpoint of its adjusted EPS outlook. The range is now $3.95 to $4.10, versus the previous range of $3.85 to $4.15, reflecting its third quarter performance and confidence in the Company’s ability to deliver a strong fourth quarter.
The Company is raising its full-year outlook for net cash provided from operations and free cash flow and now expects approximately $300 million and $210 million, respectively, with free cash flow up approximately $25 million from the prior outlook, driven by the strong year-to-date performance.
The Company cannot provide a reconciliation of forward-looking non-GAAP segment operating margin or adjusted EPS to the corresponding GAAP measure without unreasonable effort due to the uncertainty of timing and the magnitude of items such as acquisition and integration related costs, legal costs and other settlements. These items are inherently difficult to forecast and may result in a GAAP range that is too large and variable to be meaningful.
Conference Call Information
ABM will host its quarterly conference call for all interested parties on Tuesday, September 8, 2026, at 8:30 AM (ET). The live conference call can be accessed via audio webcast at the “Investors” section of the Company's website, located at www.abm.com, or by dialing (877) 451-6152 (domestic) or (201) 389-0879 (international) approximately 15 minutes prior to the scheduled time.
A supplemental presentation will accompany the webcast on the Company's website.
A replay will be available approximately three hours after the webcast through September 22, 2026, and can be accessed by dialing (844) 512-2921 and then entering ID #13761714. A replay link of the webcast will also be archived on the ABM website for 90 days.
About ABM
ABM (NYSE: ABM) is one of the world’s largest providers of integrated facility, engineering, and infrastructure solutions. Every day, our over 100,000 team members deliver essential services that make spaces cleaner, safer, and more efficient, enhancing the overall occupant experience.
ABM serves a wide range of market sectors including commercial real estate, aviation, mission critical, and manufacturing and distribution. With over $8 billion in annual revenue and a blue-chip client base, ABM delivers innovative technologies and sustainable solutions that enhance facilities and empower clients to achieve their goals. Committed to creating smarter, more connected spaces, ABM is investing in the future to meet evolving challenges and build a healthier, thriving world. ABM: Driving possibility, together.
For more information, visit www.abm.com
Cautionary Statement under the Private Securities Litigation Reform Act of 1995
This press release contains both historical and forward-looking statements about ABM Industries Incorporated (“ABM”) and its subsidiaries (collectively referred to as “ABM,” “we,” “us,” “our,” or the “Company”). We make forward-looking statements related to future expectations, estimates and projections that are uncertain, and often contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “may,” “outlook,” “plan,” “predict,” “should,” “target,” or other similar words or phrases. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions that are difficult to predict. For us, particular uncertainties that could cause our actual results to be materially different from those expressed in our forward-looking statements include: our success depends on our ability to gain profitable business despite competitive market pressures; our results of operations can be adversely affected by labor shortages, turnover, and labor cost increases; we may not be able to attract and retain qualified personnel and senior management we need to support our business; investments in and changes to our businesses, operating structure, or personnel relating to our strategic initiatives, including the implementation of strategic transformations, enhanced business processes, and technology initiatives may not have the desired effects on our financial condition and results of operations; our ability to preserve long-term client relationships is essential to our continued success; our use of subcontractors or joint venture partners to perform work under customer contracts exposes us to liability and financial risk; our international business involves risks different from those we face in the United States that could have an effect on our results of operations and financial condition; decreases in commercial office space utilization due to hybrid work models and increases in office vacancy rates could adversely affect our financial condition; negative changes in general economic conditions, such as recessionary pressures, high interest rates, durable and non-durable goods pricing, changes in energy prices, or changes in consumer goods pricing, could reduce the demand for services and, as a result, reduce our revenue and earnings and adversely affect our financial condition; we may experience breaches of, or disruptions to, our information technology systems or those of our third-party providers or clients, or other compromises of our data that could adversely affect our business; our ongoing implementation of new enterprise resource planning and related boundary systems could adversely impact our ability to operate our business and report our financial results; acquisitions, divestitures, and other strategic transactions could fail to achieve financial or strategic objectives, disrupt our ongoing business, and adversely impact our results of operations; we may not realize the growth opportunities and synergies that are anticipated from the WGNSTAR acquisition; we manage our insurable risks through a combination of third-party purchased policies and self-insurance, and we retain a substantial portion of the risk associated with expected losses under these programs, which exposes us to volatility associated with those risks, including the possibility that changes in estimates to our ultimate insurance loss reserves could result in material charges against our earnings; our risk management and safety programs may not have the intended effect of reducing our liability for personal injury or property loss; unfavorable developments in our class and representative actions and other lawsuits alleging various claims could cause us to incur substantial liabilities; we are subject to extensive legal and regulatory requirements, which could limit our profitability by increasing the costs of legal and regulatory compliance; a significant number of our employees are covered by collective bargaining agreements that could expose us to potential liabilities in relation to our participation in multiemployer pension plans, requirements to make contributions to other benefit plans, and the potential for strikes, work slowdowns or similar activities, and union organizing drives; our business may be materially affected by changes to fiscal and tax policies; negative or unexpected tax consequences could adversely affect our results of operations; future increases in the level of our borrowings and interest rates could affect our results of operations; impairment of goodwill and long-lived assets could have a material adverse effect on our financial condition and results of operations; if we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be negatively impacted, which could harm our operating results and investor perceptions of our Company and as a result may have a material adverse effect on the value of our common stock; our business may be negatively impacted by adverse weather conditions; catastrophic events, disasters, pandemics, and terrorist attacks could disrupt our services; and actions of activist investors could disrupt our business. For additional information on these and other risks and uncertainties we face, see ABM’s risk factors, as they may be amended from time to time, set forth in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent filings. We urge readers to consider these risks and uncertainties in evaluating our forward-looking statements.
Use of Non-GAAP Financial Information
To supplement ABM’s consolidated financial information, the Company has presented net income and net income per diluted share as adjusted for items impacting comparability for the third quarter and first nine months of fiscal years 2026 and 2025. These adjustments have been made with the intent of providing financial measures that give management and investors a better understanding of the underlying operational results and trends as well as ABM’s operational performance. In addition, the Company has presented earnings before interest, taxes, depreciation and amortization, and excluding items impacting comparability (adjusted EBITDA) for the third quarter and first nine months of fiscal years 2026 and 2025. Adjusted EBITDA is among the indicators management uses as a basis for planning and forecasting future periods. The Company also presents total segment operating profit, which is the sum of the segment operating profit of each of its segments, and total segment operating margin, defined as total segment operating profit divided by total revenue, because management believes they are useful as they represent the aggregate value of income/profit created by its segments and exclude items not directly related to the segments for performance evaluation purposes. The Company has also presented free cash flow, which is defined as net cash provided by (used in) operating activities less additions to property, plant and equipment. The presentation of these non-GAAP financial measures is not meant to be considered in isolation or as a substitute for financial statements prepared in accordance with accounting principles generally accepted in the United States of America. (See accompanying financial tables for supplemental financial data and corresponding reconciliations to certain GAAP financial measures.)
We round amounts to millions but calculate all percentages and per-share data from the underlying whole-dollar amounts. As a result, certain amounts may not foot, crossfoot, or recalculate based on reported numbers due to rounding. Unless otherwise noted, all references to years are to our fiscal year, which ends on October 31.
Contact: Investor Relations:Paul Goldberg (212) 297-9721 [email protected] ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESCONSOLIDATED INCOME STATEMENT INFORMATION (UNAUDITED)
Three Months Ended July 31, (in millions, except per share amounts) 2026 2025 Increase /
(Decrease)Revenues $2,317.1 $2,224.0 4.2%Operating expenses 2,031.0 1,949.6 4.2%Selling, general and administrative expenses 171.3 177.5 (3.5)%Restructuring and related expenses 7.8 — NM*Amortization of intangible assets 15.5 13.4 15.8%Operating profit 91.5 83.4 9.6%Income from unconsolidated affiliates 1.2 1.3 (2.1)%Interest expense (29.5) (25.3) (16.6)%Income before income taxes 63.2 59.4 6.4%Income tax provision (13.5) (17.6) 23.3%Net income $49.7 $41.8 18.9%Net income per common share Basic $0.84 $0.67 25.4%Diluted $0.84 $0.67 25.4%Weighted-average common and common equivalent shares outstanding Basic 58.9 62.5 Diluted 59.3 62.8 Dividends declared per common share $0.290 $0.265 *Not meaningful (due to variance greater than or equal to +/-100%)
ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESCONSOLIDATED INCOME STATEMENT INFORMATION (UNAUDITED)
Nine Months Ended July 31, (in millions, except per share amounts) 2026 2025 Increase /
(Decrease)Revenues $6,850.6 $6,450.5 6.2%Operating expenses 6,027.5 5,645.7 6.8%Selling, general and administrative expenses 512.2 521.7 (1.8)%Restructuring and related expenses 14.6 — NM*Amortization of intangible assets 43.4 39.9 8.8%Operating profit 253.0 243.3 4.0%Income from unconsolidated affiliates 3.6 3.4 7.2%Interest expense (81.6) (72.1) (13.2)%Income before income taxes 175.0 174.6 0.2%Income tax provision (43.5) (47.0) 7.5%Net income $131.6 $127.6 3.1%Net income per common share Basic $2.22 $2.04 8.8%Diluted $2.20 $2.03 8.4%Weighted-average common and common equivalent shares outstanding Basic 59.4 62.6 Diluted 59.7 63.0 Dividends declared per common share $0.870 $0.795 *Not meaningful (due to variance greater than or equal to +/-100%)
ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESSELECTED CONSOLIDATED CASH FLOW INFORMATION (UNAUDITED)
Three Months Ended July 31,(in millions) 2026 2025 Net cash provided by operating activities $146.8 $175.0 Additions to property, plant and equipment (18.4) (24.8)Purchase of businesses, net of cash acquired — (18.6)Other 0.9 0.1 Net cash used in investing activities $(17.4) $(43.3)Proceeds from issuance of share-based compensation awards, net 1.1 1.1 Repurchases of common stock, including excise taxes — (27.2)Dividends paid (17.0) (16.5)Deferred financing costs paid (1.4) — Borrowings from debt 656.5 490.5 Repayment of borrowings from debt (744.7) (512.0)Changes in book cash overdrafts (7.1) 3.1 Repayment of finance lease obligations (1.0) (1.1)Cash paid to settle the contingent consideration liability — (59.0)Net cash used in financing activities $(113.5) $(121.2)Effect of exchange rate changes on cash and cash equivalents (0.3) — ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESSELECTED CONSOLIDATED CASH FLOW INFORMATION (UNAUDITED)
Nine Months Ended July 31,(in millions) 2026 2025 Net cash provided by operating activities $275.0 $101.0 Additions to property, plant and equipment (75.4) (58.6)Purchase of businesses, net of cash acquired (242.1) (16.7)Other 1.6 0.5 Net cash used in investing activities $(315.8) $(74.8)Taxes withheld from issuance of share-based compensation awards, net (8.8) (8.5)Repurchases of common stock, including excise taxes (94.7) (48.5)Dividends paid (51.2) (49.4)Deferred financing costs paid (2.7) (8.0)Borrowings from debt 1,733.5 1,409.3 Repayment of borrowings from debt (1,523.9) (1,212.0)Changes in book cash overdrafts (2.4) (43.0)Repayment of finance lease obligations (3.3) (3.3)Cash paid to settle the contingent consideration liability — (59.0)Net cash provided by (used in) financing activities $46.4 $(22.5)Effect of exchange rate changes on cash and cash equivalents 0.9 1.0 ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEET INFORMATION (UNAUDITED)
(in millions) July 31, 2026 October 31, 2025ASSETS Current assets Cash and cash equivalents $110.5 $104.1Trade accounts receivable 1,478.8 1,471.1Costs incurred in excess of amounts billed 209.8 193.7Prepaid expenses 111.3 91.2Other current assets 82.0 78.6Total current assets 1,992.4 1,938.7Other investments 32.1 48.6Property, plant and equipment 211.9 177.2Right-of-use assets 91.8 95.1Other intangible assets, net of accumulated amortization 328.5 243.2Goodwill 2,741.2 2,591.1Other noncurrent assets 203.0 175.5Total assets $5,601.0 $5,269.5LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Current portion of long-term debt, net $41.8 $29.4Trade accounts payable 430.8 401.2Accrued compensation 190.5 195.0Accrued taxes—other than income 44.6 48.1Deferred Revenue 153.4 74.7Insurance claims 204.5 200.8Income taxes payable 3.8 4.0Current portion of lease liabilities 27.7 28.2Other accrued liabilities 304.7 324.1Total current liabilities 1,401.8 1,305.7Long-term debt, net 1,732.2 1,537.1Long-term lease liabilities 80.4 83.7Deferred income tax liability, net 69.0 39.9Noncurrent insurance claims 470.2 459.3Other noncurrent liabilities 53.1 54.3Noncurrent income taxes payable 4.1 3.9Total liabilities 3,810.8 3,483.8Total stockholders’ equity 1,790.2 1,785.6Total liabilities and stockholders’ equity $5,601.0 $5,269.5 ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESREVENUES AND OPERATING PROFIT BY SEGMENT (UNAUDITED)
Three Months Ended July 31, Increase/
(Decrease)
(in millions) 2026 2025 Revenues Business & Industry $1,012.2 $1,038.7 (2.6)%Manufacturing & Distribution 481.0 408.9 17.6%Aviation 328.1 291.8 12.5%Education 235.8 235.1 0.3%Technical Solutions 259.9 249.5 4.2%Total Revenues $2,317.1 $2,224.0 4.2%Operating profit Business & Industry $75.0 $73.8 1.5%Manufacturing & Distribution 40.5 36.4 11.4%Aviation 18.4 19.7 (6.9)%Education 23.0 21.1 8.7%Technical Solutions 21.5 19.4 10.8%Segment operating profit $178.3 $170.4 4.6%Segment operating margin 7.7% 7.7% Corporate (85.4) (85.7) 0.3%Adjustment for income from unconsolidated affiliates, included in Aviation and Technical Solutions (1.2) (1.3) 2.1%Adjustment for tax deductions for energy efficient government buildings, included in Technical Solutions (0.2) — NM*Total operating profit 91.5 83.4 9.6%Income from unconsolidated affiliates 1.2 1.3 (2.1)%Interest expense (29.5) (25.3) (16.6)%Income before income taxes 63.2 59.4 6.4%Income tax provision (13.5) (17.6) 23.3%Net income $49.7 $41.8 18.9% *Not meaningful (due to variance greater than or equal to +/-100%)
ABM INDUSTRIES INCORPORATED AND SUBSIDIARIESREVENUES AND OPERATING PROFIT BY SEGMENT (UNAUDITED)
Nine Months Ended July 31, Increase/
(Decrease)
(in millions) 2026 2025 Revenues Business & Industry $3,093.2 $3,077.2 0.5%Manufacturing & Distribution 1,367.1 1,201.2 13.8%Aviation 936.6 822.0 14.0%Education 696.7 688.2 1.2%Technical Solutions 757.0 662.0 14.4%Total Revenues $6,850.6 $6,450.5 6.2%Operating profit Business & Industry $231.3 $236.2 (2.1)%Manufacturing & Distribution 117.5 115.6 1.6%Aviation 47.3 48.4 (2.5)%Education 60.9 48.9 24.6%Technical Solutions 46.7 49.4 (5.4)%Segment operating profit $503.7 $498.6 1.0%Segment operating margin 7.4% 7.7% Corporate (246.3) (251.8) 2.2%Adjustment for income from unconsolidated affiliates, included in Aviation and Technical Solutions (3.6) (3.4) (7.2)%Adjustment for tax deductions for energy efficient government buildings, included in Technical Solutions (0.7) (0.1) NM*Total operating profit 253.0 243.3 4.0%Income from unconsolidated affiliates 3.6 3.4 7.2%Interest expense (81.6) (72.1) (13.2)%Income before income taxes 175.0 174.6 0.2%Income tax provision (43.5) (47.0) 7.5%Net income $131.6 $127.6 3.1% *Not meaningful (due to variance greater than or equal to +/-100%)
ABM INDUSTRIES INCORPORATED AND SUBSIDIARIES
RECONCILIATIONS OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)
(in millions, except per share amounts)
Three Months Ended July 31, Nine Months Ended July 31, 2026 2025 2026 2025 Reconciliation of Net Income to Adjusted Net Income Net income $49.7 $41.8 $131.6 $127.6 Items impacting comparability(a)(b) Restructuring and related(c) 7.8 — 14.6 — Legal costs and other settlements 1.4 (2.6) 1.1 2.5 Acquisition and integration related costs(d) 0.5 4.7 8.7 11.4 Transformation initiative costs(e) 6.3 11.1 20.5 30.1 Other(f) 0.3 0.7 1.0 2.9 Total items impacting comparability 16.3 13.8 46.0 46.8 Income tax impact (g)(h) (4.5) (3.9) (12.8) (13.3)Items impacting comparability, net of taxes 11.8 9.9 33.2 33.5 Adjusted net income $61.5 $51.7 $164.8 $161.1 Three Months Ended July 31, Nine Months Ended July 31, 2026 2025 2026 2025 Reconciliation of Net Income to Adjusted EBITDA Net Income $49.7 $41.8 $131.6 $127.6 Items impacting comparability 16.3 13.8 46.0 46.8 Income taxes provision 13.5 17.6 43.5 47.0 Interest expense 29.5 25.3 81.6 72.1 Depreciation and amortization 30.7 27.4 86.5 78.9 Adjusted EBITDA $139.6 $125.8 $389.2 $372.4 Net Income margin as a % of revenues 2.1% 1.9% 1.9% 2.0% Three Months Ended July 31,
Nine Months Ended July 31,
2026
2025
2026
2025
Reconciliation of Net Income per Diluted Share to Adjusted Net Income per Diluted Share Net income per diluted share $0.84 $0.67 $2.20 $2.03 Items impacting comparability, net of taxes 0.20 $0.16 0.56 0.53 Adjusted net income per diluted share $1.04 $0.82 $2.76 $2.56 Diluted shares 59.3 62.8 59.7 63.0 Three Months Ended July 31, Nine Months Ended July 31, 2026 2025 2026 2025 Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow Net cash provided by operating activities $146.8 $175.0 $275.0 $101.0 Additions to property, plant and equipment (18.4) (24.8) (75.4) (58.6)Free cash flow $128.4 $150.2 $199.6 $42.4 (a) The Company adjusts income to exclude the impact of certain items that are unusual, non-recurring, or otherwise do not reflect management's views of the underlying operational results and trends of the Company.
(b) After communications with the staff of the Securities and Exchange Commission, we have revised the definition of our non-GAAP financial measures, including adjusted net income, adjusted earnings per share, and adjusted EBITDA, to no longer exclude the positive or negative impact of “prior year self-insurance adjustments”. Prior year self-insurance adjustments reflect the net changes to our self-insurance reserves for our general liability, workers’ compensation, automobile, and health insurance programs, related to claims from incidents that occurred in previous years.
(c) Represents costs associated with restructuring program to further streamline our operations and improve the efficiency of our support functions.
(d) Represents acquisition and integration related costs associated with recent acquisitions.
(e) Represents discrete transformational costs that primarily consist of general and administrative costs for developing technological needs and alternatives, project management, testing, training and data conversion, consulting and professional fees for i) new enterprise resource planning system, ii) client facing technology, iii) workforce management tools and iv) data analytics. These costs are not expected to recur beyond the deployment of these initiatives.
(f) Nine months ended July 31, 2025 include a parking tax audit settlement related to prior years.
(g) The Company's tax impact is calculated using the federal and state statutory rate of 27.72% and 28.11% for FY2026 and FY2025, respectively. We calculate tax from the underlying whole-dollar amounts, as a result, certain amounts may not recalculate based on reported numbers due to rounding.
(h) The three and nine months ended July 31, 2025 include a $0.1 million charge related to ERC refunds received from IRS. The nine months ended July 31, 2025 include a $0.1 million benefit for uncertain tax positions with expiring statues.
Chewy zveřejní hospodářské výsledky za 2. čtvrtletí ve středu před otevřením trhu; analytici čekají EPS 36 centů a výnosy 3,32 miliardy USD. Akcie v pátek klesly o 1,3 % na 23,66 USD.
Chewy, Inc. (NYSE:CHWY) will release its second earnings report before the opening bell on Wednesday, Sept. 9.
Analysts expect the Plantation, Florida-based company to report quarterly earnings of 36 cents per share, up from 33 cents per share in the year-ago period. The consensus estimate for CHWY’s quarterly revenue is $3.32 billion. It reported $3.1 billion last year, according to Benzinga Pro.
On June 10, Chewy reported better-than-expected first-quarter results, but the online pet retailer lowered its fiscal 2026 sales outlook.
Chewy shares fell 1.3% to close at $23.66 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
RBC Capital analyst Steven Shemesh maintained an Outperform rating with a price target of $34 on Aug. 26, 2026. This analyst has an accuracy rate of 59%. Rosenblatt analyst Scott Devitt initiated coverage on the stock with a Neutral rating and a price target of $25 on Aug. 20, 2026. This analyst has an accuracy rate of 80%. UBS analyst Michael Lasser maintained a Neutral rating and cut the price target from $32 to $24 on June 11, 2026. This analyst has an accuracy rate of 78%. JP Morgan analyst Doug Anmuth maintained an Overweight rating and slashed the price target from $35 to $29 on June 11, 2026. This analyst has an accuracy rate of 84%. Citizens analyst Andrew Boone maintained a Market Outperform rating and cut the price target from $45 to $28 on June 11, 2026. This analyst has an accuracy rate of 72%. Trending
Considering buying CHWY stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Public Employees Retirement System of Ohio ve 2. čtvrtletí koupil nový podíl ve Wingstop, 7 840 akcií za zhruba 1,36 mil. USD. Wingstop zároveň oznámil meziroční růst tržeb za čtvrtletí o 6,5 %.
Public Employees Retirement System of Ohio purchased a new stake in Wingstop Inc. (NASDAQ:WING – Free Report) during the second quarter, according to its most recent filing with the SEC. The fund purchased 7,840 shares of the restaurant operator’s stock, valued at approximately $1,360,000.
Other hedge funds have also bought and sold shares of the company. Vident Advisory LLC increased its holdings in Wingstop by 3.9% in the 4th quarter. Vident Advisory LLC now owns 959 shares of the restaurant operator’s stock worth $229,000 after acquiring an additional 36 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in Wingstop by 1.7% during the fourth quarter. Quadrant Capital Group LLC now owns 2,628 shares of the restaurant operator’s stock valued at $627,000 after purchasing an additional 45 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Wingstop by 1.1% during the first quarter. Oregon Public Employees Retirement Fund now owns 5,672 shares of the restaurant operator’s stock valued at $879,000 after purchasing an additional 59 shares in the last quarter. SBI Securities Co. Ltd. grew its position in shares of Wingstop by 76.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 138 shares of the restaurant operator’s stock valued at $33,000 after purchasing an additional 60 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al grew its position in shares of Wingstop by 1.5% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 4,784 shares of the restaurant operator’s stock valued at $1,141,000 after purchasing an additional 70 shares during the period.
Wingstop Price Performance WING stock opened at $109.21 on Tuesday. Wingstop Inc. has a 1 year low of $105.43 and a 1 year high of $313.56. The firm has a market capitalization of $2.97 billion, a PE ratio of 25.94, a price-to-earnings-growth ratio of 1.30 and a beta of 1.79. The business has a 50 day simple moving average of $132.06 and a 200-day simple moving average of $160.34.
Wingstop (NASDAQ:WING – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The restaurant operator reported $1.18 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.16. The firm had revenue of $185.56 million for the quarter, compared to the consensus estimate of $190.25 million. Wingstop had a negative return on equity of 16.31% and a net margin of 16.15%.The firm’s revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.00 earnings per share. On average, equities research analysts expect that Wingstop Inc. will post 4.5 EPS for the current year. Wingstop Increases Dividend The business also recently declared a quarterly dividend, which was paid on Saturday, September 5th. Stockholders of record on Saturday, August 15th were issued a dividend of $0.33 per share. The ex-dividend date was Friday, August 14th. This represents a $1.32 annualized dividend and a dividend yield of 1.2%. This is a boost from Wingstop’s previous quarterly dividend of $0.30. Wingstop’s payout ratio is presently 31.35%.
Analyst Ratings Changes A number of analysts have recently commented on WING shares. Citigroup cut their target price on shares of Wingstop from $237.00 to $208.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Piper Sandler set a $173.00 price objective on Wingstop in a report on Wednesday, July 29th. Wells Fargo & Company cut their price objective on Wingstop from $170.00 to $165.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Royal Bank Of Canada reduced their target price on Wingstop from $225.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Finally, BTIG Research decreased their target price on Wingstop from $305.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.81.
View Our Latest Analysis on WING
About Wingstop (Free Report)
Wingstop Inc (NASDAQ: WING) is a fast-casual restaurant chain specializing in chicken wings and related menu items. Founded in 1994 in Garland, Texas, the company has built its brand around bold, chef-inspired wing flavors and a streamlined service model that caters to dine-in, takeout, delivery and catering orders.
The company’s core offerings include both bone-in and boneless chicken wings tossed in a variety of proprietary rubs and sauces, such as Original Hot, Lemon Pepper, and Mango Habanero.
See Also Five stocks we like better than Wingstop 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding WING? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wingstop Inc. (NASDAQ:WING – Free Report).
Receive News & Ratings for Wingstop Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wingstop and related companies with MarketBeat.com's FREE daily email newsletter.
Starteepo vyzvala Xerox ke strategickému přezkumu finanční divize XFS, kterou oceňuje na 1,3–1,5 miliardy USD. Akcie Xeroxu v premarketu rostou až o 8 %.
Společnost Starteepo, vedená českým investorem Františkem Bostlem, vyzvala společnost Xerox, v níž navýšila svůj podíl na 7,34 procenta včetně opcí, k přijetí kroků, které by odemkly hodnotu pro akcionáře. Zároveň požaduje strategické přezkoumání podnikání Xeroxu v oblasti finančních služeb. Akcie Xeroxu reagují v premarketu růstem až o osm procent.
Pražská investiční společnost je aktuálně se zmíněným podílem 7,34 procenta včetně opcí po firmách Blackrock a Vanguard třetím největším akcionářem Xeroxu. V otevřeném dopise firmu vyzývá ke snížení zadlužení rozvahy a k disciplinovanějšímu nakládání s kapitálem.
„Starteepo oceňuje pokrok současného managementu při integraci Lexmarku, zvyšování ziskovosti a snižování zadlužení. Za další významnou příležitost považuje Xerox Financial Services (XFS), finanční divizi zajišťující financování zařízení zákazníkům. Podle analýzy Starteepo by XFS mohla mít hodnotu 1,3–1,5 miliardy dolarů, tedy přibližně 7,69 USD na akcii Xeroxu. Fond proto navrhuje zvýšit transparentnost výsledků XFS a zahájit strategické posouzení možností jejího dalšího rozvoje, včetně zapojení externího kapitálu, joint venture, částečné monetizace či případného prodeje,“ uvádí Bostlova společnost v tiskové zprávě.
Zmíněná hodnota XFS podle Starteepo – 7,69 USD na akcii – značí více než dvojnásobek ceny akcií celé společnosti, které v pátek na newyorské burze uzavřely na ceně 3,32 USD.
Xerox vyrábí tiskárny, skenery, spotřební materiál a příslušenství. Akcie firmy za posledních 12 měsíců ztratily přibližně 13 procent, což tržní hodnotu dostalo na úroveň kolem 418 milionů dolarů, píše agentura Bloomberg.
Starteepo také uvedla, že divize XFS by měla zvážit takzvanou optimalizovanou kapitálovou strukturu, v níž by financování portfolia poskytovala třetí strana, zatímco Xerox by si ponechal správu služeb a vztahy se zákazníky. Starteepo poukázalo na to, že podobné modely financování využívají například společnosti HP, Siemens nebo General Electric.
„Domníváme se, že pokračující snižování zadlužení, větší transparentnost divize XFS a vybudování kapitálově nenáročné platformy společně povedou k růstu hodnoty vlastního kapitálu společnosti. V konečném důsledku vidíme méně zadlužený a nově přeceněný Xerox jako firmu, která bude lépe schopna podílet se na konsolidaci odvětví a dosahovat prémiového ocenění. Jsme přesvědčeni, že po úspěšném snížení zadlužení rozvahy a následném přecenění společnosti by Xerox mohl být pro potenciální zájemce o převzetí v budoucnu oceněn až na 3,3 mld. USD hodnoty vlastního kapitálu, což představuje více než 18 USD na akcii, pokud by se společnost rozhodla dále zvažovat další strategické alternativy,“ stojí dále v dopise Starteepo.
Group 1 Automotive plánuje nabídnout seniorní nezajištěné dluhopisy za 625,0 milionu USD splatné v roce 2032 a 625,0 milionu USD splatné v roce 2035, aby financovala akvizici aktiv dealerství Hennessy Automobile Companies. Pokud transakce neproběhne, část dluhopisů splatných v roce 2032 bude muset být splacena za 100 % emisní ceny.
, /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), a Fortune 250 automotive retailer with 249 dealerships located in the U.S. and U.K, today announced that, subject to market conditions, it intends to offer for sale $625.0 million in aggregate principal amount of senior unsecured notes due 2032 (the "2032 Notes") and $625.0 million in aggregate principal amount of senior unsecured notes due 2035 (the "2035 Notes" and, together with the 2032 Notes, the "Notes").
The Company intends to use the net proceeds of the offering, together with cash on hand, to fund the purchase price for its previously announced acquisition of certain dealership assets and related real estate from Hennessy Automobile Companies, Inc. and certain of its affiliates (the "Hennessy Acquisition") and to pay related fees and expenses. Because the closing of the Hennessy Acquisition is expected to occur after the closing of the offering, the Company intends to use the net proceeds, pending the closing of the Hennessy Acquisition, to repay a portion of the outstanding borrowings under the acquisition line under its revolving credit facility, which the Company expects to reborrow at the closing of the Hennessy Acquisition to fund a portion of the purchase price.
If the Hennessy Acquisition is not consummated on or prior to the later of (x) January 6, 2027 (the "Outside Date") and (y) such date to which the Outside Date under the purchase agreement relating to the Hennessy Acquisition may be extended in accordance with the terms thereof (such later date, the "Special Mandatory Redemption Outside Date"), or upon the occurrence of certain other events, including the termination of the purchase agreement related to the Hennessy Acquisition prior to the Special Mandatory Redemption Outside Date, the Company will be required to redeem all of the 2032 Notes then outstanding at a redemption price equal to 100% of the initial issue price thereof, plus accrued and unpaid interest, if any, from the issue date, to, but excluding, the redemption date (the "Special Mandatory Redemption"). In that case, the Company intends to use the net proceeds of the offering that are not used to fund the Special Mandatory Redemption to repay borrowings under the Company's revolving credit facility and for general corporate purposes.
The Notes to be offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and thus, the Notes may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Notes are being offered to persons reasonably believed to be qualified institutional buyers in an offering exempt from registration pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside of the United States in compliance with Regulation S under the Securities Act. This announcement shall not constitute an offer to sell or a solicitation of an offer to buy any of these Notes or any security, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.
ABOUT GROUP 1 AUTOMOTIVE, INC.
Group 1 owns and operates 249 automotive dealerships, 310 franchises, and 32 collision centers in the United States and the United Kingdom that offer 37 brands of automobiles. Through its dealerships and omni-channel platform, the Company sells new and used cars and light trucks; arranges related vehicle financing; sells service contracts; provides automotive maintenance and repair services; and sells vehicle parts.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which are statements related to future, not past, events and are based on our current expectations and assumptions regarding our business, the economy and other future conditions. In this context, the forward-looking statements include statements regarding the proposed offering, the intended use of proceeds and the pending Hennessy Acquisition. These forward-looking statements often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "should," "foresee," "may" or "will" and similar expressions. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting us will be those that we anticipate. Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause actual results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the impacts of sustained levels of inflation, including reduced affordability of automobiles for consumers, (c) developments in U.S. and global trade policy, including the imposition by the U.S. of significant tariffs on the import of automobiles and certain materials used in our parts and services business and the resulting consequences (including, but not limited to, retaliatory tariffs by non-U.S. nations, supply chain disruptions, vehicle and part cost increases and demand decreases, and potential recessions in the U.S. and U.K.) and the passage of the "One Big Beautiful Bill," including the associated impact on tax deductions in the domestic car industry and the elimination of certain clean energy tax credits, which could impact incentives for electric vehicle production and sales, (d) the level of manufacturer incentives, (e) our ability to comply with extensive laws, regulations and policies applicable to our operations, including BEV mandates in the U.K., and their impact on new vehicle demand, (f) our ability to obtain an inventory of desirable new and used vehicles (including as a result of changes in the international trade environment), (g) our relationship with our automobile manufacturers and the willingness of manufacturers to approve future acquisitions, (h) our cost of financing and the availability of credit for consumers, (i) our ability to complete acquisitions and dispositions, including the pending Hennessy Acquisition, on a timely basis, if at all and the risks associated therewith, (j) our ability to successfully integrate recent and future acquisitions, including the Hennessy Acquisition, and realize the expected benefits from consummated acquisitions, (k) foreign exchange controls and currency fluctuations, (l) the armed conflicts in Ukraine and the Middle East, including that between the U.S. and Iran, (m) broader macroeconomic challenges in the U.K., including inflationary pressures, fluctuations in interest and foreign exchange rates and overall economic volatility, which could further impact vehicle affordability, demand and our financial performance in that market, (n) our ability to maintain sufficient liquidity to operate, and (o) a material failure in or breach of our vendors' information technology systems and other cybersecurity incidents. For additional information regarding known material factors that could cause our actual results to differ from our projected results, please see our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.
Investor contacts:
David Helderman
Senior Manager, Investor Relations
Group 1 Automotive, Inc.
[email protected]
Media contacts:
Pete DeLongchamps
Senior Vice President, Manufacturer Relations, Financial Services and Corporate Development
Group 1 Automotive, Inc.
[email protected]
Kimberly Barta
Head of Advertising, Brand and Communications
Group 1 Automotive, Inc.
[email protected]
GE Aerospace kupuje Consolidated Precision Products za 11,75 mld. USD, aby rozšířila svou výrobu klíčových komponentů pro letecké motory. Dokončení transakce se očekává ve druhém pololetí 2027 po schválení regulačními orgány.
Americký výrobce leteckých motorů GE Aerospace oznámil akvizici Consolidated Precision Products (CPP) od Warburg Pincus a Berkshire Partners za 11,75 mld. USD. GE Aerospace je zákazníkem CPP již více než 15 let. Dokončení transakce se očekává ve druhém pololetí roku 2027 a podléhá schválení regulatorními orgány.
Podle generálního ředitele GE Aerospace H. L. Culpa Jr. jsou investice do výrobních kapacit potřebné pro to, aby společnost dokázala uspokojit současnou silnou poptávku v oblasti motorů pro komerční letectví i v oblasti obranného průmyslu.
Podle prohlášení společnosti bude akvizice financována částkou 7 mld. USD v hotovosti, přičemž zbývající část pokryje nový dluh. Transakce oceňuje CPP přibližně na 18násobek EBITDA očekávaného v roce 2027 po započtení předpokládaných čistých synergií. Bez jejich započtení odpovídá ocenění přibližně 26násobku EBITDA.
Vývoj akcie Akcie General Electric Aerospace (GE) v předburzovní fázi obchodování posilují o 0,43 % na 338,56 USD.
Archer Aviation v srpnu vzrostla o 24,6 % po zprávě o dohodě na koupi tří dceřiných firem Boeingu. Insitu už je zisková a roční tržby dosahují zhruba 200 milionů USD.
Archer Aviation (ACHR -0.87%) stock had a big month in August. The company's share price gained 24.6% across the stretch, according to data from S&P Global Market Intelligence. The S&P 500 gained 2.6% in the month, and the Nasdaq Composite rose 3.9%.
In addition to the bullish backdrop for the broader market, Acher's valuation got a big boost following news that the company had entered into a deal to purchase three subsidiaries from Boeing. Despite the big pop, Archer stock is still down roughly 24% year to date.
Image source: Getty Images.
Archer stock surged on Boeing deal news On Aug. 10, Archer Aviation published a press release announcing that it had entered into an agreement to purchase Boeing's Wisk Aero, SkyGrid, and Insitu subsidiaries.
Wisk is a longtime player in the eVTOL space and has logged more than 1,700 test flights. SkyGrid provides air-traffic management solutions and develops autonomous flight technologies. Insitu is a designer and manufacturer of drones and also provides related software and services. In exchange for these three businesses, Boeing will receive a large stake in Archer. The deal will be facilitated with the creation of newly created stock, and Boeing will own a 16.5% stake in Archer following the completion of the transaction.
Notably, the press release states that Insitu is already profitable and generating roughly $200 million in annual sales -- so the integration of the unit should immediately have a big impact on Archer's sales profile and an accretive impact on margins.
Premium Feature
Moneyball Superscore
59/100
Today's Change
(
-0.87
%) $
-0.05
Current Price
$
5.71
What's next for Archer? Archer stock has seen a modest pullback early in September's trading. The company's share price is down roughly 1.2% in the month amid some volatility for the broader market connected to concerns about inflation and the bond market.
With Archer using newly issued shares to fund its acquisitions from Boeing, investors are looking at a high level of stock dilution on the horizon. On the other hand, the deal still appears to be a promising development for long-term Archer shareholders. Boeing is a great partner to have in the aerospace and defense industry, and the deal creates opportunities along multiple lines.
Along with providing Archer with three new units that create sales and earnings opportunities, Wisk, SkyGrid, and Insitu will likely have meaningful synergies with the company's eVTOL and VTOL projects and autonomous aviation capabilities. The acquired businesses will also likely provide valuable data for the company's AI-powered ZEE foundation model for aviation, autonomous navigation, and related applications.
Archer is a volatile stock and could face outsized pressures if the market becomes more risk-averse in response to macroeconomic pressures, but the deal with Boeing has seemingly made the company stronger and given it more ways to grow.
Celtic Bank si vybrala Jack Henry pro modernizaci jádrového systému a integrace s fintechy, aby zlepšila digitální bankovnictví, provozní efektivitu a škálování při růstu.
Jack Henry will accelerate the bank's fintech integration capabilities and help the bank scale for growth. This leading small business lender will be able to improve the loan financing experience for customers nationwide. Celtic Bank will utilize Jack Henry core processing along with numerous other tech solutions. , /PRNewswire/ -- Jack Henry® (Nasdaq: JKHY) announced today that Celtic Bank has selected Jack Henry to support its progressive technology strategy, allowing the bank to choose the right tools to grow its business lines while improving user experience, efficiency, and scale.
Salt Lake City-based Celtic Bank is focused on technology-enabled banking, helping businesses across all 50 states grow through financing and banking-as-a-service (BaaS) capabilities. With $5 billion in assets, the bank is consistently ranked among the nation's leading SBA lenders.
The bank selected Jack Henry's modern core processing platform, along with a suite of technology solutions. Banno Business™ will provide a modern digital banking experience for small business and commercial clients, while Enterprise Workflow will automate operational workflows and approvals, improving efficiency across the organization. Additionally, Jack Henry's open ecosystem offers the flexibility to choose from more than 1,000 third-party technology integrations.
"We were looking for more than core technology; we wanted a long-term technology strategy," said Jake Barney, Chief Financial Officer at Celtic Bank. "As our business continues to grow, we needed a technology provider that could deliver modern customer experiences, improve operational efficiency, and enable a variety of open integrations for our BaaS business. We found all these qualities in Jack Henry."
Jack Henry's strategy of delivering modern service components in the public cloud was also a key factor in Celtic Bank's decision. "We believe the core should enable innovation, not define it," Barney added. "Jack Henry's decoupled approach gives us the flexibility to choose the solutions that best fit our business, while providing a realistic path to modernization and the public cloud. It gives us the freedom to evolve our technology on our own terms as our business continues to grow."
"Celtic Bank has built an impressive business by taking a differentiated approach to business banking," said Jonathan Baltzell, President of Bank Solutions at Jack Henry. "Their strategy requires technology that's flexible enough to adapt to a diverse set of business lines while continuing to evolve with changing customer expectations. We're proud to help bring that vision to life."
About Jack Henry & Associates, Inc. ®
Jack Henry® (Nasdaq: JKHY) is a well-rounded financial technology company that strengthens connections between financial institutions and the people and businesses they serve. We are an S&P 500 company that prioritizes openness, collaboration, and user centricity – offering banks and credit unions a vibrant ecosystem of internally developed modern capabilities as well as the ability to integrate with leading fintechs. For 50 years, Jack Henry has provided technology solutions to enable clients to innovate faster, strategically differentiate, and successfully compete while serving the evolving needs of their accountholders. We empower more than 7,200 clients with people-inspired innovation, personal service, and insight-driven solutions that help reduce the barriers to financial health. Additional information is available at www.jackhenry.com.
Andrew Guggenhime prodal 2 705 akcií Vaxcyte kvůli daňovým odvodům po vestingu RSU. Firma měla na konci června 2,51 miliardy USD v hotovosti a investicích, ale za půl roku vykázala ztrátu 604,9 milionu USD.
President and CFO Andrew Guggenhime reported the disposition of 2,705 shares of Vaxcyte, Inc. (PCVX -0.02%), according to a recent SEC Form 4 filing.
Transaction summaryMetricValueTransaction value~$165,492Shares sold (directly held)2,705Post-transaction shares (total)164,321Post-transaction shares (directly held)102,471Post-transaction shares (indirectly held)61,850Post-transaction value$10.12 millionTransaction value based on SEC Form 4 weighted average sale price ($61.18); post-transaction value based on the September 2 market close ($61.58).
Key questionsWhat was the specific nature of this disposition?
The transaction involved 2,705 shares that were surrendered directly to the company to satisfy tax withholding obligations. This occurred automatically upon the vesting of restricted stock units and was not a discretionary open-market sale.How is the insider's total equity structured?
Guggenhime retains about 164,000 shares of Vaxcyte, consisting of 102,000 shares held directly and 61,850 shares held indirectly via ALG 2025 Grat Holdings LLC. The total position was valued at $10.12 million based on the September 2 market close.What is the recent performance context for the security?
Vaxcyte shares have seen a 95% return over the one-year period ending September 2. This performance context coincides with the ongoing clinical development of the company's experimental vaccine candidates, including VAX-24.Company OverviewMetricValueShare Price (as of market close 2026-09-01)$60.81Market Capitalization$9.0 billionNet Income (TTM)-$1.1 billionOne Year Share Price Change+95%Company SnapshotVaxcyte is a clinical-stage biotechnology company focused on developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine currently in clinical trials.The company operates a development-stage business model centered on advancing proprietary vaccine candidates through clinical trials with the objective of eventual commercialization and licensing partnerships with established pharmaceutical entities.Vaxcyte's primary target markets include healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly in immunocompromised and elderly populations.Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention. The company's strategic approach leverages advanced conjugate vaccine technology to create multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector.
What this transaction means for investorsGuggenhime handed 2,705 shares back to Vaxcyte to settle taxes on vested restricted stock, roughly 1.6% of the 164,000 shares he holds directly and through a family entity. More importantly, he carries the president and CFO titles at a company with no revenue, which makes the financing question his to answer.
On that front, Vaxcyte held $2.51 billion in cash and investments at the end of June, up slightly from $2.44 billion at the end of last year, and Guggenhime said in the August 5 release that the balance sheet leaves the company "well positioned to execute" on clinical, manufacturing and commercial-readiness milestones, as spending climbs to meet those milestones. Operating expenses reached $302.8 million in the second quarter against $226.2 million a year earlier, and the six-month net loss came to $604.9 million.
Some of that spending funds manufacturing for a commercial launch that requires trial data Vaxcyte doesn't have yet, but good results potentially coming in the fourth quarter make the buildout look prescient. Anything short of that leaves the company having pre-paid for a product it can't yet sell, with more readouts to get through before it can even file.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) will release its second earnings report before the opening bell on Wednesday, Sept. 9.
Analysts expect the Katy, Texas-based company to report quarterly earnings of $2.08 per share, up from $1.94 per share in the year-ago period. The consensus estimate for ASO’s quarterly revenue is $1.65 billion. It reported $1.60 billion last year, according to Benzinga Pro.
On Sept. 3, Academy Sports + Outdoors announced the appointment of Matthew (Matt) M. Pasch to the role of executive vice president and chief people officer.
Academy Sports shares gained 2.9% to close at $44.94 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Evercore ISI Group analyst Greg Melich maintained an In-Line rating and cut the price target from $60 to $55 on July 27, 2026. This analyst has an accuracy rate of 72%. Barclays analyst Adrienne Yih maintained an Equal-Weight rating and lowered the price target from $55 to $50 on June 11, 2026. This analyst has an accuracy rate of 65%. Goldman Sachs analyst Kate McShane maintained a Buy rating and cut the price target from $67 to $60 on June 10, 2026. This analyst has an accuracy rate of 69%. UBS analyst Michael Lasser maintained a Neutral rating and lowered the price target from $56 to $55 on June 10, 2026. This analyst has an accuracy rate of 78%. JP Morgan analyst Christopher Horvers maintained a Neutral rating and cut the price target from $60 to $59 on June 10, 2026. This analyst has an accuracy rate of 69%. Trending
Considering buying ASO stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Penzijní systém Public Employees Retirement System of Ohio ve 2. čtvrtletí koupil nový podíl v H&R Block za zhruba 1,46 mil. USD. H&R Block zároveň vykázala EPS 2,38 USD, nad odhady 2,21 USD o 0,17 USD.
Public Employees Retirement System of Ohio bought a new stake in shares of H&R Block, Inc. (NYSE:HRB – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 38,343 shares of the company’s stock, valued at approximately $1,460,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in HRB. Elevation Wealth Partners LLC lifted its stake in shares of H&R Block by 34.5% during the second quarter. Elevation Wealth Partners LLC now owns 1,040 shares of the company’s stock valued at $40,000 after acquiring an additional 267 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in H&R Block by 1.4% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 22,496 shares of the company’s stock worth $980,000 after purchasing an additional 309 shares during the period. Vise Technologies Inc. increased its position in H&R Block by 7.4% in the third quarter. Vise Technologies Inc. now owns 4,486 shares of the company’s stock worth $227,000 after purchasing an additional 311 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in H&R Block by 54.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 895 shares of the company’s stock worth $34,000 after purchasing an additional 314 shares during the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in H&R Block by 10.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,835 shares of the company’s stock valued at $194,000 after purchasing an additional 348 shares during the period. 90.14% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets Several research analysts have recently issued reports on the stock. Weiss Ratings raised shares of H&R Block from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Zacks Research downgraded shares of H&R Block from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 27th. Stephens assumed coverage on shares of H&R Block in a report on Tuesday, July 28th. They issued an “equal weight” rating and a $47.00 price objective on the stock. The Goldman Sachs Group raised their price objective on shares of H&R Block from $29.00 to $33.00 and gave the company a “sell” rating in a research note on Wednesday, August 12th. Finally, Barrington Research lifted their target price on shares of H&R Block from $50.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, H&R Block presently has a consensus rating of “Hold” and a consensus target price of $46.67.
Check Out Our Latest Research Report on H&R Block H&R Block Price Performance Shares of HRB opened at $48.93 on Tuesday. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 12.69. H&R Block, Inc. has a 1 year low of $28.16 and a 1 year high of $58.67. The stock has a market cap of $6.20 billion, a P/E ratio of 8.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. The stock’s 50-day moving average price is $45.93 and its two-hundred day moving average price is $37.96.
H&R Block (NYSE:HRB – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported $2.38 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.17. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. H&R Block had a negative return on equity of 214.84% and a net margin of 18.59%.H&R Block’s revenue was up 255.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.27 EPS. H&R Block has set its FY 2027 guidance at 6.040-6.240 EPS. On average, equities analysts predict that H&R Block, Inc. will post 6.11 earnings per share for the current year.
H&R Block Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 6th. Shareholders of record on Thursday, September 3rd will be paid a $0.46 dividend. The ex-dividend date of this dividend is Thursday, September 3rd. This is a boost from H&R Block’s previous quarterly dividend of $0.42. This represents a $1.84 annualized dividend and a yield of 3.8%. H&R Block’s payout ratio is currently 32.17%.
H&R Block Profile (Free Report)
H&R Block (NYSE: HRB) is a leading provider of tax preparation services and software solutions, serving individual and small-business clients through a combination of retail offices, online platforms and mobile applications. The company offers assisted tax preparation at its network of retail offices, where clients work with trained tax professionals, as well as do-it-yourself (DIY) software and online filing services designed to guide users through the complexities of federal and state tax returns.
Founded in 1955 by brothers Henry W.
Featured Articles Five stocks we like better than H&R Block 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for H&R Block Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H&R Block and related companies with MarketBeat.com's FREE daily email newsletter.
Editas Medicine jmenovala Dana Oryho do funkce hlavního lékařského ředitele. Má vést klinický vývoj, zatímco firma posouvá EDIT-401 do klinického testování.
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development
CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today.
With more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines, Dr. Ory will oversee the company's clinical development strategy and operations as Editas advances EDIT-401, its lead in vivo development candidate for the potential treatment of hyperlipidemia, toward the clinic, while supporting the progression of the company's broader pipeline.
Prior to joining Editas, Dr. Ory served as Chief Medical Officer at Arbor Biotechnologies, where he oversaw the global clinical trial for the company's lead in vivo gene editing program. Previously, he served as Chief Medical Officer at Casma Therapeutics, leading clinical development programs focused on rare genetic and neurodegenerative diseases. Before joining industry, Dr. Ory spent more than two decades at Washington University School of Medicine in St. Louis, where he served as the Alan A. and Edith L. Wolff Professor of Cardiology and conducted research in cholesterol metabolism and Niemann-Pick disease type C (NPC), helping advance the understanding of cholesterol homeostasis and its role in cardiovascular disease.
“Dan joins Editas at an exciting time as EDIT-401 nears clinical development for the potential treatment of hyperlipidemia, and as we continue advancing our leadership in in vivo gene editing,” said Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. “He brings deep expertise in cardiovascular medicine and the development of genetic medicines, together with a proven track record of advancing innovative therapies from scientific discovery through clinical development. His expertise in cardiovascular disease and cholesterol metabolism, combined with his experience leading clinical development for innovative genetic medicine programs, including in vivo gene editing, will strengthen our ability to execute our clinical strategy and advance our mission of developing transformative in vivo gene editing medicines for patients.”
“I am excited to join Editas as the company advances EDIT-401 toward the clinic,” said Dr. Ory. “The opportunity to apply in vivo gene editing to cardiovascular disease, an area where significant unmet need remains, represents an exciting new frontier in medicine. EDIT-401 has the potential to redefine the treatment paradigm as a best-in-class therapeutic for hyperlipidemia through a one-time gene editing approach, and I have been impressed by the strength of the science and the talented team behind it. I look forward to working alongside my colleagues to advance EDIT-401 into the clinic, progress the broader pipeline, and work to ultimately deliver transformative medicines for patients living with serious diseases.”
About Dan Ory, M.D.
Dr. Ory, M.D., is an accomplished biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine.
Most recently, Dr. Ory served as Chief Medical Officer at Arbor Biotechnologies, where he led the company's clinical development strategy and advancement of its next-generation gene editing pipeline. Previously, he served as Chief Medical Officer at Casma Therapeutics, where he oversaw clinical development programs focused on rare genetic and neurodegenerative diseases.
Before transitioning to industry, Dr. Ory was the Alan A. and Edith L. Wolff Professor of Cardiology at Washington University School of Medicine in St. Louis, where his laboratory made significant contributions to the understanding of cholesterol metabolism and advanced the field of Niemann-Pick disease type C (NPC), a rare neurodegenerative cholesterol storage disorder. He also led multiple clinical trials in NPC disease and was scientific co-founder of Vtesse Therapeutics, a rare disease company. Clinically, Dr. Ory’s practice was focused on preventive and diagnostic cardiology, specializing in cardiovascular risk assessment and the application of stress echocardiography and nuclear perfusion imaging to guide the evaluation and management of patients at risk for coronary artery disease.
During his academic career, he authored more than 160 peer-reviewed publications and is an inventor on numerous patents related to cardiovascular and rare disease research. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) and is a member of both the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP).
Dr. Ory received an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed postdoctoral training at the Whitehead Institute at MIT, an internal medicine residency at Brigham and Women's Hospital, and a fellowship in cardiology at Massachusetts General Hospital.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated on the expected timelines or at all; and uncertainties as to whether the Company’s cash resources are sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements for the period anticipated. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
Structure Therapeutics oznámila pozitivní klinická data ze svých perorálních programů ACCG-2671 a aleniglipron pro léčbu obezity. Aleniglipron dosáhl až 16,2% průměrného snížení hmotnosti za 72 týdnů, ACCG-2671 ukázal až 3,3% pokles po jedné dávce.
ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial
First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027
Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial
ACCOMPLISH-1 and ACCOMPLISH-2 registrational Phase 3 clinical trials for aleniglipron enrollment ongoing; topline data expected in 2H 2028
Company to host conference call today at 8:30 a.m. ET
SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today reported positive clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), and aleniglipron, an oral, non-peptide, small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
Structure announced positive topline data for ACCG-2671 in a Phase 1/2a single ascending dose (SAD) trial in healthy participants without obesity. In the SAD trial, ACCG-2671 demonstrated a long half-life of approximately 6 days supporting potential once-weekly dosing, with no serious adverse events (SAEs) or events of liver enzyme elevations. Exploratory findings showed pharmacodynamic (PD) activity and evidence of target engagement, including a 3.3% mean reduction in body weight following a single dose, as well as an encouraging decrease in CTX-1, a biomarker of bone resorption relevant to bone health. Based on these encouraging findings, the Company has initiated the multiple ascending dose (MAD) portion of the Phase 1/2a clinical trial with topline data expected in the first half of 2027.
Structure also reported positive 72-week results for aleniglipron in the ACCESS open-label extension (OLE) clinical trial. Participants receiving the 180 mg dose of aleniglipron achieved up to 16.2% body weight loss at 72 weeks, with no evidence of a plateau in weight loss. Compared with ACCESS participants who previously initiated dosing with a 5 mg starting dose, placebo participants who crossed over to aleniglipron in the OLE started with a lower 2.5 mg dose and demonstrated improved tolerability. Across all dose groups, fewer than 5% of participants discontinued treatment due to adverse events, and no off-target safety signals were observed. These results reinforce aleniglipron’s previously observed clinical profile, with consistent, potentially best-in-class weight loss and favorable tolerability, further supporting the ongoing Phase 3 ACCOMPLISH program which initiated in August 2026.
“ACCG-2671 represents the first reported clinical data for an oral small molecule amylin receptor agonist, and we believe its initial observed clinical profile is quite unique,” said Raymond Stevens, Ph.D., Chief Executive Officer of Structure Therapeutics. “In addition, the 72-week OLE results demonstrate aleniglipron’s exceptional consistency and potential for a best-in-class oral small molecule weight loss profile, particularly when considering a short exposure period at the top dose in our dose range finding study. The Phase 3 clinical trial now underway puts Structure in a very strong position to be highly competitive. There remains a clear need for oral therapies that have the potential to combine greater convenience with scalable and cost-effective manufacturing, broaden access and choices for the large and diverse worldwide population living with obesity.”
Blai Coll, M.D., Ph.D., Chief Medical Officer of Structure Therapeutics, added, “The early results of ACCG-2671 represent an innovative step in targeting the amylin mechanism. In the SAD clinical trial, ACCG-2671 exceeded our expectations with its significant potency along with a prolonged half-life enabling the potential for once weekly dosing. The 3.3% body weight reduction and bone health biomarker changes after a single dose are also very encouraging signs of target engagement, and we are excited to be enrolling our 12-week MAD clinical trial of ACCG-2671 in participants living with obesity.”
Dr. Coll continued, “We are equally encouraged by the OLE results, which reinforce aleniglipron’s consistent and potentially class-leading weight loss profile. Participants achieved up to 16.2% body weight loss at 72 weeks with no evidence of weight loss plateau, and fewer than 5% discontinued treatment due to adverse events. Together, these results demonstrate exciting momentum across two complementary oral small molecule programs with the potential to meaningfully expand treatment options for chronic weight management.”
ACCG-2671 (Oral Small Molecule DACRA): Phase 1 SAD Topline Clinical Trial Results
The SAD portion of the Phase 1/2a clinical trial evaluated the safety, tolerability, pharmacokinetics (PK) and exploratory PD effects of ACCG-2671 in 31 healthy adult participants without obesity. A wide range of doses were explored in this first-in-human study to inform the appropriate starting dose and titration regimen for the MAD study. Participants received a single dose of 1, 2, 5, or 10 mg of ACCG-2671 or placebo.
ACCG-2671 demonstrated a favorable plasma PK profile showing rapid absorption with Tmax at 1 – 1.5 hours. Exposure was consistent with dose proportionality, and the terminal half-life was approximately 6 days supporting further evaluation of daily and weekly dosing.
ACCG-2671 was generally well tolerated with a favorable safety profile. There were no SAEs, no drug related treatment-emergent adverse events (TEAEs) leading to treatment discontinuation, and no events of drug-induced liver injury. No nausea or vomiting was reported in the placebo, 1 mg or 2 mg dose cohorts. Dose-related gastrointestinal events emerged at 5mg, with nausea (4/5 participants) and vomiting (3/5 participants), and at 10 mg (6/6 participants). These findings informed the starting doses and gradual titration strategies currently being evaluated in the ongoing MAD clinical trial.
Exploratory findings with a single dose of ACCG-2671 indicated encouraging and early PD activity. A single 10 mg dose (n=6) was associated with mean body weight reductions of 3.3% at Day 24. CTX-1, a well-recognized biomarker of bone resorption, decreased by approximately 60% on Day 2 across the active dose cohorts. Together, these findings provide evidence of target engagement and support further evaluation of ACCG-2671 as a potential monotherapy as well as part of combination regimens.
Structure has begun dosing in the MAD portion of the ongoing Phase 1/2a study of ACCG-2671. The randomized, placebo-controlled MAD portion will evaluate the safety, tolerability and PK of multiple ascending oral doses of ACCG-2671 administered for 84 days across five cohorts of participants living with obesity. The clinical trial will evaluate different doses and titration regimens, dosing frequencies, with daily and weekly dosing regimens, and includes a cohort of participants receiving a stable dose of an injectable GLP-1 receptor agonist, providing an initial assessment of ACCG-2671 when administered in combination with a GLP-1 receptor agonist. The encouraging SAD results observed to date, together with the data from the ongoing MAD clinical trial, could further establish ACCG-2671’s potential as a differentiated and valuable treatment option, both as monotherapy and combination therapy with GLP-1 receptor agonists. Topline data for the MAD portion of the Phase 1/2a clinical trial are expected in the first half of 2027.
Aleniglipron (Oral Small Molecule Selective GLP-1 Receptor Agonist): ACCESS OLE Results
The ACCESS OLE clinical trial is a prespecified 36-week extension of the Phase 2b ACCESS clinical trial (NCT06693843) designed to evaluate the longer-term safety and tolerability of aleniglipron and the durability of weight loss through 72 weeks of treatment. 87% of eligible participants who completed the initial 36-week double-blind treatment period in ACCESS entered the OLE. Participants continued once-daily treatment in the OLE trial, with doses titrated every four weeks, while participants originally assigned to placebo crossed over to aleniglipron at Week 36 starting with a lower 2.5 mg dose. The OLE also evaluated whether the lower starting dose improved gastrointestinal tolerability. Since participants were titrated to the highest dose of 180 mg after Week 60, this resulted in relatively limited exposure to the 180 mg dose by Week 72.
Most participants enrolled in the OLE portion of the study completed the 72 weeks on treatment. Building on previously reported interim results from the ACCESS OLE at 56 weeks in March 2026, aleniglipron demonstrated continued weight reduction at 72 weeks. Participants originally randomized to the 45 mg, 90 mg and 120 mg arms in the ACCESS trial who continued into the OLE and dosed up to 180 mg, achieved weight loss of 11.6%, 14.4% and 16.2%, respectively, with no evidence of weight loss plateau in the two top doses. More than one-third of participants in the highest dose cohorts, 90 mg and 120 mg, achieved more than 20% body weight reduction, with mean absolute body weight loss of 35.9 and 40.5 pounds, respectively.
Participants, who were originally assigned to placebo in the ACCESS clinical trial and crossed over into the OLE at week 36, started with a 2.5 mg dose of aleniglipron, titrated every four weeks and achieved weight loss of 9.0%, or 22.7 pounds, after 36 weeks of treatment.
Aleniglipron’s safety and tolerability profile remained consistent through 72 weeks. Treatment discontinuations due to TEAEs occurred in fewer than 5% of participants in the OLE. Placebo participants who crossed over into the OLE with a 2.5 mg starting dose and were gradually up-titrated every four weeks to 180 mg demonstrated improved gastrointestinal tolerability compared with the 5 mg starting dose in the double-blind portion of ACCESS.
There were no cases of drug-induced liver injury and all observed liver-enzyme elevations resolved without treatment discontinuation consistent with prior aleniglipron clinical trials.
The efficacy seen in the 72-week OLE trial, especially given that participants were titrated to the highest 180 mg dose at approximately Week 60 and most dose groups had not yet reached an efficacy plateau, demonstrated aleniglipron’s durable, clinically meaningful and competitive weight reduction and a consistent and promising long-term safety and tolerability profile, reinforcing its potential as a differentiated once-daily oral GLP-1 receptor agonist for chronic weight management.
Aleniglipron is currently being evaluated in the ongoing Phase 3 ACCOMPLISH program, comprising two randomized, double-blind, placebo-controlled clinical trials. ACCOMPLISH-1 (NCT07654361) is enrolling up to 3,600 adults living with obesity or overweight with at least one weight-related comorbidity, while ACCOMPLISH-2 (NCT07654374) is enrolling up to 1,100 adults living with obesity or overweight and type 2 diabetes mellitus (T2DM). In both trials, participants will receive placebo or one of three aleniglipron maintenance doses, 45 mg, 90 mg or 180 mg, following a 2.5 mg starting dose and dose escalation at four-week intervals. The program is designed to evaluate the long-term efficacy and safety of aleniglipron and support global regulatory marketing applications for chronic weight management. We expect topline data in the second half of 2028.
Upcoming Milestones in Q4 2026
Additional clinical data expected in the fourth quarter of 2026 could further define aleniglipron’s differentiated clinical profile in terms of the quality of weight loss, treatment of patients with T2DM and the transition from approved injectable incretin medicines. Expected data readouts include:
Phase 2 Body Composition clinical trial (NCT07169942): Results from a 44-week study evaluating aleniglipron’s effects on body fat and overall body composition.Phase 2 T2DM clinical trial (NCT07400588): Results in adults living with T2DM and obesity or overweight.Phase 1 SWITCH clinical trial: Results evaluating the transition from approved injectable GLP-1 medicine to once-daily oral aleniglipron. Conference Call and Webcast Information
Structure Therapeutics will host a conference call and webcast today, September 8, 2026 at 8:30 a.m. Eastern Time. A live webcast of the call will be available on the Investor Relations page of Structure Therapeutics’ website at https://ir.structuretx.com/events-presentations/events.
The webcast can also be accessed directly HERE.
To access the call by phone, participants should visit this link HERE to receive dial-in details.
The webcast will be made available for replay on Structure Therapeutics’ website beginning approximately two hours after the live event. The replay of the webcast will be available for at least 90 days.
About ACCG-2671
ACCG-2671 is an investigational, oral small molecule dual amylin and calcitonin receptor agonist being developed as a potential first-in-class oral amylin therapy for obesity and related metabolic diseases. Amylin is a clinically validated metabolic hormone that plays an important role in regulating appetite, food intake and body weight. Discovered through Structure Therapeutics’ structure-based drug discovery platform, ACCG-2671 is being evaluated in a Phase 1b/2a clinical program. Its oral small molecule profile could support development both as a monotherapy and as a potential combination backbone with GLP-1 receptor agonists and other metabolic therapies.
About Aleniglipron
Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, a clinically validated target for the treatment of obesity and type 2 diabetes mellitus. Discovered through Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed as a biased G protein-coupled receptor agonist that selectively activates the G-protein signaling pathway.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company’s future plans and prospects; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron, ACCG-2671 and any other of the Company’s investigational compounds; any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials; the belief that aleniglipron represents a potentially best-in-class small molecule GLP-1 agonist and has the potential to become a differentiated once-daily oral GLP-1 receptor agonist for chronic weight management; the belief that data to date from the Company’s trials support the ongoing Phase 3 ACCOMPLISH program; the belief that the Company is in a very strong position to be highly competitive; the belief that oral small molecules have the potential to combine convenient administration with scalable manufacturing; the belief that the Company’s oral amylin and GLP-1 programs have the potential to meaningfully expand treatment options for people living with obesity; the belief that ACCG-2671 represents a potentially first-in-class small molecule amylin agonist and its potential development as a monotherapy and as a complementary combination backbone with GLP-1 receptor agonists; and the expected timing of data results from the Phase 1/2a ACCG-2671 MAD trial, Phase 3 aleniglipron trials and other ongoing clinical trials. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial; the preliminary nature of the results due to the length of the study and sample size and the results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company’s Phase 3 clinical program and other clinical studies; the Company’s ability to advance aleniglipron, ACCG-2671, ACCG-3535, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive products or approaches limiting the commercial value of the Company’s product candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Roivant uvedl, že experimentální lék mosliciguat splnil hlavní cíle středně pokročilé klinické studie u plicní hypertenze spojené s plicním onemocněním. Akcie v premarketu vzrostly asi o 20 %.
Roivant (ROIV.O) said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
Roivant has been expanding its late-stage pipeline after winning U.S. approval last month for skin and muscle disease treatment Lisraya.
The drug developer said the experimental drug, mosliciguat, met the study's main goal, reducing pressure and resistance in lung blood vessels by 56.3% compared with placebo after 16 weeks of treatment.
Pulmonary hypertension develops in patients with interstitial lung disease when scarring damages blood vessels in the lungs, forcing the heart to work harder to pump blood.
Mosliciguat also met secondary goals, the company said, helping patients walk 35.2 meters farther in a six-minute walking test compared with placebo after 16 weeks.
A blood test marker linked to heart strain fell 53.2% compared with placebo at Week 16.
Benefits continued through Week 24, with patients walking 52.7 meters farther than those on placebo and showing further reductions in the heart-stress marker.
The trial enrolled 135 patients across 87 sites in 20 countries.
Treatment options for the condition currently include inhaled treprostinil products such as United Therapeutics' (UTHR.O) Tyvaso and Tyvaso DPI and Liquidia's Yutrepia, as well as off-label use of PDE5 inhibitors such as Viatris' (VTRS.O) Viagra and Lilly's (LLY.N) Cialis, which help improve blood flow through the lungs.
Roivant has already started a late-stage study and plans to enroll about 375 patients worldwide, it said.
Intellia Therapeutics oznámila, že FDA přijala žádost o registraci biologického přípravku pro lonvo-z a udělila jí priority review. Rozhodnutí má padnout 10. března 2027.
FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027. Additionally, FDA has advised the company that it is not currently planning to hold an advisory committee to discuss the application. If approved, lonvo-z would be the world’s first in vivo CRISPR-based therapy and the only one-time treatment for HAE.
“Today marks an important milestone for the patients we are committed to serving and for Intellia’s pioneering work in the field of in vivo gene editing,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “Backed by compelling Phase 3 data, we believe lonvo-z could fundamentally change the way HAE is treated and are excited by its potential to become the world's first approved in vivo CRISPR-based therapy. With the FDA’s Priority Review underway, our team is well prepared to deliver this one-time treatment to patients who are waiting for new options.”
Joshua Jacobs, M.D., Medical Director, Allergy and Asthma Clinical Research, Inc., and a HAELO trial investigator, added, “HAE is an unpredictable disease that can be responsible for profound disability and place patients at risk for fatal attacks. Today’s announcement is exciting because it advances us one step closer to potentially having a one-time treatment option available for patients who continue to be burdened by this chronic disease.”
The BLA is supported by positive data from Intellia’s global Phase 3 HAELO clinical trial, which was fully enrolled with 80 patients in just nine months and was designed to evaluate the efficacy and safety of a one-time 50 milligram dose of lonvo-z in adults and adolescents aged 16 years and older with Type 1 or Type 2 HAE. HAELO met its primary and all key secondary endpoints, demonstrating an 87% reduction (p<0.0001) in mean monthly attacks for lonvo-z compared with placebo during the efficacy evaluation period (weeks 5 to 28). In addition, 62% of patients in the lonvo-z arm were entirely attack free and HAE therapy free for the six-month efficacy evaluation period, compared with 11% of patients in the placebo arm (p<0.0001). As of the February 10, 2026 data cutoff, all patients who received lonvo-z at baseline or in crossover after week 28 remained free from long-term prophylaxis therapy.
Favorable safety and tolerability data were observed for lonvo-z as of the data cutoff. The most common treatment emergent adverse events during the primary observation period (infusion through week 28) that were higher in the lonvo-z group compared to placebo were infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection. All reported treatment emergent adverse events were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.
About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Hereditary Angioedema
HAE is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks may still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (formerly known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologics license application (“BLA”) for lonvo-z, such as whether the FDA will hold an advisory committee to discuss the BLA and the timing of such review and approval based on the Prescription Drug User Fee Act ("PDUFA") target action date of March 10, 2027 for the BLA; its belief that lonvo-z could fundamentally change the way HAE is treated and has the potential to become the world's first approved in vivo CRISPR-based therapy; and its expectations regarding its preparations for and the potential success of the commercial launch of lonvo-z, if approved.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the review and approval of the BLA for lonvo-z and the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc. [email protected]
Media Contact:
Mike Tattory
Vice President
LifeSci Communications [email protected]
Rigetti podepsala s americkým ministerstvem obchodu konečnou dohodu o financování ve výši 100 milionů USD na urychlení výzkumu a vývoje supravodivého kvantového počítání. Prostředky podpoří tři projekty zaměřené na škálování této technologie.
BERKELEY, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced that its wholly owned subsidiary, Rigetti & Co, LLC, has signed a definitive agreement with the U.S. Department of Commerce (the “Department”) for an award of $100 million in funding to accelerate superconducting quantum computing R&D.
The funding is allocated under the CHIPS Research and Development Office Broad Agency Announcement pursuant to the CHIPS Act.
Under this definitive agreement, Rigetti will pursue three R&D projects that aim to address major technical bottlenecks in scaling superconducting quantum computing and will accelerate the Company’s roadmap towards utility-scale quantum computing:
Compressing readout electronics into an integrated, miniaturized packageExpanding cryogenic capacity by orders of magnitude using a new cryostat architectureDeveloping the fabrication capabilities for high-connectivity chip architectures
Quantum computing has tremendous promise to dramatically transform critical areas including cryptography, chemistry, materials science, mathematical optimization, and AI/machine learning. Governments worldwide are investing in this emerging technology given the national security and economic implications of quantum advantage.
“We are proud to be selected by the U.S. government to accelerate R&D and progress against our roadmap to deliver commercially viable quantum computing capabilities,” says Dr. Subodh Kulkarni, Rigetti CEO. “Solving crucial challenges in scaling gives us the opportunity to transform the industry by putting large-scale quantum computers in the hands of America’s quantum computing researchers faster. Shortening the time to build quantum systems at scale and reducing their cost will also allow for broader adoption, which will strengthen our domestic quantum computing ecosystem.”
The Department will receive a minority, non-controlling equity stake in Rigetti as a condition for receiving the funds to enhance the return for the U.S. taxpayer.
About Rigetti
Rigetti is a pioneer in full-stack quantum computing. Rigetti quantum computers are based on superconducting qubits, which are widely believed to be the leading qubit modality given their maturity, clear path to scaling, and fast gate speeds. Rigetti quantum computing systems achieve gate speeds of 50-70 nanoseconds, which is about 10,000 times faster than trapped-ion systems and 100 times faster than neutral-atom systems.
Rigetti sells on-premises 9-qubit to 108-qubit quantum computing systems, which support national laboratories and quantum computing centers. Rigetti’s Cepheus 36-qubit to 108-qubit systems are based on the Company’s proprietary chiplet-based technology and include the Company’s control electronics. Rigetti’s 9-qubit Novera QPU supports a broader R&D community with a high-performance, on-premises QPU designed to plug into a customer’s existing cryogenic and control systems.
The Company operates quantum computers over the cloud through its Rigetti Quantum Cloud Services (QCS) platform, enabling global enterprise, government, and research clients to pursue R&D. The Company’s proprietary quantum-classical infrastructure provides high-performance integration with public and private clouds for practical quantum computing.
Rigetti developed the industry’s first multi-chip quantum processor for scalable quantum computing systems. Leveraging this proprietary technology, Rigetti deployed the industry’s largest multi-chip quantum computer in 2026 with Cepheus-1-108Q, based on twelve 9-qubit chiplets tiled together. The Company designs and manufactures its chips in-house at Fab-1, the industry’s first dedicated and integrated quantum device manufacturing facility. Learn more at https://www.rigetti.com/.
Cautionary Language and Forward-Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the federal securities laws, including with respect to the Company’s expectations regarding its future success and performance including expectations with respect to its R&D; achieving the aim of the three R&D projects being pursued under the definitive agreement; the promise quantum computers have to dramatically transform critical areas including cryptography, chemistry, materials science, mathematical optimization, and AI/machine learning; the timeline for building quantum systems at scale and reducing their costs; and the Company’s ability to receive funding amounts as contemplated by the definitive agreement, including the timeline for such funding. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the Company’s issuance of securities to the Department pursuant to the definitive agreement (including dilution to existing stockholders); the Company’s ability to achieve milestones, technological advancements, including with respect to its technology roadmap; Company’s ability to deliver products to customers in time or at all, including actions by customers, such as controls over their facilities and cancelling orders; the ability of the Company to obtain government contracts successfully and in a timely manner and the availability of government funding; the potential of quantum computing; the success of the Company’s partnerships and collaborations; the Company’s ability to accelerate its development of multiple generations of quantum processors; the outcome of any legal proceedings that may be instituted against the Company or others; the ability to maintain relationships with customers and suppliers and attract and retain management and key employees; costs related to operating as a public company; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, or competitive factors; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and expansion plans; the expected use of proceeds from the Company’s past and future financings or other capital; the sufficiency of the Company’s cash resources; unfavorable conditions in the Company’s industry, the global economy or global supply chain, including rising inflation and interest rates, deteriorating international trade relations, political turmoil, natural catastrophes, military conflicts, and terrorist attacks; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other documents filed by the Company from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements other than as required by applicable law. The Company does not give any assurance that it will achieve its expectations.
IREN oznámila, že její 2GW Sweetwater Hub byl podmíněně připojen do procesu ERCOT Batch Zero jako Base Load. Sweetwater 1 a Sweetwater 2 jsou součástí oznámeného portfolia více než 5GW globálního vývoje datových center.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- IREN Limited (NASDAQ: IREN) (“IREN”) today announced that its 2GW Sweetwater Hub (Sweetwater 1 and Sweetwater 2) has been conditionally included in the Electric Reliability Council of Texas (“ERCOT”) Batch Zero process as Base Load.
Sweetwater 1 (1,400MW) and Sweetwater 2 (600MW) form part of IREN’s announced >5GW global data center development portfolio.
At Sweetwater 1, IREN’s high-voltage substation was energized earlier this year, and construction of 300MW (gross) of data center capacity continues with delivery targeted for Q4 2027.
Additional large-scale projects within IREN’s broader development pipeline have also been included in Batch Zero. Consistent with its approach to date, IREN will include these projects in its announced development portfolio following the execution of the relevant grid connection agreements.
ERCOT’s classifications remain conditional and subject to ongoing approval processes.
IREN will continue to coordinate closely with relevant transmission and distribution service providers, grid operators, regulators, and local communities as it develops future data center capacity.
About IREN
IREN is a vertically integrated AI Cloud platform, delivering data centers, compute and software for AI training and inference. IREN’s platform is underpinned by its expansive portfolio of land and grid-connected power in renewable-rich regions across North America, Europe and APAC.
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or IREN’s future financial or operating performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, expectations as to receipt of government approvals, satisfaction of conditions relating to existing government approvals and classifications, execution of grid connection agreements, expansion, build out and delivery of data center capacity, and other trends we expect to affect our business. These statements often include words such as “anticipate,” “believe,” “may,” “can,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “target”, “will,” “estimate,” “predict,” “potential,” “continue,” “scheduled”. Forward-looking statements may also be made, verbally or in writing, by members of our Board or management team in connection with this news release.
These forward-looking statements are based on management’s current expectations and beliefs. These statements are neither promises nor guarantees, but involve and are subject to known and unknown risks, uncertainties and other important factors that may cause IREN’s actual results, performance or achievements to differ materially from any future results performance or achievements expressed or implied by the forward-looking statements, including IREN’s ability to successfully execute on its growth strategies and operating plans, achieve its targeted annualized AI Cloud Services revenue, continue to develop its existing data center sites, design and deploy direct-to-chip liquid and air cooling systems, provide software, and operate and expand its AI Cloud Services business, along with other important factors discussed under the caption “Risk Factors” in IREN’s Annual Report on Form 10-K, filed with Securities and Exchange Commission (the “SEC”) on August 27, 2026 and our other filings with the SEC. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statement included in this press release speaks only as of the date of such statement. Except as required by law, IREN disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Bernstein drží pro IREN cílovou cenu 100 USD, což by znamenalo zhruba zdvojnásobení ceny akcie. Firma mezitím hlásila tržby 137,2 milionu USD a GAAP čistou ztrátu 684,0 milionu USD.
A top Wall Street analyst is standing behind a bold price target on IREN while the stock sits deep in the red, and the gap between where shares trade today and where the bulls say they belong tells a story…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
IREN (NASDAQ:IREN) trades at $44.68. The Wall Street consensus target sits at $77.84, implying roughly 74% upside. Bernstein’s Gautam Chhugani, meanwhile, carries a Street-high $100 price target, a call that would essentially double the stock from here.
IREN is a former Bitcoin miner rapidly rebuilding itself as an AI cloud and GPU data center operator, with liquid-cooled NVIDIA GB300 clusters going into sites across Texas, Oklahoma, British Columbia, Spain, and Australia. Wall Street cares because IREN has landed anchor contracts with Microsoft and NVIDIA that few peers can match. The gap between price and target matters because a stock this heavily contracted usually does not trade this far below Street models unless something has spooked the market.
Impairments and a Revenue Miss Slammed the Stock The most recent leg lower came with Q4 FY26 earnings. IREN reported revenue of $137.2 million, missing consensus by 2.52% and down 26.8% year over year as the company deliberately wound down its legacy mining business. The bigger shock was a GAAP net loss of $684.0 million, driven by a $450.4 million non-cash impairment on decommissioned mining hardware.
The selloff was violent. IREN touched a 52-week high of $76.87 earlier in the cycle before collapsing to a 52-week low of $27.05, a peak-to-trough drawdown well above 60%. Even after a sharp bounce, shares still sit roughly 42% below that high. Adjusted EBITDA fell to $19.2 million from $59.5 million the prior quarter, and near-term EPS estimates keep drifting lower, with the quarter ending September 2026 now pegged at negative $0.51 versus negative $0.26 thirty days ago.
Why the Bulls Are Doubling Down Instead of Downgrading Bernstein’s Chhugani, one of the top-ranked digital assets analysts on the Street, is modeling IREN as an AI Cloud Infrastructure and Neocloud Hyperscaler rather than a Bitcoin miner. That reframing is central to the bull case, and it puts IREN alongside the picks-and-shovels names powering the AI buildout (we profiled seven of them, from power to cooling, in a free report you can grab here). The contracts backing it are real: a $9.7 billion multi-year Microsoft deal, a $3.4 billion five-year NVIDIA AI Cloud contract with up to $2.1 billion in NVIDIA equity investment that vests as GPU deployments scale, plus a newly disclosed frontier AI lab contract.
Analysts point to specific milestones. Management says 2026 capacity is largely sold out, with $4 billion of contracted ARR targeted by year-end 2026 versus $1 billion operating currently. Recent three-year contracts are priced at more than $20 million per megawatt, with active discussions at $25 million per megawatt. IREN has also secured roughly $19 billion in funding over the preceding 12 months, quieting a major bear talking point.
Coverage skews decisively bullish. Of the analysts tracked, 1 rates it Strong Buy, 12 Buy, 3 Hold, 0 Sell, and 1 Strong Sell. Recent activity has been dominated by target increases rather than cuts, and Bernstein’s $100 sits at the top of that stack.
Neocloud Peers Are Sitting in the Same Discount Bin The entire neocloud group sold off together, and every major name still trades well below Wall Street’s target. IREN fits squarely inside that trend.
Cipher Mining (NASDAQ:CIFR) trades at $17.74 against a $32.18 target, roughly 81% implied upside. Coverage is unusually clean, with 5 Strong Buy and 12 Buy ratings and zero Holds or Sells. Recent revisions have skewed higher on AWS and Fluidstack lease progress.
TeraWulf (NASDAQ:WULF) sits at $16.51 versus a $36.34 target, an eye-catching 120% implied upside anchored by its 20-year Anthropic lease. Ratings are all bullish: 5 Strong Buy, 13 Buy, with recent revisions trending up.
Core Scientific (NASDAQ:CORZ) changes hands at $17.89 versus a $37.12 target, roughly 107% upside, backed by a 15-year AMD partnership and CoreWeave anchor tenancy. Analyst posture is 3 Strong Buy, 13 Buy, 1 Hold.
TeraWulf carries the largest implied upside in the group. IREN sits behind WULF and CORZ on that metric, but Bernstein’s $100 call, if realized, would leapfrog every peer.
Rating Mix Skews Buy, Performance Beats the Index IREN currently trades at $44.68 with a consensus target of $77.84 from 17 covering analysts, implying about 74% upside on the average and about 124% to Bernstein’s Street-high. Shares are up 18.29% year to date, ahead of the S&P 500’s 12.94%, and up 70.99% over the past year.
The near term has been rougher and then sharply better. IREN is up 26.04% over the past week and 14.89% over the past month, a bounce off the mid-August lows. Ratings shake out as follows:
Strong Buy: 1 Buy: 12 Hold: 3 Sell: 0 Strong Sell: 1 Targets are one data point among many, and the imbalance here is stark.
The Bull Case Hinges on Execution, the Bear Case on Capex The bull case holds if management can convert its $4 billion contracted ARR target and sold-out 2026 capacity into actual reported revenue in the March quarter and beyond. Horizon 1 has already been delivered to Microsoft, Horizons 2 through 4 are in flight, and financing is largely locked. If pricing per megawatt holds near $25 million and NVIDIA’s equity investment keeps vesting, Bernstein’s $100 call is defensible.
The bear case builds if the capex load starts wobbling. FY27 capex guidance of $25 to $30 billion is enormous, financing markets could tighten, and IREN still has to demonstrate flawless execution across Texas, Spain, and Australia simultaneously. Customer concentration is real, GPU obsolescence is real, and near-term losses are widening.
On balance, I lean cautiously bullish. The contracts are signed, the capital is largely raised, and the upside asymmetry is unusual. This is a high-beta way to gain AI infrastructure exposure, and position sizing reflects that risk profile.
Contact [email protected] for any questions or corrections.
Tesla spustila Cybercabs v Austinu a podle CNBC může rychle rozšířit autonomní taxislužbu i do dalších míst. Čínské automobilky se zároveň podle expertů připravují na výraznější expanzi do USA.
Na CNBC se zaměřili na „cybercabs“ Tesly, tedy její nově nabízenou službu autonomních taxíků. Tim Higgins z The Wall Street Journal si myslí, že rozjetí této služby je ale komplikovaný proces, zahrnuje budování infrastruktury a dalších podpůrných systémů. Zmínil v této souvislosti společnost Waymo a její taxíky. Zpočátku bylo podle Higginse velmi zajímavé používat jejich službu, pak se z toho stala rutina. To samé by přitom měla dosáhnout Tesla. Měla by ukázat, že její kybernetické taxíky jsou naprosto běžnou, nudnou službou, bez nehod a problémů.
Tesla rozjela službu v Austinu, ale Higgins si myslí, že firma má schopnost rychle rozjet výrobu taxíků a rozšířit rozsah služeb na další místa. Měla by v tom mít výhodu před společností Waymo, která tuto schopnost podle odborníku nemá. Nakupuje totiž své vozy od jiných výrobců a pak je upravuje tak, aby mohly fungovat jako autonomní taxíky. „Až bude vše připravené, Elon může vyrobit milion těchto věcí,“ dodal expert. V negativním scénáři by ale šlo o pomalý proces, kdy by Tesla nebyla schopná se svou technologií založenou na kamerách službu spolehlivě nabízet.
Higgins k uvedenému dodal, že Musk pevně věří v autonomní řízení založené právě na kamerách, ne na laseru. Tedy na systému LiDAR. Musk se totiž domnívá, že když lidé nepotřebují ke své orientaci lasery, auta by měla být schopná toho samého. K diskusi na CNBC přispěl i Ross Gerber z Gerber Kawasaki, který klade důraz na konkurenci, kterou představuje Waymo, ale i Uber. A k tomu se v USA objevují další společnosti, které chtějí nabízet autonomní taxíky. Na jednu stranu tak investor u autonomních služeb Tesly očekává růst, ale měl by to být jen postupný proces.
Gerber souhlasí s názory, podle kterých by Uber měl kvůli rostoucí konkurenci autonomních taxíků ztrácet. Ty druhé „si totiž nestěžují a pracují ve dne v noci“. Konkrétně by mohlo dojít k tomu, že autonomní taxíky budou jezdit za nižší ceny, což vyvolá tlak na ceny Uberu a odměny řidičů. A následně klesne atraktivita tohoto zaměstnání. K tomu se podle investora zhoršuje kvalita služeb Uberu, ale firma by mohla mít v budoucnu stále místo na trhu třeba u starších klientů. A obecně tam, kde je třeba „lidské pomoci“.
Michael Dunne z Dunne Insights pak na CNBC hovořil o tom, že dochází k velké změně na globálním automobilovém trhu. Dříve se totiž velké automobilky intenzivně zaměřovaly na čínský trh, jenže na něm postupně klesaly marže a zisky. Nyní se čínské automobilky naopak zaměřují na nové trhy, nejzajímavějším z nich jsou přitom Spojené státy. A podle experta se zdá, že se blíží okamžik, kdy na něm budou znatelně expandovat. Nyní je mimo jiné brzdí cla a další omezení včetně zákazu používání čínského softwaru v automobilech prodávaných na americkém trhu. Tak se čínské společnosti zaměřují hlavně na Mexiko a Kanadu.
Meta vzrostla po uvedení Muse Spark 1.3, která má podle firmy zlepšit kódování a snížit náklady na AI. Bank of America stále vidí 32% růstový potenciál díky cílové ceně 810 USD.
Buy Meta (NASDAQ: META). Muse Spark 1.3 is concrete proof of faster, cheaper agentic coding (fewer tool calls/tokens) and better long-horizon performance—exactly what Meta needs to turn AI spend into ad targeting, recommendations, and developer tools. BofA’s 32% upside case is supported by the valuation still lagging the earnings power implied by improved ad efficiency and lower inference costs from MTIA chips.
Key Risk: Meta’s AI upgrades fail to show up in ad pricing/engagement and margins—AI costs keep rising faster than revenue, so the multiple compresses.
GOOG buy
Buy Alphabet (NASDAQ: GOOG). If Meta’s agentic models improve ad targeting and developer tooling, the competitive pressure shifts to search/ads efficiency. Alphabet’s stronger cash generation and diversified ad stack let it defend share while benefiting from the industry’s push toward better AI-driven ad relevance and automation.
Key Risk: Meta’s AI actually boosts ad performance enough to take meaningful share and force Alphabet to spend more to catch up, hurting margins.
Meta stock NASDAQ:META jumped sharply after the company released Muse Spark 1.3, giving investors evidence that its AI spending may eventually produce returns.
The model is designed for coding and longer-running agentic tasks. Meta says it uses roughly 20% fewer tool calls and 25% fewer tokens than Muse Spark 1.2 in comparable engineering work.
Bank of America analyst Justin Post remains bullish. He has a Buy rating and an $810 price target, implying about 32% upside from Meta’s September 3 close of $610.68.
The debate is whether those advances can justify the infrastructure bill behind them.
Meta has spent much of 2026 facing questions over whether AI investment is outrunning commercially useful progress.
Muse Spark 1.3 gives bulls something more concrete.
Meta says the model handles longer-horizon tasks better, manages multiple workflows in one thread and improves coding efficiency. It is available through Muse Code and the Meta Model API.
Bernstein reiterated an Outperform rating and an $800 target, arguing that Meta’s AI-enhanced advertising engine remains a major advantage. The firm believes Meta is on track to rival or surpass Google Search in advertising revenue.
Meta does not need Muse Spark to become a standalone business on OpenAI’s scale.
Better models can improve recommendations, ad targeting, engagement and developer tools across Meta’s apps. The payoff can appear inside its existing profit engine rather than only through model sales.
Bank of America’s case rests on the gap between Meta’s execution and valuation.
Post highlighted Meta’s rapid model-release cadence and said the agentic improvements matter as the company develops a consumer AI agent internally known as Hatch.
There is also a hardware angle.
BofA estimates Meta’s planned MTIA custom-chip deployments could eventually represent 15% to 20% of its total AI capacity. Greater reliance on in-house silicon could lower computing costs as workloads expand.
At around $617 when BofA made its case, Meta traded near 18 times projected 2027 GAAP earnings, below its historical multiple of roughly 21 times and the broader market.
BofA’s $810 target is based on 24 times projected 2027 earnings.
The risk is that Meta’s AI bill remains enormous.
Its infrastructure push is raising fixed costs and pressuring margins and free cash flow, meaning new model releases must eventually translate into measurable economic returns.
KeyBanc remains constructive but more conservative, as the firm cut its target to $760 from $855 while keeping an Overweight rating.
KeyBanc said Meta Superintelligence Labs had made “meaningful progress” with Muse Spark and argued investors were “under-appreciating platform stickiness” among consumers and advertisers.
But the burden of proof keeps rising.
Investors will want evidence that Muse Spark gains adoption, that agents such as Hatch become useful products, and that MTIA chips reduce computing costs.
Tesla 3. září v Austinu uvedla Cybercab, speciální autonomní elektrické vozidlo pro svou robotaxi flotilu. Jde o důležitý krok k rozšíření služby, ale firma čelí i regulačnímu vyšetřování.
Tesla (TSLA -5.92%) has significantly lagged broader equities this year, partly because its core electric vehicle (EV) business has faced headwinds. However, the company is working on projects that could substantially improve its financial results. One of them is its humanoid robot, which CEO Elon Musk claimed will be the "biggest product ever." The other is Tesla's robotaxi fleet, which, once it scales, could transform Tesla's business for the better.
The company has made progress on both fronts recently, and it even achieved an important milestone within its robotaxi business that investors should take note of.
Image source: The Motley Fool.
Tesla's robotaxi plans take a leap forwardTesla first launched its robotaxi service in Austin in June of last year. Since then, it has expanded it to several other cities across the U.S. The company has used its Model Y, running on its Full Self-Driving (FSD) software, in its robotaxi service. However, it was always Tesla's plan to launch a purpose-built vehicle specifically for its robotaxi business. Mission accomplished. On Sept. 3, Tesla debuted the Cybercab in Austin. The Cybercab is a dedicated, autonomous electric vehicle that could become the backbone of Tesla's robotaxi fleet.
What is the advantage of the Cybercab? It is a two-seater (most ride-hailing trips involve one or two passengers, according to some research) with no steering wheel, no side mirrors, and no pedals. A smaller, more compact, and relatively simpler design that eliminates many of the features needed to make human driving possible likely means it is cheaper to manufacture. Translation: Instead of mass-producing Model Ys for its robotaxi service, relying on the Cybercab will help keep costs in check.
Premium Feature
Moneyball Superscore
65/100
Today's Change
(
-5.92
%) $
-22.29
Current Price
$
354.08
Is this the start of a sustained run?Tesla stock initially jumped in anticipation of the Cybercab launch. It's not hard to understand why. The company's core electric vehicle (EV) business has been mixed over the past couple of years. Recent second-quarter results were strong, but that was largely due to increased demand for EVs amid geopolitical tensions that drove oil prices higher.
That's hardly something Tesla can count on for sustained EV demand over the medium term. In all likelihood, demand will cool down as oil prices stabilize. But here's the interesting part.
The market has long ceased to treat Tesla as just an EV company. Tesla's robotaxi service has the potential to make the business far more profitable. True, Tesla has to spend a small fortune now to produce enough cars to put on the road and to train its FSD software to achieve increasingly better performance.
But once the fleet of robotaxis is large enough, the FSD software continues to improve, and the service achieves significant utilization, we could see revenue soar, costs and expenses decline as a percentage of the top line, and margins and profits increase significantly.
Tesla's recent launch of the Cybercab was an important step toward that goal. But again, all of this only works if Tesla can become a leader in the robotaxi industry, and although it has made significant headway, there are reasons to be skeptical.
First, Waymo, one of Tesla's biggest competitors, has a far larger fleet of robotaxis on the road. This isn't just about raw numbers. A larger fleet means a stronger data flywheel to train a self-driving software. True, Tesla also has non-robotaxi models that rely on its FSD software, but it’s worth highlighting Waymo’s lead in the robotaxi market. Second, there are still significant potential regulatory risks to consider.
A single accident with the company's robotaxi fleet will attract significant regulatory scrutiny. In fact, the U.S. government recently opened an investigation into Tesla's Cybercab shortly after it launched. Regulators want to ensure that the self-driving vehicle meets safety standards. Tesla's CEO, Elon Musk, noted that Tesla's robotaxi fleet has never been involved in a serious fatal accident.
But it's worth factoring that possibility into our analysis, especially once we consider valuation. Tesla is trading at 156.3x forward earnings. At current levels, even the hint of trouble with the robotaxi service -- since it is one of the core reasons why Tesla trades at a significant premium -- could send the stock plunging.
Case in point: Tesla's shares dropped after the Cybercab launched, erasing pre-launch gains, because some investors and analysts were disappointed with the new product, not to mention the regulatory concerns it now faces. Tesla's Cybercab milestone is still great news for shareholders, but the stock will remain volatile moving forward. Only investors comfortable with significant risk should consider initiating a position.
Google upravil vyhledávání v Evropě kvůli pravidlům EU, ale varuje, že změny zhorší uživatelský zážitek a zvýší náklady evropským firmám. Firma už dříve dostala v EU pokutu 460 milionů eur.
Alphabet's (GOOGL.O) Google on Tuesday rolled out changes to its online search results in Europe to satisfy EU antitrust regulators, a move which it said will degrade users' experience and ratchet up costs for European businesses.
The changes mark the largest reduction in quality of service at the world's most popular internet search engine in its 29-year search history, Google official told Reuters.
Google said the EU pitched the changes as levelling the playing field for companies to advertise. However, Google said it sees that in reality the changes favour price comparison sites, also known as vertical search services (VSS), linked to sectors including hotels, airlines and restaurants, such as Expedia or Booking.com. They get more prominence in search results over companies in those sectors that are listed with just a link to their websites, telephone numbers and address.
The U.S. tech giant was hit with a €460 million ($534 million) fine in July for favouring its own services in shopping, hotels, transport and sports results in search results in breach of the EU's Digital Markets Act seeking to rein in the power of Big Tech.
The European Commission gave it 60 days to comply with the DMA or risk periodic penalty payments of up to 5% of its total worldwide turnover.
The revamped search results will highlight one specialised search engine at the top of the page, followed by two others with fewer details while a carousel of hotels, airlines and restaurants for example will sit below them with key features such as real-time prices stripped out. The rankings will be determined by Google's algorithm.
"To comply with DMA requirements, we're making significant changes to Search in Europe," Nick Fox, Google's senior vice-president, knowledge & information, said in a statement to Reuters.
"These changes degrade the user experience for Europeans - boosting online intermediaries at the expense of local businesses, and removing helpful features people rely on every day. Users outside the EU will not be impacted by these changes," he said.
Google said past changes to comply with the DMA led to a 30% drop in free, direct booking traffic to European businesses and the latest changes are expected to hit them.
The company said it has tested the changes with millions of users in Europe, which show a high level of dissatisfaction as they have to retype queries to find what they want.
Google has racked up total EU antitrust penalties of €10.38 billion over nearly two decades.
The EU fines drew fire from U.S. President Donald Trump who threatened to launch a probe into the bloc's "robbing" of American companies.
Trump uvedl, že ExxonMobil míří zpět do Venezuely, i když to firma zatím nepotvrdila. Chevron mezitím rozšířil svou pozici v zemi a plánuje investovat více než 7 miliard USD.
This past January, ExxonMobil's (XOM -1.69%) CEO Darren Woods called Venezuela "uninvestable" during a meeting at the White House, a remark that didn't sit well with President Trump. Fast forward a few months, and the President recently publicly announced that "Exxon is going in" to Venezuela. While ExxonMobil hasn't confirmed plans to reenter the country following its exit two decades ago, much has changed since the year began.
Here's why investors should pay attention to the President's assertion that ExxonMobil is returning to Venezuela.
Image source: Getty Images.
Searching for clues in the details of its rival's deal At a recent press event unveiling a massive U.S. oil deal with Venezuela, President Trump highlighted that Exxon and Chevron (CVX -1.29%) are among the many big oil companies heading into Venezuela. Chevron has already confirmed its expansion in the country, noting that its two decades of patience have finally paid off. The oil giant recently announced that it has expanded its position in the country, as one of its joint ventures has been assigned rights to develop two adjacent oil fields. That supports Chevron's plans to invest more than $7 billion over the next five years to more than double its production in the country to around 600,000 barrels per day.
Premium Feature
Moneyball Superscore
70/100
Today's Change
(
-1.69
%) $
-2.74
Current Price
$
159.47
The oil giant noted in the press release announcing its expanded position that the agreements include "enhanced fiscal, commercial, and legal terms intended to support durable and competitive long-term investments." That's something ExxonMobil investors should pay close attention to, because the company has previously said it needs durable investment protections and improved economics before it would commit to returning to Venezuela. The improved terms of Chevron's deal suggest that Venezuela appears willing to make the concessions that Exxon has been seeking as a condition of its return.
While Trump's statement and Chevron's sweetened deal terms don't necessarily mean Exxon will return, they certainly hint at that to investors who are paying attention. Returning to Venezuela on improved terms would enhance Exxon's already strong plan to 2030, making it an even better oil stock to buy and hold long term.
Matt DiLallo has positions in Chevron. The Motley Fool has positions in and recommends Chevron. The Motley Fool has a disclosure policy.
Nykredit A S bought a new position in Intel Corporation (NASDAQ:INTC – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,222,470 shares of the chip maker’s stock, valued at approximately $170,693,000.
Other institutional investors have also added to or reduced their stakes in the company. Primecap Management Co. CA purchased a new stake in Intel during the second quarter valued at about $10,507,291,000. Norges Bank purchased a new position in shares of Intel in the 4th quarter worth about $2,233,159,000. Legal & General Group Plc purchased a new position in shares of Intel in the 2nd quarter worth about $4,096,110,000. Capital Research Global Investors increased its position in shares of Intel by 285.9% during the 4th quarter. Capital Research Global Investors now owns 26,619,928 shares of the chip maker’s stock valued at $982,279,000 after purchasing an additional 19,722,010 shares during the last quarter. Finally, Capital World Investors increased its position in shares of Intel by 20.3% during the 4th quarter. Capital World Investors now owns 104,060,268 shares of the chip maker’s stock valued at $3,839,833,000 after purchasing an additional 17,557,147 shares during the last quarter. Institutional investors own 64.53% of the company’s stock.
Intel Stock Performance Shares of INTC stock opened at $95.80 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.25 and a current ratio of 1.60. Intel Corporation has a fifty-two week low of $24.05 and a fifty-two week high of $142.35. The stock has a 50 day moving average price of $99.73 and a two-hundred day moving average price of $88.55. The company has a market capitalization of $483.22 billion, a P/E ratio of -45.40, a PEG ratio of 10.58 and a beta of 2.22.
Intel (NASDAQ:INTC – Get Free Report) last released its quarterly earnings data on Thursday, July 23rd. The chip maker reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.21. Intel had a positive return on equity of 2.62% and a negative net margin of 19.79%.The firm had revenue of $16.13 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. The business’s quarterly revenue was up 25.2% compared to the same quarter last year. Intel has set its Q3 2026 guidance at 0.380-0.380 EPS. Analysts expect that Intel Corporation will post 1.01 earnings per share for the current year. Intel News Roundup Here are the key news stories impacting Intel this week:
Positive Sentiment: Intel CEO Lip-Bu Tan reportedly purchased approximately $10 million of Intel shares, a vote of confidence in the turnaround. The company’s latest quarter also showed revenue of about $16.1 billion, including strong data-center growth. Intel CEO share purchase and quarterly growth Positive Sentiment: Investors are broadening the AI trade beyond Nvidia. Intel gained alongside AMD as Nvidia lagged during the latest session, suggesting increased interest in alternative beneficiaries of AI infrastructure spending. AMD and Intel outperform Nvidia Positive Sentiment: Intel is positioning itself in enterprise and edge AI through contributions to the Linux Foundation’s TRACE open specification for trusted and verifiable AI workloads. The development could strengthen Intel’s role in secure AI infrastructure. Intel’s trusted AI standards efforts Neutral Sentiment: Some analysts remain bullish after Intel’s more than 140% 2026 rally, with one published target implying substantial additional upside. That optimism supports sentiment, but the size of the rally raises questions about whether expectations are already reflected in the stock. Intel upside forecast Negative Sentiment: A prominent Mizuho analyst lowered or reset Intel’s price target while comparing Intel with Arm. The move may weigh on shares because it signals that the recent rally could have outpaced near-term fundamentals. Analyst downgrades Intel price target Negative Sentiment: Nvidia’s expanding CPU and AI infrastructure strategy presents a competitive threat to Intel in data-center processors. Nvidia’s ecosystem investments, including a reported Intel stake, may support Intel financially but also make the company’s performance increasingly dependent on Nvidia-led demand. Nvidia CPU strategy and Intel competition Negative Sentiment: Intel’s comeback may require substantial capital and shareholder dilution, with one analysis highlighting a potential $23 billion dilution cost. Investors remain focused on whether manufacturing and AI investments can generate sufficient returns to justify that financing. Intel potential dilution analysis Analyst Ratings Changes A number of analysts recently weighed in on INTC shares. Moffett Nathanson downgraded Intel to a “neutral” rating in a research report on Thursday, June 11th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $110.00 price objective on shares of Intel in a research note on Monday, July 27th. Robert W. Baird increased their target price on shares of Intel from $75.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Wall Street Zen lowered shares of Intel from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Stifel Nicolaus decreased their target price on shares of Intel from $120.00 to $110.00 and set a “hold” rating on the stock in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, thirty-one have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $107.01.
Read Our Latest Research Report on Intel
Insiders Place Their Bets In other news, CEO Lip Bu Tan purchased 105,263 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average price of $95.00 per share, with a total value of $9,999,985.00. Following the transaction, the chief executive officer directly owned 1,314,669 shares of the company’s stock, valued at approximately $124,893,555. This represents a 8.70% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by insiders.
About Intel (Free Report)
Intel Corporation, founded in 1968 by Robert Noyce and Gordon E. Moore and headquartered in Santa Clara, California, is a leading global designer and manufacturer of semiconductor products. The company is historically notable for introducing the first commercial microprocessor and for driving the x86 architecture that underpins many personal computers and servers. Intel’s core business spans the design, fabrication and marketing of processors, chipsets and related components for a wide range of computing applications.
Intel’s product portfolio includes client and mobile processors marketed under brands such as Intel Core and Pentium, as well as high-performance Xeon processors for data centers and cloud infrastructure.
See Also Five stocks we like better than Intel 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding INTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intel Corporation (NASDAQ:INTC – Free Report).
Receive News & Ratings for Intel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intel and related companies with MarketBeat.com's FREE daily email newsletter.
Adobe jmenovalo Anila Chakravarthyho novým CEO s nástupem 1. prosince; Shantanu Narayen přejde do role výkonného předsedy. Akcie po oznámení klesly o 6,7 %.
Adobe (ADBE -6.73%) has picked its next CEO. The company said on Sept. 3 that Anil Chakravarthy, the insider who runs its customer experience orchestration business, will become president and CEO on Dec. 1.
Shantanu Narayen, who has run Adobe since 2007, will move to executive chair the same day. The news landed after the market closed, and shares fell 6.7% the next day to $266.51 as of this writing -- about 28% below the stock's 52-week high.
A change at the top is rare here: Adobe has handed the CEO job over exactly once in the past 19 years. Bruce Chizen resigned as CEO as of Nov. 30, 2007, and Narayen (then Adobe's president and chief operating officer) took over the next day.
Chakravarthy steps in 19 years later to the day.
Here's what the stock did after that first handover.
Image source: Getty Images.
The last handover came at a terrible timeThe Adobe that Chizen passed along was thriving. Fiscal 2007 revenue rose 23% year over year to about $3.2 billion, and net income climbed 43% to about $724 million.
But the business ran on software licenses back then. Customers bought Creative Suite and Acrobat outright, and revenue depended on their appetite for the next upgrade.
That appetite was about to vanish. Narayen's first trading day as CEO ended with the stock at about $42.
Twelve months later, shares closed at $21, a loss of about half. They went on to trade below $16 by March 2009. Two full years after the handover, the stock still sat around $36, down about 15%.
Was the new CEO the problem?Narayen had little to do with that first-year collapse, in my view. After all, the Great Recession began in December 2007, the very month he took over. The S&P 500 (^GSPC -0.38%) itself lost about 45% during his first 12 months.
Adobe's business model made a bad stretch worse. When corporate budgets froze, customers skipped the upgrade, and the damage showed up on a delay. Revenue growth decelerated to 13% in fiscal 2008. Then revenue fell 18% in fiscal 2009 to about $2.9 billion, and net income dropped by more than half that year.
Zooming out makes the same point. From about $42 at the handover, shares have gained more than 500% over Narayen's nearly 19 years. And the company he hands over is targeting $26.5 billion to $26.6 billion of revenue this fiscal year -- more than eight times fiscal 2007's total.
The next CEO starts in a better spotThe differences this time mostly favor the incoming CEO. Narayen isn't leaving. Chizen, by contrast, exited the top job and stayed on as a strategic advisor for a year.
Narayen also telegraphed the change back in March, saying he would step down once the board picked a successor. And Chakravarthy, for his part, ran Informatica as its CEO from 2015 to 2020 before joining Adobe.
The business is arguably stronger, too.
Chakravarthy takes over $27.1 billion of annualized recurring revenue. In Adobe's fiscal second quarter of 2026, which ended May 29, revenue grew 13% year over year, reaching a record $6.62 billion. Management raised its full-year targets in June.
Another recession could still hurt. But subscription revenue doesn't vanish the way skipped upgrades did in 2008.
Not everything favors him, though. Friday's sell-off wasn't only about who got the job. David Wadhwani, who ran Adobe's creativity and productivity business and was reportedly a contender for the job, is leaving the company.
And the worry that artificial intelligence will disrupt software makers, which has weighed on the stock since 2024, hasn't gone anywhere. Narayen, not Chakravarthy, will still be CEO for Thursday's fiscal third-quarter report, due Sept. 10.
Premium Feature
Moneyball Superscore
80/100
Today's Change
(
-6.73
%) $
-19.24
Current Price
$
266.51
Ultimately, I think this record says more about entry prices than about new CEOs. Investors who bought shares on Narayen's first trading day as CEO paid about 26 times adjusted earnings for the fiscal year that had just ended, right as a recession was starting. Today, shares sell for about 9.5 times the fiscal 2027 earnings that analysts project, even though revenue is still growing at a double-digit rate.
Of course, Chakravarthy could still stumble, and the executive departures add uncertainty. But the last handover suggests the first year gets decided by the economy and the starting valuation, not the new CEO.
I wouldn't sell Adobe over this transition. If anything, at this price, I'd rather buy than sell.
Public Employees Retirement System of Ohio ve 2. čtvrtletí koupil novou pozici v Gold.com za zhruba 1,463 milionu USD, když pořídil 35 148 akcií. Firma zároveň oznámila mimořádnou dividendu ve výši 0,20 USD na akcii.
Public Employees Retirement System of Ohio purchased a new position in Gold.com Inc. (NYSE:GOLD – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 35,148 shares of the company’s stock, valued at approximately $1,463,000. Public Employees Retirement System of Ohio owned 0.12% of Gold.com at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Globeflex Capital L P bought a new position in Gold.com during the second quarter valued at $2,783,000. Bank of New York Mellon Corp bought a new stake in shares of Gold.com in the second quarter valued at $7,143,000. Bank of America Corp DE lifted its position in shares of Gold.com by 116.8% during the 1st quarter. Bank of America Corp DE now owns 60,575 shares of the company’s stock valued at $2,428,000 after buying an additional 32,637 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Gold.com by 69.2% during the 1st quarter. California State Teachers Retirement System now owns 29,031 shares of the company’s stock valued at $1,164,000 after buying an additional 11,871 shares during the last quarter. Finally, Empowered Funds LLC grew its stake in shares of Gold.com by 42.5% during the 1st quarter. Empowered Funds LLC now owns 277,029 shares of the company’s stock worth $11,103,000 after acquiring an additional 82,637 shares during the period. Hedge funds and other institutional investors own 62.85% of the company’s stock.
Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on the company. Northland Securities set a $55.00 price objective on Gold.com in a report on Thursday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Gold.com in a report on Monday, August 17th. Zacks Research lowered shares of Gold.com from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 1st. DA Davidson reiterated a “buy” rating and issued a $60.00 target price on shares of Gold.com in a research note on Thursday, September 3rd. Finally, Canaccord Genuity Group lowered their price target on shares of Gold.com from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Gold.com presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.
View Our Latest Stock Report on GOLD Gold.com Trading Up 0.1% NYSE:GOLD opened at $46.19 on Tuesday. Gold.com Inc. has a 1 year low of $22.00 and a 1 year high of $66.70. The stock’s fifty day moving average price is $42.62 and its two-hundred day moving average price is $44.34. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.18 and a quick ratio of 0.29. The company has a market cap of $1.34 billion, a P/E ratio of 15.82 and a beta of 0.56.
Gold.com (NYSE:GOLD – Get Free Report) last announced its quarterly earnings results on Wednesday, September 2nd. The company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.55). Gold.com had a net margin of 0.32% and a return on equity of 18.15%. The company had revenue of $5.01 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter last year, the firm posted $0.41 earnings per share. As a group, analysts expect that Gold.com Inc. will post 3.73 EPS for the current year.
Gold.com Announces Dividend The business also recently announced a special dividend, which will be paid on Monday, September 28th. Shareholders of record on Wednesday, September 16th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Wednesday, September 16th. Gold.com’s payout ratio is presently 27.40%.
Gold.com Company Profile (Free Report)
Gold.com, Inc, together with its subsidiaries, operates as a precious metals company. It operates through three segments: Wholesale Sales & Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Sales & Ancillary Services segment sells gold, silver, platinum, and palladium in the form of bars, plates, powders, wafers, grains, ingots, and coins. This segment also offers complementary services, such as receiving, handling, inventorying, processing, packing, and shipping of precious metals and custom coins on a secure basis; and designs and produces minted silver products.
Featured Articles Five stocks we like better than Gold.com 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding GOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gold.com Inc. (NYSE:GOLD – Free Report).
Receive News & Ratings for Gold.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gold.com and related companies with MarketBeat.com's FREE daily email newsletter.
Mayfair Gold dokončila 23 průzkumných vrtů na Fenn-Gib o celkové délce 6 184 metrů a potvrdila, že plánovaná infrastruktura zůstává na vhodných místech. Prioritní cíle na South Block se posouvají k vrtání na začátku roku 2027.
, /PRNewswire/ -- Mayfair Gold Corp. ("Mayfair", "Mayfair Gold", or the "Company") (TSXV: MFG) (NYSE American: MINE) is pleased to report on its summer exploration program progress and mine geology advancement to further its operational readiness program.
2026 Summer Geology Program Highlights:
Figure 1: North Block
Figure 2: South Block
Figure 3: Map of Condemnation Drilling Program Advanced South Block targets toward drill-ready status Mapped more than 95% of known outcrops and collected 127 grab samples Completed 23 condemnation holes totalling 6,184 metres, confirming the site General Arrangement Advanced the integrated 3D geological and multi-element geochemical model Adree DeLazzer, P.Geo, Vice President, Exploration, commented, "this season's work has strengthened our geological understanding of the North and South blocks and advanced priority targets on the South Block toward planned drilling in early 2027. Integrating our mapping, sampling and structural interpretation will help us refine these targets and focus the next phase of exploration. In parallel, we are developing an integrated geological and geochemical model at Fenn-Gib to better understand the deposit and guide exploration across the broader property. We are encouraged by the South Block's potential and look forward to testing the targets developed through this work.
2026 Exploration Program
The 2026 exploration program focused on advancing the geological understanding of the North and South blocks (see figures 1 and 2 below) through systematic geological mapping, prospecting, sampling, and compilation of historical data. Over 95% of known outcrops across both blocks were reviewed, mapped and selectively sampled, providing extensive coverage of the property and adding significantly to the geological dataset available for ongoing interpretation and targeting.
A total of 127 grab samples were collected across the North and South blocks, including selected samples for gold assay and multi-element geochemical analysis. Geological and structural observations recorded during fieldwork focused on documenting structural features, lithology, alteration, and mineralization. The results of this work are being integrated with existing historical datasets to build a more complete understanding of the property.
A structural targeting program is also underway and has identified a number of areas for further evaluation. These targets are being integrated with the results of the summer mapping and sampling program to help refine areas for potential follow-up geological, geochemical, and geophysical work.
The Company is currently finalizing plans for its fall and winter exploration programs.
Infrastructure Condemnation Drilling Program
Mayfair has completed its 2026 condemnation drilling program, comprising 23 drill holes totalling 6,184 metres, including two redrills. The program was designed to test the proposed locations of key project infrastructure identified in the 2026 Pre-Feasibility Study Technical Report. The drilling results confirm that the tested locations remain suitable for the planned infrastructure, and no changes to the current site layout are required.
Condemnation Program Assay Highlights
Hole-ID
From
(Meters)
To
(Meters)
Length*
(Meters)
Au g/t
Lithology
FGN26-031
51.00
67.75
16.75
0.52
AMV
and
260.00
261.25
1.25
1.28
MV
FGN26-033
178.30
181.00
2.70
2.84
AMV
including
179.70
181.00
1.30
5.41
MV
FGN26-035
87.00
90.00
3.00
0.66
SED
and
296.50
298.00
1.50
0.51
SED
FGN26-036
49.00
50.50
1.50
3.27
SED
FGN26-037
180.90
184.00
3.10
0.64
ASED
including
183.00
184.00
1.00
1.05
ASED
and
271.00
275.00
4.00
0.62
ASED
FGN26-038
198.30
202.50
4.20
1.58
SED
including
201.00
202.50
1.50
3.50
SED
FGN26-039
91.50
92.60
1.10
0.73
SED
FGN26-040
82.50
84.00
1.50
4.45
SED
FGN26-041a
238.50
240.00
1.50
3.64
SED
and
263.00
264.50
1.50
1.11
SED
FGN26-043
224.00
225.50
1.50
0.60
SED
FGN26-048
163.00
164.50
1.50
0.50
SED
and
167.50
169.00
1.50
0.67
SED
FGN26-050
278.00
279.50
1.50
1.14
SED
and
296.00
297.50
1.50
0.52
SED
* True Thickness for condemnation drilling is unknown.
Efforts are underway to build a comprehensive 3D model integrating geology and a multi-element database. To date, over 900 inductively coupled plasma mass spectrometry assays (ICP-MS) have been taken in and around the main Fenn-Gib deposit. Mayfair is continuing to expand the database and model key elements to strengthen the geo-metallurgy model. The final product will also serve in vectoring pathfinder elements to support exploration efforts on the property scale.
Acid-based accounting assays (ABA) are also being included to further support and strengthen the various environmental baseline studies.
Finally, the previously reported grade control program yielded favorable results (see news release dated June 18, 2026). Mayfair is currently considering options to capitalise on those results and potentially do targeted infill drilling to pursue that program.
Quality Assurance and Quality Control
Mayfair Gold maintains a Quality Assurance/Quality Control (QA/QC) program aligned with NI 43-101 requirements and industry best practices. NQ size surface drilling was carried out by Black Diamond Drilling of Matheson, Ontario, and by Wiijiiwaagan Drilling Limited Partnerships of Haileybury, Ontario, under the supervision of Mayfair Gold's exploration team. The drill program includes detailed geological logging and systematic sampling of drill core at Mayfair's secure facility in Matheson, Ontario.
Drill core selected for analysis was cut longitudinally using a diamond‑blade saw. One half of the core was retained in the core box for reference, and the other half was bagged, sealed, and prepared for shipment. Analytical work was completed by Swastika Laboratories Ltd. in Swastika, Ontario. Swastika Laboratories is independent of Mayfair Gold and accredited by the Canadian Association for Laboratory Accreditation Inc. (CALA) and meets the ISO/IEC 17025 standards for gold analysis by fire assay with gravimetric finish and fire assay with flame atomic absorption spectroscopy (FAAS) finish.
Samples were delivered directly to Swastika Laboratories by Mayfair personnel. Samples are crushed to minimum 80% passing 1,700 μm. Samples are then split to obtain a 300–500 g sample using a rotary divider. 300–500 g samples are pulverized to minimum 85% passing 74 μm. Gold assays were completed using a 30‑gram fire assay with FAAS finish. Samples returning gold grades greater than 10 g/t were re‑assayed using a 30‑gram fire assay with gravimetric finish. As part of Mayfair's QA/QC protocol, one certified reference material (CRM), one coarse blank, and one coarse duplicate sample were inserted into the sequence of every 25 samples. Routine third‑party check assays are also performed.
True thickness for condemnation drilling is unknown.
Mayfair Gold is a Canadian development-stage gold company focused on advancing the 100% controlled Fenn-Gib Project in the Timmins region of Northern Ontario. Fenn-Gib hosts a 4.3 million ounce indicated mineral resource of gold (181.3Mt at an average grade of 0.74 g/t) and the expected strategy outlined in the 2026 Pre-Feasibility Study (the "PFS")1 is to develop the project under the provincial permitting process, targeting the higher-grade 1 million ounce probable mineral reserve (25.1Mt at an average grade of 1.29g/t) sitting near-surface, highlighting the optionality and scalability provided by the deposit. The PFS also outlines the potential to develop Fenn-Gib into a new Canadian gold producer, with initial development capital of C$450 million, a base-case payback period of 2.7 years, and cumulative free cash flow2 of US$896 million over the first six years of production based on a US$3,100/oz gold price. The Company is advancing permitting activities, detailed engineering, and stakeholder engagement with the goal of starting construction in 2028 with initial production in 2030. The company also remains focused on exploration around the broader land package with the goal of enhancing mineral resource scale and growth opportunities.
The geological information contained in this news release has been reviewed and approved by Adree DeLazzer, P.Geo., Vice President, Exploration of Mayfair, and the remaining technical information has been reviewed and approved by Drew Anwyll, P.Eng., Chief Executive Officer of Mayfair. Ms. DeLazzer and Mr. Anwyll are Qualified Persons as defined by National Instrument 43-101.
_________________________
1 Please refer to the technical report entitled "Fenn-Gib Gold Project NI 43-101 Technical Report and pre-Feasibility Study" dated effective December 19, 2025 available on SEDAR+ at www.sedarplus.ca for further details.
2 Free cash flow does not have a standardized meaning and may not be comparable to similar measures presented by other issuers, referred to as non-GAAP financial measures. As the Corporation is not in production, the Corporation does not have historical non-GAAP financial measures nor historical comparable measures under IFRS, and therefore the foregoing prospective non-GAAP financial measures may not be reconciled to the nearest comparable measures under IFRS.
Cautionary Note Regarding Forward-Looking Information
This news release contains certain forward-looking information within the meaning of applicable Canadian securities legislation and forward-looking statements within the meaning of applicable United States securities legislation (collectively, "forward-looking information"). The use of the words "will" and "expected" and similar expressions is intended to identify forward-looking information. Forward-looking information in this news release includes, but is not limited to, the expected strategy to develop the project under the provincial permitting process, de-risking of early years' high-grade feed and cash flow profile, the potential to bring forward higher-grade production, targeting the higher-grade mineral reserve, building and operating the Fenn-Gib Project and all disclosure related to the PFS, including commencement of construction and production. Although Mayfair Gold believes that the expectations reflected in such forward-looking information is reasonable, readers are cautioned that actual results may vary from the forward-looking information. The Company has based the forward-looking information on the Company's current expectations and assumptions about future events. This information also involves known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information, including the risks, uncertainties, and other factors identified in the annual information form and Form 40-F of the Company for the year ended December 31, 2025, available under the Company's profiles on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov, respectively. Furthermore, the forward-looking information contained in this news release is as at the date of this news release, and Mayfair does not undertake any obligation to publicly update or revise any of this forward-looking information except as may be required by applicable securities laws.
Neither the TSX Venture Exchange ("TSXV") nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
eBay odstranil devět nabídek sad pro určení pohlaví po upozornění Reuters a zahájil interní kontrolu svých ochranných mechanismů. Produkty byly nabízeny k doručení do Indie, kde je jejich použití trestné.
EBay has launched an internal review of its shopping website's safeguards after Reuters flagged that several gender-prediction kits were available for delivery to India, where using them is a criminal offence under a law meant to curb female foeticide.
After Reuters told eBay last week that nine listings on the platform showed gender-testing kits, including those made by brands such as SneakPeek and Peekaboo, being offered by third-party sellers for delivery in India, eBay removed these listings.
"These listings violated local regulations and eBay's policies, and we are reviewing these controls, including the relevant shipping and checkout experience, to determine whether further enhancements are appropriate," eBay told Reuters in a statement.
"EBay has controls in place intended to prevent certain gender-prediction products from being visible in India," it added.
EBay, which has 136 million active buyers globally, is one of the world's largest online marketplaces, where only third-party sellers list products. EBay does not have a local Indian shopping website but offers delivery to the country.
Platforms such as Amazon and eBay (EBAY.O) have previously come under scrutiny in India for listing restricted products, including banned wildlife items and e-cigarettes.
Amazon's U.S. website, which ships many products internationally to India, does list gender-testing products but does not offer India delivery, a Reuters review found.
THE INDIAN LAW
India's 1994 law on prenatal gender determination followed a sharp fall in the number of girls born for every 1,000 boys after the spread of ultrasound technology. Campaigners have said the technology let parents learn a foetus's sex early enough to abort female foetuses rather than raise a daughter.
The preference for male children is rooted in patrilineal inheritance customs, the expectation that sons support parents in their old age and dowry demands made at weddings by the groom and his family despite a decades-old ban on the practice.
Violations of the prenatal gender determination law can attract up to three years in prison, with tougher penalties for repeat offences. India's health ministry did not respond to requests for comment on Reuters findings.
Cybersecurity firm FalconFeeds first flagged the eBay listings to Reuters. The listings offered the gender-testing kits priced from $6.99 to $156.59 and with delivery to India.
One listing on eBay offered the Peekaboo kit, made by U.S.-based DNA Diagnostics Center, and marketed on the website as "get your baby's gender at 6 weeks ... accurate and easy to use", with "FREE SHIPPING".
DNA Diagnostics Center told Reuters in a statement it does not sell or distribute the kits for resale in India, adding it does not control the actions of independent third parties once a product has been purchased.
SneakPeek did not respond to a request for comment.
INDIA TARGETS GOOGLE SEARCH RESULTS
In a sign of New Delhi's growing concerns about such products, Peekaboo — though not officially sold in India — has separately been named in two August 9 Indian government notices sent to Google, seeking removal of search results that link to the company's website.
The notices, reviewed by Reuters and sent by India's health ministry, said Google's India search engine provided "violative information" that led users to web pages "directly or indirectly promoting/advertising the gender prediction of an unborn child."
Search engines can typically block specific website links from appearing in results for users in a given country.
In the notices, the ministry attached screenshots of three Google searches — "peekaboo test," "buy peekaboo test online" and "boy or girl" — that linked to the Peekaboo website. It asked Google to discontinue the practice in line with Indian laws.
A Reuters check on Tuesday found the three searches returned results linking to the Peekaboo website.
Google and India's health ministry did not respond to Reuters queries.
Micron a SanDisk v premarketu rostly díky silné poptávce po pamětech pro AI. Rizikem je však slábnoucí poptávka ve smartphonech a PC, protože vyšší ceny už tlačí výrobce k zdražování a škrtům ve specifikacích.
Micron and SanDisk stocks rose in Tuesday premarket trading, extending the memory-stock rally as investors bet on tight supply and AI demand.
The gains follow Friday’s surge, when Micron jumped 6.1% and SanDisk climbed 11.9%.
But the rally is creating a new risk.
Memory prices have risen so sharply that smartphone and PC makers are raising prices, cutting specifications and rethinking production.
TrendForce data suggests some consumers are buying devices earlier to avoid further increases.
The immediate fundamentals remain strong, as AI data centres are consuming huge amounts of DRAM and NAND, while manufacturers are directing capacity towards higher-value products such as high-bandwidth memory.
That benefits Micron through its exposure to HBM and conventional DRAM, while SanDisk remains a major beneficiary of tight NAND supply.
New capacity cannot arrive quickly.
TechInsights chief strategy officer Dan Kim told the Financial Times that no meaningful new supply is expected until at least 2028, as AI demand continues to overwhelm available capacity.
Micron’s expansion illustrates the challenge. Its planned New York complex is not expected to deliver meaningful output until 2030, while its Idaho facility is expected to begin wafer production in 2027.
Investors therefore have reason to believe the shortage can continue for the foreseeable future.
The more important risk is appearing downstream.
TrendForce said Tuesday that global smartphone production reached about 275 million units in the second quarter, down 8% from a year earlier.
The research firm raised its 2026 production forecast to 1.07 billion units, but warned that the improvement did not represent a genuine recovery.
Some consumers brought purchases forward because they feared further memory-driven device price increases, while manufacturers restored production previously cut too aggressively.
TrendForce warned that smartphone output could face renewed pressure in 2027 as those effects fade and memory contract prices continue rising.
Bernstein sees the same tension. According to Investing.com, the firm said it still believes “demand destruction in the consumer segment will eventually happen,” even as server demand absorbs additional supply.
Bernstein expects memory-price increases to slow before prices gradually peak and begin normalising from the second half of 2027 into 2028.
Demand destruction in smartphones and PCs does not automatically end the memory upcycle.
For investors tracking Micron, SanDisk and other semiconductor names through the best trading apps, the key distinction is between consumer and AI-driven demand.
AI customers are less price-sensitive because memory is essential to deploying valuable computing infrastructure. Consumer buyers can delay purchases, choose cheaper devices or accept lower specifications.
That difference is already reshaping the market.
IDC senior director Nabila Popal told The Verge that memory prices could eventually stabilise at a “new normal” that remains at least three times historical levels.
The Verge also reported that smartphone and PC makers are shifting towards premium devices, raising prices or reducing memory configurations to protect margins.
For Micron and SanDisk, the key question is becoming the mix of demand rather than demand alone.
As long as AI infrastructure spending remains strong, weaker consumer volumes may be manageable.
But if smartphone and PC demand deteriorates faster than data-centre demand expands, elevated pricing could eventually work against suppliers.
TSMC a Samsung se zavázaly používat nejnovější stroje High NA EUV od ASML pro pokročilé čipy, protože poptávka po AI zvyšuje potřebu složitější výroby. Samsung je chce nasadit na DRAM od roku 2028.
Samsung and TSMC, the world's two biggest chipmakers, have committed to using ASML's High NA extreme ultraviolet (EUV) lithography machines, as demand grows for more advanced chips.
ASML's EUV lithography machines are critical tools that are used to print circuit patterns onto silicon wafers during the chipmaking process. The High NA machines can print smaller and more intricate patterns. This tool can cost around $400 million.
Samsung, one of the world's biggest memory chipmakers, said it would use ASML's machines to produce DRAM, a key type of memory, from 2028.
Samsung said it would adopt the technology in 2030, adding that it would "extend the DRAM scaling roadmap" and make the process more efficient.
ASML stock over the last 12 months.
TSMC said it would use ASML's tools for advanced chips and expects use of High NA machines to rise, "driven primarily by the increasingly complex transistor architectures required for AI applications."
Investors see the success of High NA EUV machines as key to ASML's future growth as the stock looks to extend a 120% run over the last year.
Barclays said in a note on Tuesday that the announcements "should provide more visibility on adoption which has been a key debate," adding that the news is "a positive."
Shares of Amsterdam-listed ASML were flat-to-lower in early trading on Tuesday.
Samsung and TSMC join Intel as customers for ASML's High NA machines. In July, ASML said that Intel is using the High NA EUV technology for advanced chip manufacturing.
ASML has not given a recent forecast on how many of the machines it expects to sell but has said that it will add about 30% capacity for EUV in total in 2027.
The analysts at Barclays said the announcements give ASML more visibility into planning.
"We see ASML with a significant decision ahead on whether to further expand EUV capacity than the recently expanded targets it has already given. Demand is clearly strong," Barclays said.
TSMC and Samsung will also join ASML in an industry initiative to advance next-generation 12-inch photmask technology, upgrading from the current 6-inch format. A key part of chip production, photomasks are effectively the stencils used to print the patterns on the wafers.
ASML said the benefits of a larger photomask include better productivity and lower chipmaking costs.
Abbott Laboratories zvýšil dividendu už 54. rok v řadě a ve 2. čtvrtletí zvýšil tržby na 12,6 miliardy USD, meziročně o 13 %. Firma zároveň zvýšila celoroční odhad upraveného EPS na 5,45 až 5,60 USD.
With doubts around geopolitical issues combined with the stock market trading near record highs, it's natural to wonder whether a painful sell-off is overdue. If it is, Abbott Laboratories (ABT -0.42%) could be one of the best dividend stocks to own through the storm. Abbott is a Dividend King, a company that has increased its dividend for at least 50 consecutive years. In Abbott's case, it has raised its dividend for the past 54 consecutive years.
If the market crashes, Abbott could provide investors with a stable income stream, helping to soften the blow as they wait for a recovery.
The bigger question now is whether Abbott can keep it going.
Image source: Getty Images.
Abbott's dividend looks sustainable, even in a slowdown In the second quarter, the company reported sales of $12.6 billion, up 13% year over year, while adjusted diluted earnings per share (EPS) came in at $1.31, beating Wall Street expectations. Management is confident that momentum can continue, as the company raised its full-year adjusted EPS forecast to between $5.45 and $5.60 per share.
Meanwhile, Abbott's dividend payout ratio is about 46%, meaning the company pays out less than half of its earnings as dividends. For dividend investors, that means Abbott earns more than enough to keep paying shareholders while still leaving room to reinvest in the business. And the more the business grows, the more it can support future dividend increases.
In fact, Abbott returned $2.1 billion to shareholders in the second quarter alone through a combination of share repurchases and dividends. Today, the stock's forward dividend yield is roughly 2.3%.
So, can Abbott keep increasing its dividends?
Premium Feature
Moneyball Superscore
74/100
Today's Change
(
-0.42
%) $
-0.46
Current Price
$
108.33
New products and a major deal could lift growth in 2026 Management believes sales and earnings will accelerate in the second half of 2026, creating a favorable setup for continued dividend increases. Abbott's medical devices business has been one of its bright spots.
The segment is seeing solid growth thanks to the U.S. launch of the Volt PFA system and the international rollout of Volt and TactiFlex Duo, devices used to treat certain heart conditions.
But perhaps the biggest catalyst this year was Abbott's $21 billion acquisition of Exact Sciences. With the deal, Abbott is expanding into the fast-growing cancer diagnostics market. Granted, the acquisition closed only in March, so there is still plenty of runway ahead, especially as the new business contributes more to earnings.
Investors are already seeing promising signs that this investment is paying off. Revenue in Abbott's cancer diagnostics segment grew 13.3% in the second quarter, driven by precision oncology, international growth, and Cologuard, a noninvasive colorectal cancer screening test.
Looking ahead, this segment is well-positioned to deliver stronger growth in the second half of the year, especially as Abbott ramps up newly launched tests, care gap programs, and overseas expansion.
So, what do analysts think about Abbott stock?
Should dividend investors consider buying Abbott now? For dividend investors who own Abbott, the appeal is a compelling combination of income and stability. The company has raised its dividend for more than five decades, and its latest results prove that earnings and cash flow can support future payouts.
At the same time, Abbott's medical devices and cancer diagnostics businesses provide clear avenues for growth. If those segments continue to expand and generate cash, they could give Abbott an even stronger cushion to maintain and potentially raise its dividend, even if the broader market stumbles.
Wall Street appears bullish, with analyst offering "strong buy" rating on average. If a crash happens, investors will likely want holdings that can keep paying them while they wait it out, and Abbott Laboratories fits that profile.
NEOS Investment Management zvýšila ve 2. čtvrtletí podíl v Estée Lauder o 14 % na 40 191 akcií v hodnotě 3 173 000 USD. Firma zároveň oznámila čtvrtletní dividendu 0,35 USD na akcii.
NEOS Investment Management LLC boosted its stake in shares of The Estee Lauder Companies Inc. (NYSE:EL – Free Report) by 14.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,191 shares of the company’s stock after buying an additional 4,932 shares during the period. NEOS Investment Management LLC’s holdings in Estee Lauder Companies were worth $3,173,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. REAP Financial Group LLC purchased a new stake in Estee Lauder Companies in the fourth quarter valued at approximately $27,000. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna purchased a new stake in shares of Estee Lauder Companies in the 4th quarter valued at $27,000. DV Equities LLC acquired a new position in Estee Lauder Companies during the 4th quarter worth about $36,000. Trust Co. of Vermont purchased a new position in Estee Lauder Companies during the 2nd quarter valued at about $28,000. Finally, Kozak & Associates Inc. acquired a new position in Estee Lauder Companies in the 2nd quarter valued at about $30,000. 55.15% of the stock is owned by institutional investors and hedge funds.
Insider Activity In related news, VP Rashida La Lande sold 7,766 shares of the company’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $103.32, for a total value of $802,383.12. Following the completion of the sale, the vice president directly owned 14,357 shares of the company’s stock, valued at $1,483,365.24. This represents a 35.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.05% of the company’s stock.
Analysts Set New Price Targets Several research firms have recently commented on EL. Piper Sandler raised their price objective on shares of Estee Lauder Companies from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Morgan Stanley boosted their price target on shares of Estee Lauder Companies from $90.00 to $102.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 20th. The Goldman Sachs Group increased their price objective on Estee Lauder Companies from $100.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wells Fargo & Company boosted their target price on Estee Lauder Companies from $85.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 20th. Finally, UBS Group increased their price target on Estee Lauder Companies from $86.00 to $106.00 and gave the company a “neutral” rating in a research report on Thursday, August 20th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $104.67. Read Our Latest Research Report on Estee Lauder Companies
Estee Lauder Companies Stock Down 0.0% Estee Lauder Companies stock opened at $103.81 on Tuesday. The stock has a market cap of $37.56 billion, a PE ratio of 211.86, a P/E/G ratio of 1.20 and a beta of 1.28. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.22 and a quick ratio of 0.90. The stock’s fifty day moving average is $89.04 and its two-hundred day moving average is $86.16. The Estee Lauder Companies Inc. has a 1-year low of $66.22 and a 1-year high of $121.64.
Estee Lauder Companies (NYSE:EL – Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.07. The business had revenue of $3.64 billion for the quarter, compared to analyst estimates of $3.55 billion. Estee Lauder Companies had a return on equity of 23.52% and a net margin of 1.21%.The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $0.09 EPS. Estee Lauder Companies has set its FY 2027 guidance at 3.100-3.350 EPS. On average, sell-side analysts expect that The Estee Lauder Companies Inc. will post 3.3 EPS for the current fiscal year.
Estee Lauder Companies Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be paid a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.3%. The ex-dividend date is Monday, August 31st. Estee Lauder Companies’s dividend payout ratio is currently 285.71%.
(Free Report)
Estée Lauder Companies Inc (NYSE: EL) is a global leader in prestige beauty that develops, manufactures and markets a broad portfolio of skincare, makeup, fragrance and hair care products. Founded in 1946 by Estée Lauder, the company has grown from a small family business into a multinational consumer-products enterprise headquartered in New York City. Its activities span product research and development, brand and product marketing, manufacturing and global distribution across multiple retail channels.
The company’s portfolio includes a mix of legacy and prestige brands that target different consumer segments and price points, with well-known names such as Estée Lauder, Clinique, MAC, La Mer and Jo Malone among others.
Read More Five stocks we like better than Estee Lauder Companies 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for Estee Lauder Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Estee Lauder Companies and related companies with MarketBeat.com's FREE daily email newsletter.
Public Employees Retirement System of Ohio acquired a new stake in The Scotts Miracle-Gro Company (NYSE:SMG – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,421 shares of the basic materials company’s stock, valued at approximately $1,323,000.
A number of other large investors have also made changes to their positions in SMG. State Street Corp raised its stake in Scotts Miracle-Gro by 1.1% in the 2nd quarter. State Street Corp now owns 1,522,093 shares of the basic materials company’s stock valued at $100,397,000 after purchasing an additional 16,298 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Scotts Miracle-Gro by 161.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,289,974 shares of the basic materials company’s stock worth $78,443,000 after purchasing an additional 795,970 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Scotts Miracle-Gro by 29.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,165,367 shares of the basic materials company’s stock worth $66,368,000 after purchasing an additional 265,677 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Scotts Miracle-Gro by 0.3% during the fourth quarter. Captrust Financial Advisors now owns 1,157,714 shares of the basic materials company’s stock worth $67,553,000 after buying an additional 2,899 shares in the last quarter. Finally, Deprince Race & Zollo Inc. grew its holdings in shares of Scotts Miracle-Gro by 4.9% during the first quarter. Deprince Race & Zollo Inc. now owns 1,087,339 shares of the basic materials company’s stock worth $66,121,000 after buying an additional 51,148 shares in the last quarter. Institutional investors and hedge funds own 74.07% of the company’s stock.
Analyst Upgrades and Downgrades Several equities analysts recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Scotts Miracle-Gro from $75.00 to $76.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Wells Fargo & Company lifted their target price on shares of Scotts Miracle-Gro from $74.00 to $77.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Wall Street Zen cut shares of Scotts Miracle-Gro from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. UBS Group boosted their price target on Scotts Miracle-Gro from $70.00 to $78.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Scotts Miracle-Gro in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Scotts Miracle-Gro currently has a consensus rating of “Hold” and a consensus target price of $75.40.
Get Our Latest Report on SMG Scotts Miracle-Gro Price Performance NYSE SMG opened at $59.46 on Tuesday. The company has a market cap of $3.46 billion, a P/E ratio of 51.70 and a beta of 1.83. The Scotts Miracle-Gro Company has a 12 month low of $52.00 and a 12 month high of $75.34. The company has a 50-day moving average of $64.72 and a 200-day moving average of $63.70.
Scotts Miracle-Gro (NYSE:SMG – Get Free Report) last released its earnings results on Wednesday, July 29th. The basic materials company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.48 by $0.34. Scotts Miracle-Gro had a net margin of 2.19% and a negative return on equity of 81.90%. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company earned $2.59 earnings per share. The company’s quarterly revenue was up 1.1% on a year-over-year basis. As a group, equities research analysts anticipate that The Scotts Miracle-Gro Company will post 4.41 EPS for the current year.
Scotts Miracle-Gro Announces Dividend The business also recently declared a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Friday, August 21st were issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Friday, August 21st. Scotts Miracle-Gro’s dividend payout ratio (DPR) is 229.57%.
Insider Buying and Selling at Scotts Miracle-Gro In related news, Director Hagedorn Partnership, L.P. sold 30,000 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $67.45, for a total value of $2,023,500.00. Following the transaction, the director directly owned 13,137,641 shares of the company’s stock, valued at approximately $886,133,885.45. This trade represents a 0.23% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mark D. Kingdon sold 831 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $61.65, for a total value of $51,231.15. Following the completion of the transaction, the director directly owned 10,827 shares in the company, valued at $667,484.55. This trade represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 32,002 shares of company stock worth $2,154,734 in the last quarter. 24.40% of the stock is owned by insiders.
(Free Report)
Scotts Miracle-Gro Company is a leading developer, manufacturer and distributor of consumer lawn and garden products. The firm serves both retail and professional customers through an array of branded offerings that include lawn fertilizers, grass seed, pest and disease control solutions, plant foods and specialty products for indoor and outdoor gardening. Its portfolio spans well-known names such as Scotts®, Miracle-Gro®, Ortho® and various hydroponic and specialty garden brands.
Headquartered in Marysville, Ohio, the company traces its roots to O.M.
Further Reading Five stocks we like better than Scotts Miracle-Gro 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding SMG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Scotts Miracle-Gro Company (NYSE:SMG – Free Report).
Receive News & Ratings for Scotts Miracle-Gro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scotts Miracle-Gro and related companies with MarketBeat.com's FREE daily email newsletter.
Nykredit A/S ve 2. čtvrtletí koupila nový podíl ve Strategy, 27 417 akcií za zhruba 2,383 milionu USD. Firma zároveň oznámila čtvrtletní ztrátu 24,45 USD na akcii při tržbách 122,37 milionu USD.
Nykredit A S acquired a new stake in Strategy Inc (NASDAQ:MSTR – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,417 shares of the software maker’s stock, valued at approximately $2,383,000.
Several other hedge funds also recently added to or reduced their stakes in the stock. Fideuram Asset Management Ireland dac purchased a new stake in shares of Strategy in the fourth quarter worth about $25,000. Westfuller Advisors LLC purchased a new stake in shares of Strategy during the 1st quarter valued at about $25,000. Ancora Advisors LLC raised its holdings in shares of Strategy by 111.7% during the 2nd quarter. Ancora Advisors LLC now owns 290 shares of the software maker’s stock valued at $25,000 after buying an additional 153 shares during the period. Wilkerson Advisory Group LLC acquired a new position in Strategy during the 4th quarter worth approximately $30,000. Finally, Binnacle Investments Inc lifted its position in Strategy by 492.9% during the 2nd quarter. Binnacle Investments Inc now owns 83 shares of the software maker’s stock worth $34,000 after acquiring an additional 69 shares in the last quarter. 59.84% of the stock is owned by hedge funds and other institutional investors.
Strategy Price Performance Shares of NASDAQ MSTR opened at $142.80 on Tuesday. Strategy Inc has a fifty-two week low of $81.81 and a fifty-two week high of $365.21. The business has a 50 day moving average price of $104.87 and a two-hundred day moving average price of $128.41. The company has a quick ratio of 5.39, a current ratio of 5.39 and a debt-to-equity ratio of 0.22. The firm has a market cap of $54.87 billion, a PE ratio of -1.47 and a beta of 3.59.
Strategy (NASDAQ:MSTR – Get Free Report) last announced its earnings results on Friday, July 31st. The software maker reported ($24.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.19) by ($22.26). The business had revenue of $122.37 million during the quarter, compared to analyst estimates of $122.90 million. Strategy had a negative net margin of 6,102.95% and a negative return on equity of 74.18%. The business’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the company earned $32.52 earnings per share. Sell-side analysts expect that Strategy Inc will post -23.74 earnings per share for the current fiscal year. Insider Buying and Selling In related news, CEO Phong Le acquired 11,000 shares of Strategy stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $90.80 per share, for a total transaction of $998,800.00. Following the purchase, the chief executive officer directly owned 11,000 shares of the company’s stock, valued at $998,800. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jarrod M. Patten sold 1,850 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $130.00, for a total transaction of $240,500.00. Following the transaction, the director directly owned 28,406 shares of the company’s stock, valued at approximately $3,692,780. This represents a 6.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,950 shares of company stock valued at $1,615,809 in the last three months. Corporate insiders own 6.49% of the company’s stock.
Strategy News Summary Here are the key news stories impacting Strategy this week:
Positive Sentiment: An analyst argues that Strategy’s stock could nearly triple, citing the company’s Bitcoin holdings and the potential for a significant recovery in the cryptocurrency. This provides an upside narrative for investors despite the stock’s substantial decline over the past year. Strategy Is Down More Than 50% in 12 Months Positive Sentiment: Strategy purchased 4,603 Bitcoin for approximately $370 million, reinforcing its position as a leveraged corporate bet on Bitcoin. Bitcoin trading near $80,000 and continued corporate demand could support the value of Strategy’s holdings and improve investor sentiment. Bitcoin Trades Near $80,000 Neutral Sentiment: A Hyperliquid trader’s heavily underwater Strategy short highlights intense positioning and volatility around MSTR. Forced covering could provide short-term support, but the report does not change Strategy’s underlying fundamentals. Trader Wins 26 Bets in a Row Negative Sentiment: Shares recently decreased after the Bitcoin acquisition, with coverage reporting a decline of about 4.2%. Investors may be concerned that continued purchases increase exposure to Bitcoin’s volatility, while Saylor’s bullish commentary and upcoming U.S. crypto legislation add further event risk. Strategy Stock Drops Following Bitcoin Purchase Negative Sentiment: Strategy’s dependence on Bitcoin means its valuation can move sharply with cryptocurrency prices and market risk appetite. The company’s latest reported quarter also included a large loss and a significant earnings miss, adding to concerns about financial volatility. Analyst Ratings Changes Several analysts have issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Strategy from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. HC Wainwright set a $325.00 target price on shares of Strategy in a research report on Monday, August 3rd. Alliance Global Partners initiated coverage on shares of Strategy in a research note on Tuesday, September 1st. They issued a “buy” rating and a $217.00 target price for the company. TD Cowen lowered their price target on shares of Strategy from $400.00 to $260.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $350.00 price target (down from $450.00) on shares of Strategy in a report on Wednesday, August 26th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Strategy has a consensus rating of “Moderate Buy” and an average target price of $236.41.
View Our Latest Stock Analysis on Strategy
Strategy Profile (Free Report)
Strategy, formerly known as MicroStrategy, Incorporated (NASDAQ: MSTR) is a global provider of enterprise analytics and mobility software. The company’s flagship platform offers business intelligence, data discovery, and advanced visualizations that enable organizations to analyze large volumes of data and deliver actionable insights. In addition to traditional on-premises deployments, Strategy provides a range of cloud-based services and managed offerings that allow customers to leverage the power of its analytics tools without managing complex infrastructure.
Founded in 1989 by Michael J.
See Also Five stocks we like better than Strategy 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding MSTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strategy Inc (NASDAQ:MSTR – Free Report).
Receive News & Ratings for Strategy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strategy and related companies with MarketBeat.com's FREE daily email newsletter.
Public Employees Retirement System of Ohio ve druhém čtvrtletí koupil novou pozici v Iridium Communications za zhruba 1,586 milionu USD. Firma nakoupila 28 918 akcií.
Public Employees Retirement System of Ohio purchased a new position in shares of Iridium Communications Inc (NASDAQ:IRDM – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 28,918 shares of the technology company’s stock, valued at approximately $1,586,000.
A number of other hedge funds also recently made changes to their positions in the stock. Quadrant Capital Group LLC raised its position in shares of Iridium Communications by 107.5% in the 4th quarter. Quadrant Capital Group LLC now owns 1,430 shares of the technology company’s stock worth $25,000 after buying an additional 741 shares during the period. Larson Financial Group LLC raised its holdings in shares of Iridium Communications by 392.8% in the 3rd quarter. Larson Financial Group LLC now owns 1,508 shares of the technology company’s stock worth $26,000 after purchasing an additional 1,202 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of Iridium Communications in the 4th quarter valued at about $27,000. CIBC Private Wealth Group LLC acquired a new position in shares of Iridium Communications in the 3rd quarter valued at about $32,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Iridium Communications by 10,363.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,988 shares of the technology company’s stock worth $35,000 after purchasing an additional 1,969 shares during the period. Institutional investors and hedge funds own 84.36% of the company’s stock.
Insider Buying and Selling at Iridium Communications In other news, insider Kathleen Morgan sold 33,192 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $50.35, for a total value of $1,671,217.20. Following the completion of the transaction, the insider directly owned 124,871 shares in the company, valued at approximately $6,287,254.85. This represents a 21.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Fitzpatrick sold 209,233 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $50.22, for a total transaction of $10,507,681.26. Following the sale, the director directly owned 58,306 shares of the company’s stock, valued at approximately $2,928,127.32. The trade was a 78.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 375,919 shares of company stock valued at $18,878,997. 2.70% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades A number of analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Iridium Communications from $26.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Iridium Communications in a research note on Friday, July 10th. William Blair lowered shares of Iridium Communications from an “outperform” rating to a “hold” rating in a research report on Monday, June 29th. New Street Research raised shares of Iridium Communications from a “neutral” rating to a “buy” rating in a research note on Wednesday, July 22nd. Finally, Oppenheimer lifted their target price on shares of Iridium Communications from $48.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Iridium Communications has a consensus rating of “Hold” and an average target price of $38.67. View Our Latest Analysis on IRDM
Iridium Communications Price Performance IRDM stock opened at $47.21 on Tuesday. The firm has a market cap of $5.00 billion, a P/E ratio of 53.65, a price-to-earnings-growth ratio of 3.81 and a beta of 0.87. The company has a debt-to-equity ratio of 3.70, a quick ratio of 2.31 and a current ratio of 2.78. Iridium Communications Inc has a 1 year low of $15.65 and a 1 year high of $57.18. The stock has a 50-day simple moving average of $48.66 and a 200-day simple moving average of $41.05.
Iridium Communications (NASDAQ:IRDM – Get Free Report) last released its quarterly earnings results on Wednesday, July 22nd. The technology company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.19). The company had revenue of $225.24 million for the quarter, compared to analyst estimates of $220.32 million. Iridium Communications had a return on equity of 22.57% and a net margin of 10.55%.The business’s revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted $0.20 earnings per share. On average, equities analysts predict that Iridium Communications Inc will post 0.95 earnings per share for the current fiscal year.
Iridium Communications Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Iridium Communications’s payout ratio is presently 68.18%.
(Free Report)
Iridium Communications Inc operates a global satellite communications network that delivers voice and data services across land, sea and air. The company’s unique architecture relies on a constellation of 66 low-Earth orbit satellites, enabling real-time connectivity in regions beyond the reach of terrestrial wireless networks. Iridium’s core offerings include satellite voice and messaging services, broadband data terminals, push-to-talk (PTT) interoperability and machine-to-machine (M2M) solutions for the Internet of Things (IoT).
Iridium serves a diverse range of markets, including maritime shipping, aviation, government and defense, energy, and enterprise.
Further Reading Five stocks we like better than Iridium Communications 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding IRDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iridium Communications Inc (NASDAQ:IRDM – Free Report).
Receive News & Ratings for Iridium Communications Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iridium Communications and related companies with MarketBeat.com's FREE daily email newsletter.
HSBC Holdings PLC ve 2. čtvrtletí snížila svůj podíl v CubeSmart o 31,4 % a prodala 391 687 akcií. Po transakci držela 855 192 akcií v hodnotě 34,085 milionu USD.
Hsbc Holdings PLC lowered its stake in CubeSmart (NYSE:CUBE – Free Report) by 31.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 855,192 shares of the real estate investment trust’s stock after selling 391,687 shares during the quarter. Hsbc Holdings PLC owned 0.38% of CubeSmart worth $34,085,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of CubeSmart in the second quarter worth approximately $1,349,164,000. Norges Bank bought a new stake in CubeSmart during the 4th quarter valued at $395,968,000. Canada Pension Plan Investment Board bought a new stake in CubeSmart during the 2nd quarter valued at $288,512,000. Bank of New York Mellon Corp purchased a new stake in CubeSmart during the 2nd quarter valued at $74,199,000. Finally, Millennium Management LLC boosted its position in CubeSmart by 201.5% during the 4th quarter. Millennium Management LLC now owns 2,739,600 shares of the real estate investment trust’s stock valued at $98,763,000 after buying an additional 1,830,993 shares during the period. Hedge funds and other institutional investors own 97.61% of the company’s stock.
Wall Street Analyst Weigh In A number of equities analysts have issued reports on the stock. Raymond James Financial started coverage on shares of CubeSmart in a research report on Wednesday, July 15th. They issued an “outperform” rating and a $44.00 price objective on the stock. KeyCorp reiterated a “sector weight” rating on shares of CubeSmart in a report on Tuesday, August 4th. Royal Bank Of Canada reiterated an “outperform” rating and set a $47.00 target price on shares of CubeSmart in a report on Tuesday, August 4th. Mizuho cut their target price on CubeSmart from $42.00 to $41.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 2nd. Finally, UBS Group boosted their price target on CubeSmart from $41.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, July 10th. Six investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $43.45.
Check Out Our Latest Research Report on CUBE CubeSmart Price Performance Shares of NYSE CUBE opened at $39.51 on Tuesday. CubeSmart has a 1 year low of $35.09 and a 1 year high of $43.26. The company has a debt-to-equity ratio of 1.34, a current ratio of 0.07 and a quick ratio of 0.07. The company’s 50-day moving average is $40.93 and its 200 day moving average is $39.98. The stock has a market capitalization of $8.90 billion, a P/E ratio of 27.25, a P/E/G ratio of 6.50 and a beta of 1.05.
CubeSmart (NYSE:CUBE – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The real estate investment trust reported $0.39 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.25). The company had revenue of $286.49 million during the quarter, compared to analysts’ expectations of $281.12 million. CubeSmart had a return on equity of 12.35% and a net margin of 29.41%.The business’s quarterly revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the business earned $0.65 earnings per share. CubeSmart has set its Q3 2026 guidance at 0.640-0.660 EPS and its FY 2026 guidance at 2.540-2.600 EPS. On average, sell-side analysts expect that CubeSmart will post 2.57 earnings per share for the current year.
CubeSmart Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date is Thursday, October 1st. CubeSmart’s dividend payout ratio (DPR) is presently 146.21%.
About CubeSmart (Free Report)
CubeSmart (NYSE: CUBE) is a publicly traded real estate investment trust (REIT) specializing in the ownership, operation and management of self-storage facilities across the United States. The company’s portfolio comprises properties in primary and secondary markets, catering to both individual and business customers seeking flexible, short-term and long-term storage solutions. CubeSmart’s facilities feature a range of unit sizes, climate-controlled options and advanced security features, supported by on-site managers and centralized customer service operations.
In addition to traditional self-storage units, CubeSmart offers specialty services such as vehicle and boat storage, retail sales of packing and moving supplies, and tenant insurance programs.
Featured Stories Five stocks we like better than CubeSmart 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding CUBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CubeSmart (NYSE:CUBE – Free Report).
Receive News & Ratings for CubeSmart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CubeSmart and related companies with MarketBeat.com's FREE daily email newsletter.
Ohio Public Employees Retirement System ve 2. čtvrtletí koupil nový podíl v Travel + Leisure za zhruba 1,416 milionu USD. Institucionální investoři drží 87,54 % akcií TNL.
Public Employees Retirement System of Ohio bought a new stake in Travel + Leisure Co. (NYSE:TNL – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 18,528 shares of the company’s stock, valued at approximately $1,416,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in TNL. BlackRock Inc. acquired a new stake in Travel + Leisure in the second quarter valued at about $543,957,000. Invesco Ltd. raised its stake in Travel + Leisure by 4.2% during the fourth quarter. Invesco Ltd. now owns 3,632,657 shares of the company’s stock worth $256,211,000 after acquiring an additional 146,484 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Travel + Leisure by 46.8% in the second quarter. AQR Capital Management LLC now owns 2,682,604 shares of the company’s stock worth $138,449,000 after acquiring an additional 855,151 shares during the last quarter. LSV Asset Management lifted its holdings in shares of Travel + Leisure by 1.1% in the fourth quarter. LSV Asset Management now owns 1,612,657 shares of the company’s stock worth $113,741,000 after acquiring an additional 17,377 shares during the last quarter. Finally, Quantinno Capital Management LP boosted its stake in shares of Travel + Leisure by 21.7% in the 1st quarter. Quantinno Capital Management LP now owns 1,305,515 shares of the company’s stock valued at $90,329,000 after purchasing an additional 232,711 shares in the last quarter. Institutional investors own 87.54% of the company’s stock.
Insider Buying and Selling at Travel + Leisure In other Travel + Leisure news, insider Geoffrey Richards sold 33,744 shares of Travel + Leisure stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $75.65, for a total transaction of $2,552,733.60. Following the transaction, the insider directly owned 1,600 shares of the company’s stock, valued at approximately $121,040. The trade was a 95.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George Herrera sold 500 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $75.16, for a total value of $37,580.00. Following the completion of the sale, the director owned 1,353 shares in the company, valued at $101,691.48. This trade represents a 26.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 87,135 shares of company stock worth $6,541,139. Company insiders own 4.01% of the company’s stock.
Travel + Leisure Trading Down 0.2% NYSE:TNL opened at $66.21 on Tuesday. The stock has a market cap of $4.05 billion, a P/E ratio of 18.09, a price-to-earnings-growth ratio of 0.45 and a beta of 1.15. The stock’s 50-day moving average is $73.67 and its 200-day moving average is $71.92. Travel + Leisure Co. has a 1-year low of $58.07 and a 1-year high of $81.00. Travel + Leisure (NYSE:TNL – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $1.88 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.88. Travel + Leisure had a net margin of 5.81% and a negative return on equity of 46.91%. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the business earned $1.65 EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. As a group, equities analysts forecast that Travel + Leisure Co. will post 7.7 EPS for the current year.
Travel + Leisure Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 16th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date is Wednesday, September 16th. Travel + Leisure’s payout ratio is 65.57%.
Wall Street Analysts Forecast Growth Several brokerages recently issued reports on TNL. Barclays lifted their price target on shares of Travel + Leisure from $74.00 to $77.00 and gave the company an “equal weight” rating in a report on Thursday, July 23rd. Citigroup reissued a “market outperform” rating on shares of Travel + Leisure in a research note on Thursday, July 23rd. The Goldman Sachs Group raised shares of Travel + Leisure from a “neutral” rating to a “buy” rating and set a $85.00 target price on the stock in a research note on Monday, June 1st. Zacks Research downgraded shares of Travel + Leisure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Travel + Leisure in a research note on Tuesday, July 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.82.
Read Our Latest Research Report on TNL
About Travel + Leisure (Free Report)
Travel + Leisure Co (NYSE: TNL) is a leisure travel company headquartered in Orlando, Florida, that specializes in vacation ownership, membership programs and branded travel experiences. The company operates an extensive portfolio of vacation clubs and destination services, offering members access to resorts, hotels, cruises and guided tours in markets around the world. Through its flagship membership brands, Travel + Leisure Co provides curated vacation packages, exchange services and unique travel itineraries that cater to both individual and family travelers.
In addition to its membership offerings, Travel + Leisure Co manages a network of resort properties and hospitality assets across North America, the Caribbean, Europe and Asia-Pacific.
Featured Stories Five stocks we like better than Travel + Leisure 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane Want to see what other hedge funds are holding TNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travel + Leisure Co. (NYSE:TNL – Free Report).
Receive News & Ratings for Travel + Leisure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travel + Leisure and related companies with MarketBeat.com's FREE daily email newsletter.
